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CHAPTER 1 INTRODUCTION 
1.1 Introduction to the ribosome 
The bacterial ribosome was first described as a small particulate component of the 
cytoplasm and later a ribonucleoprotein by Dr. George Emil Palade in 1955 where he 
used electron microscopy to characterize the then newly-discovered organelle from rat 
and chicken cells.1 This work later led Palade and two other scientists, Albert Claude 
and Christian de Duve, to be awarded the Nobel Prize in physiology or medicine in 1974. 
These three scientists were awarded the Nobel Prize for their work focusing on the 
"discoveries concerning the structural and functional organization of the cell".2 The term 
"ribosome" was later introduced by editor Richard B. Roberts in the introduction portion 
of the 1958 publication "Microsomal Particles and Protein Synthesis".3  
Although ribosomes were a hot subject of research in the mid-1950s and early-1960s, 
focus would soon shift away from these organelles. The main challenge to be addressed 
was to determine the exact mechanistic function of the ribosome, and although it was 
known that the ribosomes were enzymes capable of synthesizing proteins and that they 
consisted of ribonucleic acids (RNA) as well as proteins, limited technology hindered 
research activity during that time period to discover detailed functions. It was also 
difficult for chemists and biologists to consider that RNA could in fact catalyze reactions 
since little to no information was available to support the hypothesis. It wasn't until the 
1980s that evidence really began to accumulate that RNA could in fact catalyze 
chemical reactions,4-6 which then led to ribosomal RNA (rRNA)-focused research well 
into the beginning of the 21st century and reviving interest in ribosomes.7-10 By this time, 
it was clear that the ribosome, composed of RNA and protein, was capable of performing 
translation with the RNA component acting as the catalyzing force for function.  
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1.1.1 Components that form the bacterial and eukaryotic ribosome 
The ribosome is composed of two major subunits, known as the large and small 
subunits, which are characterized by the sedimentation rate known as the Svedberg 
unit.11 Through a process known as ultracentrifugation, a particle's mass, density, and 
size will lead to a specific rate of sedimentation. One Svedberg (S) is equal to 10-13 s, 
and the numerical value associated with a Svedberg unit is in direct relation to rate, not 
weight.  
In the case of the bacterial ribosome, as shown in Figure 1.1, the large subunit is 
known as the 50S subunit and the small subunit is known as the 30S subunit. When the 
50S and 30S subunits associate, they form the full 70S ribosome. The eukaryotic 
ribosome is larger than the bacterial ribosome with a small subunit of 40S and a large 
subunit of 60S, which together comprise the full 80S ribosome. As this thesis work 
focuses exclusively on the bacterial ribosome, all figures and explanations will be in 
reference to the E. coli system. It is important to note, however, that although the 
bacterial and eukaryotic ribosomes differ in overall size, they have many essential 
regions for function that are highly conserved.12  
As shown in Figure 1.1, the large and small subunits of the E. coli bacterial ribosome 
can be further broken down into the individual components, ribosomal RNA (rRNA) and 
ribosomal proteins (rproteins). The 50S subunit comprises 5S rRNA, which contains 120 
nucleotides, and 23S rRNA, which contains 2904 nucleotides. The 50S also contains 34 
rproteins. The 30S subunit is made up of the 16S rRNA, containing 1542 nucleotides, 
and 21 rproteins.13  
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Figure 1.1 Subunits of the E. coli bacterial ribosome.13 (A) The large 50S subunit 
(2AW4), which is composed of 23S rRNA in yellow, the 5S rRNA in red, and 34 rproteins 
in green. (B) The small 30S subunit (2AVY) is composed of 16S rRNA in grey and 21 
rproteins in cyan. (C) Ribosome association of the large and small subunits forms the full 
70S ribosome (2AVY, 2AW4). 
 
As described in Section 1.1, the detailed function of the ribosome was not 
mechanistically understood until the latter portion of the 20th century, and although there 
is still much to learn about this essential organelle, work has been completed to 
determine the order of factors and components necessary for ribosomal assembly. The 
bulk of this work was performed by Masayasu Nomura and co-workers.14 His work 
revolved around the accepted premise that ribosomal subunits are self-assembling. His 
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group performed a series of partial reconstruction experiments in which they would 
systematically remove a factor, or protein, essential to the self-assembly function 
individually. If one macromolecular component is left out, the entire subunit could not 
self-assemble and one could then observe which portions did not assemble. This not 
only provided an order of assembly for each component of the macromolecule, but also 
the significance of individual factors relative to one another. 
1.1.2 Function and significance of the bacterial ribosome 
The central dogma of molecular biology, as illustrated in Figure 1.2, was initially 
described by Francis Crick in the late 1950s to explain the flow of genetic information 
amongst living organisms, and later published in the early 1970s. To summarize briefly, 
DNA first produces complementary DNA through a process called replication. Then, 
DNA can further produce RNA via transcription. Finally, RNA produces proteins through 
a process called translation.15 Translation is performed by ribosomes, in which the 
reaction is catalyzed primarily by RNA. Ribosomes are therefore essential for cellular 
vitality. 
 
Figure 1.2 The central dogma of molecular biology.15 This chart shows the flow of 
genetic information as expressed by living organisms. DNA can undergo replication to 
produce more DNA, and RNA can undergo reverse transcription to make DNA. DNA can 
also produce RNA through a process called transcription. RNA can make proteins 
through translation.  
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The biological role of the ribosome was first understood by Paul Zamecnik when he 
used carbon-14 labeling of amino acids and found them incorporated into proteins when 
studying the ribosome.16 He was later credited with the discovery of tRNA, an intricate 
part of the translation system.17-19 
Ribosomes perform protein synthesis in a finite series of steps, namely, initiation, 
elongation, and termination, in an overall process known as translation. As shown in 
Figure 1.3, initiation begins when the 30S subunit encounters a single-stranded mRNA 
transcript. This encounter occurs when the 30S is charged with fMet-tRNAfMet. The 
recognition of the codon AUG is not the only step necessary to begin initiation. The 
mRNA transcript must also have the Shine-Dalgarno sequence20 incorporated 
approximately 10 nucleotides upstream of start codon sequence. This sequence is 
purine rich and complements a pyrimidine-rich "anti-Shine Dalgarno" sequence located 
on the 16S rRNA.20  
This binding motif allows the 30S to identify the correct start codon of the mRNA 
transcript for translation. Initiation factors are also crucial, as they are responsible for re-
activating 70S ribosomes for protein synthesis. In bacteria, there are several monomeric, 
water soluble protein factors that aid translation. Initiation factor one (IF-1) assists 
initiation factor three (IF-3) in binding to the 30S subunit of an inactivated 70S ribosome 
to promote subunit dissociation. IF-3 then recruits new mRNA to bind the 30S.  
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Figure 1.3 Translation initiation of the bacterial ribosome. A) An inactivated 70S 
ribosome is approached by IF-3, which promotes subunit association. IF-3 remains 
bound to the 30S subunit. B) An mRNA with the start codon AUG and Shine-Dalgarno 
sequence upstream of the start codon sequence is recruited to the 30S subunit along 
with IF-1 and IF-2-GTP-fmet-tRNAfMet complex. This combination forms the 30S initiation 
complex. C) IF-1 and IF-3 are released, allowing for subunit association, and hydrolysis 
of GTP releases IF-2.  The 70S initiation complex is formed, allowing for elongation to 
begin. 
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Initiation factor two (IF-2) complexed with GTP, fMet-tRNAfMet, and mRNA is then able 
to bind to the reactivated 30S subunit (as described earlier in conjunction with the 
complement binding of the Shine Dalgarno – anti-Shine Dalgarno sequences). IF-1 
binds to the aminoacyl-tRNA site (A site), located in h44 of the 30S subunit,12 to prevent 
premature binding of tRNA. IF-3 then proceeds to destabilize any tRNA that lacks the 
three G-C base-pairs of the anticodon stem of the fMet-tRNAfMet in order to discriminate 
between matched and mismatched codons. This step prevents the incorporation of 
erroneous tRNAs. 
Once the appropriate AUG start codon is coupled with the fMet-tRNAfMet, IF-1 and IF-3 
dissociate from the 30S subunit allowing subunit association with the 50S to occur.21-22 
When subunit association takes place, IF-2 is stimulated causing hydrolysis of its bound 
GTP. A conformational change of the 30S releases IF-2. 
To briefly summarize translation initiation, the focus is on the activation of the 30S 
subunit before any subunit association with the 50S subunit occurs. This process works 
to identify the start sequence of an mRNA transcript. There are three protein factors 
responsible for facilitating this process, which are summarized in Table 1.1. 
Table 1.1 Proteins responsible for translation initiation in bacteria 
Initiation Factor Function 
IF-1 Assists binding of IF-3 to the 30S subunit 
of the inactivated 70S ribosome. It also 
binds to the A site, preventing tRNAs from 
prematurely binding. 
IF-2 Acts as a GTPase and aids in the binding 
of the initiator fMet-tRNAfMet and GTP to 
the 30S subunit. 
IF-3 Releases mRNA and tRNA from the 30S 
subunit of the inactivated 70S ribosome. It 
also facilitates new mRNA binding and 
prevents premature binding of tRNA. 
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 The second stage in translation is known as elongation, which works in a cyclic 
fashion requiring three main steps with the end goal of producing growing peptide 
chains. These steps are decoding, transpeptidation, and translocation. As shown in 
Figure 1.4, decoding occurs when EF-Tu-GTP binds to an aminoacyl-tRNA.23-24 This 
complex can then bind to the ribosome. Hydrolysis of GTP in this complex facilitates 
binding of the aminoacyl-tRNA to the ribosomal A site. This binding event is based on 
codon-anticodon complementarity, and when the complex forms, EF-Tu and hydrolyzed 
GDP are released. EF-Tu facilitates tRNA binding in an efficient manner.25-26 GDP is 
replaced by EF-Ts, allowing for a new GTP to bind EF-Tu (thereby re-releasing EF-Ts). 
To clarify, EF-TS works to recycle EF-Tu for elongation by removing the hydrolyzed 
GDP and recruiting a fresh GTP. 
 
Figure 1.4 Translation elongation of the bacterial ribosome. Elongation is broken 
down into three steps: decoding, transpeptidation, and translocation. These steps work 
in a cyclic fashion in conjunction with the three elongation factors (EF-Tu, EF-Ts, Ef-G, 
not pictured) until the polypeptide is complete.  
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The second major step of elongation is transpeptidation.27-29 Peptide-bond formation 
occurs during this process. Bond formation occurs with the nucleophilic displacement of 
the tRNA bound to the peptidyl transferase-tRNA site (P site) by the amino group of the 
aminoacyl-tRNA in the A site. The peptidyl transferase center (PTC) is located entirely in 
the 50S subunit and is the sole region where peptide-bond formation occurs. 
The third and final step of elongation, prior to cycling back to decoding, is 
translocation, in which the uncharged tRNA in the P site is transferred to the exit site (E 
site). At the same time, the peptidyl-tRNA in the A site is moved to the P site, which 
allows the ribosome to repeat the elongation cycle for the next amino-acylated tRNA. 
Translocation works in a ratchet-like motion between the 30S and 50S subunits.30-32 
Note that ratchet-like motion refers to the tool known as a ratchet, which is latched onto 
a socket. The socket will rotate a bolt into a continuous clock-wise or counter-clockwise 
motion. It's important to understand that the ratchet tool itself only moves in a repetitive 
forward-reverse motion and does not actually make the full revolution that the socket 
makes in order to tighten or loosen the corresponding bolt. When the motion of the 
ribosome is referred to in a ratchet-like motion in this report, please note that the two 
subunits are moving back and forth analogous to the ratchet tool, not in continuous 
revolution as in the function of the socket.  
Translocation is facilitated by EF-G.33-34 EF-G is able to promote translocation through 
GTP binding and hydrolysis, just like EF-Tu had done earlier in the elongation cycle. In 
fact, EF-G and EF-Tu have a very intricate balance as they bind to the same site of the 
ribosome, and so only one process can occur at any given time point within a single 
ribosome. Table 1.2 summarizes the proteins responsible for elongation. Note that these 
proteins have eukaryotic analogues not discussed in this report. 
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          Table 1.2 Proteins responsible for translation elongation in bacteria 
Elongation Factor Function 
EF-Tu Binds the aminoacyl-tRNA and GTP  
EF-Ts Displaces GDP from EF-Tu 
EF-G               Stimulates translocation through GTP binding and 
hydrolysis 
 
The third and final stage of translation, termination, occurs when the ribosome 
encounters a stop-codon sequence. In this case, there are three possible codons, unlike 
that of the single start-codon sequence that contains one possible code. In bacteria, the 
stop-codon possibilities are UAA, UAG, and UGA, and when the ribosome encounters 
any one of those three codes, there are no aminoacylated tRNAs that complement those 
codons. As shown in Figure 1.5, this event stimulates the release of the polypeptide 
chain, which can then move on to fold into a functional protein. The ribosome then 
begins the cycle again by dissociating into the 30S and 50S subunits. In order to 
facilitate termination, proteins known release factors work to recognize the termination 
codon sequences. RF-1 recognizes UAA and UAG. RF-2 recognizes UAA and UGA.35-36 
These factors facilitate the release of the newly synthesized peptide. RF-3 complexed to 
GTP then binds to the ribosome and induces hydrolysis.37-38 This step allows the release 
of RF1 or RF2 based on the termination sequence.  
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Figure 1.5 Translation termination of the bacterial ribosome. The release factor one 
(RF-1) or release factor two (RF-2), not shown, recognize the stop codon UAA. This 
stimulates the recruitment of RF-3 bound to GTP, which, upon hydrolysis, recruits EF-G 
bound to GTP and the ribosome recycling factor (RRF) upon its release. Upon a second 
hydrolysis of the GTP bound to EF-G, the mRNA, remaining tRNA, and termination 
factors are released, leaving an inactivated 70S ribosome. 
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Ribosome recycling factor (RRF) can then bind to the A site in conjunction with EF-G-
GTP complex.37 The hydrolysis of EF-G allows RRF to be translocated to the P site, in a 
similar fashion described in the elongation segment of this process, which shifts the 
remaining tRNAs out and into the E site. This process ultimately releases the RRF and 
hydrolyzed EF-G-GTP complex with mRNA, leaving behind an inactive 70S ribosome. 
All of the termination proteins responsible for translation termination in bacteria are listed 
in Table 1.3. 
Table 1.3 Proteins responsible for translation termination in bacteria 
Termination Factor Function 
RF-1 Recognizes UAA and UAG stop codons 
RF-2 Recognizes UAA and UGA stop codons 
RF-3 Releases RF-1/RF-2 through GTP hydrolysis 
RRF In conjunction with EF-G to induce subunit 
dissociation 
 
The inactive ribosome can be recycled by reactivation with the binding of IF-3 as 
described in the initiation portion of the translation process and an entirely different 
protein can be synthesized. Note that translation as described here does not account for 
exceptions such as the engineering or incorporation of non-canonical or modified amino 
acids or different charged tRNAs with variable codon sequences outside the genetic 
code. These exceptions will not be covered in this work; although, it is important to note 
that they do exist.39-40 Without the ribosome's ability to carry out translation, new proteins 
could not be made. These proteins are very diverse and are synthesized based on the 
cell's need for them in order to survive. Organisms need living cells to survive, making 
ribosomes significant for organism vitality. 
1.1.3 Ribosomal RNA structure and modifications 
Ribosomal RNA is essential due to its catalytic activity in protein synthesis. Although 
this fact wasn't readily realized when the ribosome function was initially discovered, it 
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was later found that removing rproteins from ribosomes followed by activity assays 
provided evidence that the rRNA was responsible for the catalytic activity.41-42 
Information on rRNA expanded greatly when the secondary structures of the 5S (Figure 
1.6), 16S (Figure 1.7), and 23S rRNAs (Figure 1.8) were determined.12, 43-44 Finally, 
solving the crystal structures of ribosomes verified the role of rRNA as the catalytic 
domain for translation.45-57 
 
Figure 1.6 Secondary Structure of the 5S rRNA. This figure was adapted from the 
Comparative RNA Website (CRW) established by the Gutell laboratory.12 The 5S rRNA 
does not contain modifications and is part of the 50S subunit.  
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Figure 1.7 Secondary Structure of the 16S rRNA. This figure was adapted from the 
Comparative RNA Website (CRW) established by the Gutell laboratory.12 Domain 
nucleotide allocations were determined from Woese and coworkers43 and work from Xu 
and Culver.44 Modified RNA nucleotides are labeled with arrows in each of the four 
domains according to their assigned color; for an example, modifications found in 
domain I are visualized with red arrows. Literature responsible for modification 
determination and discovery can be found in Table 1.4. 
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Figure 1.8 (shown on two pages) The secondary structure of the 23S rRNA. This 
figure was adapted from the Comparative RNA Website (CRW) established by the Gutell 
laboratory.12 Domain nucleotide allocations were determined from Steitz and coworkers58 
and work from Gutell and Noller.59 Modified RNA nucleotides are labeled with arrows in 
each of the six domains according to their assigned color; for an example, modifications 
found in domain II are visualized with blue arrows. Literature responsible for modification 
determination and discovery can be found in Table 1.5. 
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Ribosomal RNA was also discovered to contain modified bases that were incorporated 
post-transcriptionally. References correlating to each of these modifications can be 
found in Table 1.4 and Table 1.5. Of these 35 modifications within the 23S and 16S 
rRNAs, approximately two-thirds of them are classified as methyltransferases. The 
remaining third are pseudouridine synthases, an enzyme isomerase classification. 
Removing these modifications have been shown to diminish function60-61 such as subunit 
association.62 Table 1.4 gives a list of all of the modifications present in E. coli 16S 
rRNA. Included in the table are the enzymes responsible and their classification (MT: 
methyltransferase; PS: pseudouridine synthase). Table 1.5 gives the same information 
for the 23S rRNA modifications. The 5S rRNA does not contain modified bases. 
Table 1.4 Nucleotide modifications in E. coli 16S rRNA 
Base Modification Position Enzyme Enzyme 
Class 
References 
G m2G 966 RsmD MT 63-66 
G m7G 527 RsmG MT 67-69 
G m2G 1207 RsmC MT 64-65, 70-72 
G m2G 1516 RsmJ MT 64, 71, 73 
C m5C 967 RsmB  MT 74-76 
C m5C 1407 RsmF  MT 77-79 
C m4Cm 1402 RsmH MT 80-81 
A m26A 1518 RsmA MT 82-88 
A m26A 1519 RsmA MT 82-88 
U m3U 1498 RsmE MT 89-90 
U Ψ 516 RsuA PS 91-93 
MT: methyltransferase; PS: pseudouridine synthase 
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Table 1.5 Nucleotide modifications in E. coli 23S rRNA 
Base Modification Position Enzyme Enzyme 
Class 
References 
G m1G 745 RlmA(I) MT 94-96 
G m2G 1835 RlmG MT 64, 97-98 
G m7G 2069 RlmKL  MT 64, 99-101 
G Gm 2251 Mrm1  MT 102 
C m5C 1962 Rlml  MT 103-105 
C Cm 2498 RlmM MT 81, 106 
C s2C 2501 - - 107 
A m6A 1618 RlmF  MT 108 
A m6A 2030 RlmJ MT 109-110 
A m2A 2503 Cfr  MT 111-117 
U Ψ 746 RluA PS 118-123 
U m5U 747 RlmCD MT 124 
U Ψ 955 RluC  PS 125-128 
U Ψ 1911 RluD  PS 127, 129-135 
U Ψ 1915 RluD  PS 127, 129-135 
U m3Ψ 1915 RluH  MT 132, 136-137 
U Ψ 1917 RluD  PS 127, 129-135 
U m5U 1939 RlmD  MT 138-141 
U D 2446 - - - 
U Ψ 2457 RluE  PS 142-143 
U Ψ 2504 RluC  PS 125-128 
U Um 2552 RlmE  MT 144-148 
U Ψ 2580 RluC  PS 125-128 
U Ψ 2604 RluF  PS 142, 149-150 
U Ψ 2605 RluB  PS 142, 151 
MT: methyltransferase; PS: pseudouridine synthase 
 
1.1.4 Antibiotic resistance associated with targeting bacterial ribosomes 
Antibiotic resistance is an increasing problem in the medical world, leaving previously 
potent drugs unusable to treat common bacterial infections.152  Approximately half of the 
known antibiotics target the bacterial ribosome; however, target modification at the rRNA 
level is a common mechanism leading to resistance.153 To add to this problem, many of 
the current antibiotics have overlapping binding sites on the ribosome, leading to 
multidrug resistance as illustrated in Figure 1.9. The bacterial ribosome is an ideal drug 
target because it is an essential organelle needed for cell survival.  
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Figure 1.9 Antibiotic binding locations on the 50S and 30S bacterial subunits. The 
50S subunit (left, yellow, 2AW4) has the peptidyl transferase center (PTC) highlighted in 
light purple mesh and helix 69 (H69) in cyan mesh. The 30S subunit (right, grey, 2AVY) 
has the aminoacyl site (A site) in red mesh. The following color codes are used: (left, 
50S) red, thiostrepton;154 green, avilamycin;155 blue, macrolide antibiotics;156 purple, 
streptogramin A,156 and burgundy, thermorubin on H69;157 (right, 30S) blue, 
tetracycline;158 purple, pactinomycin;159 orange, hygromycin;159 red, spectinomycin B;160 
green, aminoglycoside antibiotics;161 burgundy, thermorubin.157  
 
The antibiotic resistance problem is associated with several issues, which is why it is 
so difficult to overcome this challenge. These issues include the general non-compliance 
of patients when it comes to sticking to antibiotic regiments. Many people stop taking 
antibiotics when they feel better, which gives remaining bacteria the opportunity to 
develop a tolerance to these drugs. Another issue involves over-exposure of antibiotics 
in everyday items like soap and food. One such example is triclosan, an antibiotic that's 
been used in everyday commercial products such as detergents, soaps, and toothpaste 
for the past 30 years.162 It was initially used as a pesticide and found to be present in 
over 75% of human urine samples tested in 2008.162 The last major issue contributing to 
resistance is general bacterial exposure. From an evolutionary standpoint, bacteria will 
develop resistance to toxins, or antibiotics, produced from other bacteria in order to 
survive their own environment. Most of the antibiotics known to us today were derived 
from natural products produced by bacteria. In efforts to avoid problems already 
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associated with antibiotic resistance in regards to the ribosome, the challenge is to 
identify novel regions that are still crucial for overall function but not currently targeted by 
natural compounds. 
1.2 The 23S ribosomal RNA and helix 69 
1.2.1 The 23S ribosomal RNA domains 
The 23S rRNA is located within the 50S large subunit as shown in Figure 1.1A. It 
contains 2,904 nucleotides13 and is subdivided into six different domains.59 Although the 
literature shows the domain nucleotide allocations at slightly different locations,163 the 
nomenclature developed by Steitz and coworkers58 in conjunction with Noller and 
Gutell59 is used in this thesis (Figure 1.8). Within the 23S rRNA of the bacterial 
ribosome, there are 25 modifications to the canonical RNA base (Table 1.5).164-167 
Nearly half of these modifications are pseudouridine, modified post-transcriptionally by 
various pseudouridine synthases, of which nine are located within domains II, IV, and V.  
 
1.2.2 Helix 69 interactions and modifications associated with its structure 
Helix 69 (H69 with a capital H denoting location within the 50S) has a stem-loop motif 
located near the decoding region,55 and is a critical component of the protein synthesis 
machinery.168-169 H69 contains a highly conserved modified nucleotide, pseudouridine 
(Ψ), which plays a role in rRNA structure and function as shown in Figure 1.10. 12, 170-171 
In the bacterial ribosome, these modifications are located in the loop region of H69, and 
there are three pseudouridines present at positions 1911, 1915, and 1917. The 1915-
position Ψ is methylated. 
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Figure 1.10 Secondary structures of H69 analogues. The wild-type bacterial H69 
(left),12 modified (middle), and unmodified (right) analogues were used this work. 
 
Helix 69 is an interesting drug target because its conservation suggests that bacteria 
need it for proper function in essential ribosomal processes. This would theoretically 
mean that a bacterium is less likely to make changes to the structure in order to develop 
resistance mechanisms. The location of H69 at the interface of the ribosomal subunits, 
as shown in Figure 1.11, is also of interest, since developing potent binders for this site 
could disrupt subunit association, a process necessary for ribosome function.  
 
The H69 region of 23S rRNA interacts with important components of the bacterial 
ribosome; it forms intersubunit bridge B2a with h44 (with a lower case h to represent the 
location within the 30S subunit) of the small subunit and has simultaneous interactions 
Figure 1.11 The location of H69 relative to the 70S 
full ribosome and essential translational regions. 
H69, in cyan, is located at the juncture between the 
30S and 50S ribosomal subunits. It makes a direct 
interaction with helix 44 (h44), known as the aminoacyl-
tRNA site (A site), in red. Its proximity to essential 
translational machinery and at the interface of the two 
subunits makes H69 an interesting target for further 
inquiry.  
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with A-site and P-site tRNAs.55, 60 Although conserved across phylogeny,12, 171 the roles 
of H69 are not yet fully elucidated; however, it has been implicated in essential ribosome 
functions such as ribosome recycling,172 tRNA selection,169 translational fidelity,168, 173-174 
and subunit association.60, 134, 175 H69 has three modified bases, two Ψs and one 3-
methylpseudouridine (m3Ψ), which are believed to be important for ribosome function.61, 
170, 175-178 Figure 1.12 shows the structures of these modified nucleosides compared to 
the unmodified uridine.  
 
Figure 1.12 Nucleoside structures of pseudouridine, 3-methylpseudouridine, and 
uridine. Pseudouridine (Ψ, left) is a post-transcriptional modification of uridine (U, right). 
The difference between these two structures is the 120° rotation of the base in 
pseudouridine, forming a C–C glycosidic bond versus the canonical C–N glycosidic bond 
shown in uridine. Three-methylpseudouridine (m3Ψ, middle) differs from Ψ only with a 
methylation on the 3-position of the base. 
 
1.2.3 The roles of helix 69 and antibiotics 
As described earlier in this chapter, H69 has been implicated to have a role in 
essential processes, which makes it an ideal target for antibiotics. What makes this 
particular target challenging is that the exact function(s) and mechanism(s) by which it 
performs its function are not entirely known, offering opportunities to learn more about 
H69. In addition, evidence shows that some antibiotics, namely aminoglycosides179 and 
several peptide antibiotics,180 target H69 as a secondary binding site. More recently, the 
antibiotic thermorubin was found to target H69 directly; however, due to low solubility, it 
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was not available for human use.157 This evidence provides a platform that H69 could be 
a primary target for antibiotics as it does appear that binding, even as a secondary 
target, inhibits ribosomal function. Identifying compounds that target H69 with favorable 
drug properties could prove fruitful in the world of antibiotics.  
1.3 RNA-ligand interactions with peptides 
1.3.1 Peptides as RNA-targeting ligands 
As natural building blocks of proteins, peptides make ideal ligands for targeting 
novel/essential regions of the bacterial ribosome, amongst other cellular machinery, 
because they are less likely to be detected as foreign invaders by an organism's immune 
system. The caveat is that not all peptides make it to their target destination in their 
natural state and most often require modification. This may include the incorporation of 
additional functional groups or direct modifications to the peptide backbone to increase 
their structural integrity, making it difficult for degradation to occur, or additional delivery 
support to increase the likelihood of these ligands reaching their target.181-183  
Because RNA is inherently dynamic with a high degree of conformational variability, it 
is very challenging to design ligands with the specificity and affinity necessary to bind 
effectively to their RNA targets. Ideally one conformation will be more pronounced than 
others, allowing the opportunity for ligands to bind and produce an effect (inhibition). 
Alternatively, the ligand design allows for binding to multiple conformational states. 
Despite these two approaches and the challenges associated with each, peptides have 
been used to target RNA with success.184  
Vancomycin, a complex cyclic glycopeptide that targets gram-positive bacteria, has 
been used as a last-resort antibiotic to fight particularly difficult bacterial infections such 
as methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile.185-186 
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Vancomycin was originally isolated from Amycolatopsis orientalis by Edmund Kornfeld of 
Eli Lilly in 1953.187 Peptide libraries have also been used to identify potent ligands to 
RNA targets.184, 188-189 In other approaches, peptides have been combined with small 
molecules in a fragment-based drug design approach. Compounds previously known to 
target RNA but lost efficacy due to resistance mechanisms have been conjugated to 
peptides for renewed activity.190-192 Further elaboration on a fragment-based drug design 
approach will be addressed in the future directions portion of this work.  
1.3.2 The future of peptides in antibiotics 
Although peptides have been used to target RNA and have also been utilized as 
drugs, they are challenging to work with because of difficulty crossing cellular barriers, 
relatively large size, lack of stereochemical complexity, susceptibility to protease 
degradation, and sometimes poor solubility. Their intended target may be inaccessible to 
solvent or conformationally unavailable for binding. Such obstacles may outweigh the 
desire to use these natural products in biochemical studies; however, peptides, with 
amino acids as their building blocks, have a wide array of functional groups. 
Furthermore, the compounds not limited to just the 20 canonical amino acids, and may 
contain unnatural amino acids. Modified peptide libraries can be generated, increasing 
the number of peptide ligands available to target H69 or other RNA constructs. 
Increasing the complexity of the compound by incorporating different functional groups 
for targeting RNA could enhance binding affinity and selectivity. In addition, changes to 
the peptide backbone such as the production of peptoids can increase cellular 
permeability and make these ligands more "druggable".193-196 
Under the right conditions, peptides could make excellent drugs because as natural 
products, they may not be perceived as a foreign entity and therefore drug resistance 
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would be less efficient. According to Dale Boger, a chemist credited with identifying the 
synthetic route to vancomycin (glycopeptide) production, it took approximately 30 years 
for gram-positive bacteria to begin showing resistance to vancomycin (2013 Spring 
National ACS meeting in New Orleans, LA). 
1.4 Objectives associated with this thesis work 
New functional sites on the ribosome that are not already targeted by current 
antibiotics and have a lower chance of modification need to be identified. For these 
purposes, helix 69 (H69) of the bacterial ribosome 50S subunit will be considered as a 
novel drug target. The stem-loop motif, located near the decoding region,55 is a critical 
component of the protein synthesis machinery.168-169 H69 contains a highly conserved 
modified nucleotide, Ψ, which plays a role in rRNA structure and function.12, 170-171  
To achieve the main goals of this project, three specific aims were developed:  
Aim 1) Peptides that have specificity for bacterial H69 rRNA were identified. 
Variants of the heptapeptide sequence, NQVANHQ, identified from phage-display 
selections,197 were generated by using solid-phase peptide synthesis and the binding 
affinity, selectivity, and stoichiometry were determined using electrospray ionization 
mass spectrometry (ESI MS). 
Aim 2) Biophysical and biochemical properties of the selected peptides were 
determined. Peptides selected for bacterial H69 rRNA binding were characterized 
(affinity, selectivity, stoichiometry) by using biophysical techniques such as ESI MS and 
isothermal titration calorimetry (ITC). Circular dichroism (CD) spectroscopy and 
enzymatic footprinting were also performed to attain biophysical properties of these 
peptides. 
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Aim 3) A dual binding mode of known antibiotics and peptides to helix 69 was 
established. Work performed to identify the dissociation constant of the aminoglycoside 
antibiotic neomycin with H69198 suggested the possibility of a dual binding mode with 
H69 peptides. Information regarding dual binding can be used for the development of 
novel compounds that incorporate both peptide and aminoglycoside components. 
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CHAPTER 2 EXPERIMENTAL DESIGN UTILIZING BIOCHEMICAL AND 
BIOPHYSICAL METHODOLOGIES 
2.1 Abstract 
In order to synthesize and identify novel peptide binders to H69, several biophysical 
and biochemical methods were employed, all of which are discussed in this chapter. 
First, modified variants of the parent sequence NQVANHQ had to be synthesized; 
therefore, solid-phase peptide synthesis will be detailed, followed by a brief description 
of each of the biophysical and biochemical methods used to investigate and characterize 
peptide-RNA interactions. These methods include electrospray ionization and matrix 
assisted laser desorption ionization time-of-flight mass spectrometries, circular 
dichroism, and isothermal titration calorimetry. Purification of each peptide studied was 
performed by using high performance liquid chromatography. Lastly, a screening assay 
was designed to identify RNA-binding peptides from small pool of peptides containing six 
position 1 variants. Background information including adaptations from appropriate 
references will be itemized for each technique along with generic protocols within this 
chapter. Details of individual experiments will be paired with data discussed in other 
chapters in order to reduce unnecessary repetition within this work. 
2.2 Solid-phase peptide synthesis (SPPS) 
2.2.1 Introduction to solid-phase peptide synthesis 
Solid-phase peptide synthesis (SPPS) was first described by Robert Bruce Merrifield in 
a 1963 publication,199 which earned him the 1984 Nobel Prize in Chemistry for "his 
development of methodology for chemical synthesis on a solid matrix".200 This approach 
allows for the orthogonal addition of amino acids on a growing peptide chain anchored to 
a solid support, and was designed to replace solution-phase peptide synthesis. Solution-
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phase peptide synthesis involved a problematic process involving multiple steps, or long 
production profiles, for each addition, which ultimately reduced the yield of the final 
product with each amino acid added. Details of solution-phase peptide synthesis will not 
be discussed within this work.  
In general, SPPS begins on the carboxyl-terminus (C-terminus) and ends on the 
amino-terminus (N-terminus) to maintain the chirality of the side chains of each amino 
acid added. Temporary and permanent protective groups are incorporated to maintain 
control of addition location and to prevent the side chain of each amino acid from doing 
additional chemistry. Once the peptide is completely synthesized, a trifluoroacetic acid 
cocktail containing various scavenger chemicals is added to remove and help prevent 
permanent protective groups from reattaching to the peptide. Solid-phase peptide 
synthesis has the advantage of being performed at room temperature with shorter 
production profiles for each addition of amino acids, allowing for a greater yield of 
product. 
2.2.2 Materials for solid-phase peptide synthesis and purification 
Materials used in this technique included products from Novabiochem (LaJolla, CA), 
an EMD Millipore company (Billerica, MA), such as the amino acids with 
fluorenylmethyloxycarbonyl (fmoc) temporary protective groups as well as  O-(1H-
benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTu) and the 
solid support Rink Amide AM 200-400 mesh. Organic solvents used during the synthesis 
and workup such as dichloromethane (DCM), N,N-dimethylformamide (DMF), diethyl 
ether, diisopropylethylamine (DIPEA), piperidine, trifluoroacetic acid (TFA), 
triisopropylsilane, anisole, and thioanisole were obtained from Sigma-Aldrich (St. Louis, 
MO). Kaiser test reactants such as ninhydrin, phenol, potassium cyanide and ethanol 
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(EtOH) were purchased from Sigma-Aldrich (St. Louis, MO). Pyridine was purchased 
from EMD Millipore (Billerica, MA). Tentagel solid supports, Tentagel HL NH2 HL12902 
75 μm and Tentagel M NH2 10 μm, were purchased from RAPP-polymere (Tübingen, 
Germany).  Acetonitrile (ACN) used during the purification of peptides was purchased 
from Sigma-Aldrich (St. Louis, MO). 
2.2.3 Instrumentation used to perform solid-phase peptide synthesis 
A Burrel Wrist-Action® laboratory shaker (Burrell Scientific LLC, Pittsburgh, PA) was 
used to perform SPPS. The shaker was composed of two arms capable of holding six 
vessels in each arm. Vessels, which varied in size for different scales of synthesis, were 
made of glass and contained a glass frit. The vessels also contained a Teflon stopcock 
and cap. A rubber hose and water vacuum unit was also engineered to safely remove 
organic solvents during the wash steps of SPPS. The entire reaction and all equipment 
and materials were used inside a chemical-safe hood with constant ventilation.  
2.2.4 Protocol of solid-phase peptide synthesis 
Manual peptide synthesis using standard fmoc chemistry199 as the temporary 
protective group was utilized throughout this work. The solid support used varied based 
on the purpose of the synthesis. Peptides used for electrospray ionization mass 
spectrometry, circular dichroism, and isothermal titration calorimetry required amidation 
on the C-terminus (RINK Amide AM 200-400 mesh solid support) to simulate the parent 
sequence identified from the parent structure (NQVANHQ197) from previous phage 
display experiments. Peptides used in the screening assay in which the solid support 
was still required for selection and visualization, were synthesized on a Tentagel solid 
support and the modifications to the synthesis described in this section are highlighted in 
Section 2.8.2.  
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SPPS began with the swelling of the solid support (beads) in DCM. Deprotection of the 
fmoc group from the solid support, when the solid support actually contained a 
temporary protective group, took place using 20% piperidine base in DMF as shown in 
Figure 2.1.  
 
Figure 2.1 Deprotection of fmoc temporary protective group. A chemical scheme 
illustrating how 20% piperidine in DMF solution removed the fmoc protective group from 
the solid support resulting in the availability of primary amine for amino acid coupling.  
 
Beads were washed ten times at 10x resin volume using DMF prior to the addition of 
amino acids containing both temporary fmoc and permanent protective groups, and the 
synthesis took place in DMF. Amino acids were added in order from the carboxyl-
terminus to the amino-terminus. A solution containing 3 eq. of the protected amino acid, 
3 eq. HBTu, and 6 eq. of DIPEA was added to the peptide vessel and shaken for a 
minimum of 2 h. Figure 2.2 gives the chemistry associated with a coupling event using 
fmoc-Gly-OH as the amino acid being coupled to the solid support.  
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Figure 2.2 Coupling of an amino acid using HBTu and DIPEA. The amino acid 
glycine with fmoc protective group is added to the vessel with HBtu and DIPEA. The 
DIPEA deprotonates the carboxyl group of the amino acid producing a negative charge. 
HBTu is then free to couple to the amino acid producing urea as a byproduct. The 
primary amine from the solid support is then able to attack the carbonyl of the HBTu 
bound to the amino acid, freeing the HBTu and coupling to the amino acid. 
 
The fmoc temporary protective groups associated with each amino acid were removed 
with the dilute piperidine solution in DMF and washed ten times at 10x resin volume with 
DMF prior to the addition of the next amino acid. The Kaiser test,201 described in Section 
2.2.5, was also used to determine whether coupling or decoupling had taken place after 
each step in the synthesis. Note that this test works specifically on primary amines and 
the results are qualitative, and should therefore only be used as a general consensus of 
synthesis productivity; that is, since no reaction goes to 100% completion, beads may 
show incomplete coupling/decoupling in a mixture with beads that showed the 
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anticipated result. Additionally, synthesis with anything other than primary amines 
exposed after decoupling, such as proline, gave indeterminate results. 
Once all amino acids were successfully added to the solid support, see Figure 2.3, the 
beads were washed ten times at 10x resin volume each with DMF, DCM, and diethyl 
ether, and allowed to dry overnight. After complete drying, treatment with 94:2:2:2 TFA: 
triisopropylsilane: anisole: thioanisole was used to cleave the permanent protective 
groups from the amino-acid side chains and solid support. An instruction manual from 
Applied Biosystems indicating different combinations of TFA with scavengers, as well as 
information on which protective groups are ideal for the various amino acids, was used 
when planning the synthesis of different peptides.202 Amino acids can be purchased with 
different permanent and temporary protective groups, and although the temporary 
protective groups used in this work was always fmoc,203 literature is available to 
determine which protective groups are ideal for various syntheses.204 The cleavage 
reaction took place at RT for 3 to 6 h. The workup following chemical cleavage involved 
washing away the cleavage cocktail with cold diethyl ether. The liquid contents were 
drained into 50 mL Falcon® tubes containing diethyl ether that was chilled in the -20 °C 
freezer during the length of the cleavage reaction. 
Note that this workup pertains to SPPS reactions with RINK Amide AM resins only and 
the work up with Tentagel resins is explained in Section 2.8.2. With the peptide present 
in the cold diethyl ether, the tubes were balanced, vortexed, and centrifuged at 8,000 
RPM at 4 °C for 6 min which forced the peptide into a tight pellet at the bottom of the 
tube. The diethyl ether was then drained and replaced with fresh cold diethyl ether. The 
pellet was disturbed by vortexing to allow thorough washing with the diethyl ether. This 
process was repeated two additional times for a total of three cold diethyl ether washes. 
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A minimal amount of ddH2O with 0.1% TFA was added to dissolve the peptide pellet, 
and purification (HPLC) and subsequent lyophilization produced the peptide as a white 
powder. 
 
Figure 2.3: General schematic of solid-phase peptide synthesis. SPPS involves the 
addition of individual amino acids with side chains protected with temporary protective 
groups (blue triangles) and permanent protective groups (red triangles), when 
necessary, in an orthogonal fashion. After completion of amino-acid coupling, treatment 
with the trifluoroacetic acid cocktail removes the solid support (grey - for amidated 
peptides discussed in this work) and all permanent protective groups (red triangles) 
yielding the final product.  
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Quantification of the peptide took place by concentrating pure isolated stocks from 
HPLC purification into a pre-weighed, autoclaved, 1.7 mL Eppendorf tube of which a 
final mass would determine how much peptide was available for experiments. In 
addition, the concentration was verified using a Beckman Coulter DU800 
spectrophotometer at wavelength 205 nm. Samples were read in triplicate and 
absorbances averaged prior to using Beer's law for concentration determination.205 
MALDI-TOF MS was used to characterize the peptides for size and purity (Section 
2.3.2). 
2.2.5 Kaiser test used to monitor SPPS progress 
A hot water bath was produced using a 100 mL beaker filled with approximately 75 mL 
of ddH2O and a hot plate. A small amount of beads were removed from the SPPS vessel 
and placed in a 12 x 75 mm Pyrex test tube. The beads were washed three times at 10x 
resin volume with DMF, DCM, and diethyl ether carefully in order leave the beads in the 
tube. The solvent was removed with a glass pipet and the Kaiser test reagents were 
added in the following order using solutions previously prepared and stored in 50 mL 
squeeze bottles capable of being dispensed one drop at a time: 4 drops of solution A 
(ninhydrin 5% w/v in EtOH), 2 drops of solution B (phenol 4:1 w/v in EtOH), and 2 drops 
of solution C (2% v/v of 1 mmol/L aqueous solution in pyridine). The tube was left in the 
hot water bath for 5 min and removed using forceps. Beads were then observed for 
reaction progression. Blue or purple beads indicated incomplete coupling or successful 
deprotection and clear beads indicated complete coupling or unsuccessful deprotection.  
2.2.6   Purification of synthesized peptides 
Purification of peptides was done using high performance liquid chromatography 
(HPLC). This system efficiently separates peptide products with a reverse-phase liquid 
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chromatography column. In this case, a Phenomenox® C18 Luna Column with the 
following specifications - C18, 10.00 x 250 mm, 5 μm, 100 Å - was used for all 
purifications. In order to determine the column volume (CV), the following formula was 
used: C18: π(52)(250) = 19.6 mL/CV. With a flow rate of 5 mL/min, it would take 4 min to 
attain one CV. A Waters HPLC 600 controller with 2996 detector and autosampler was 
used to complete this experimentation. There were four lines available and utilized for 
purification. Line A contained ddH2O + 0.1% TFA (1 mL TFA/1000 mL solvent). Line B 
contained HPLC-grade ACN + 0.08% TFA (0.8 mL TFA/1000 mL solvent). Line C 
contained only ddH2O, and line D contained only HPLC-grade ACN. All solvents were 
degassed for a minimum of 1 h. The sparge rate for pre-degassing was 50 mL/min and 
was maintained throughout the experiment. The program design was based on running 
a minimum of 3 CVs of solvent at each phase.  
Over the course of 85 min, 3 CVs of ddH2O + 0.1% TFA was followed by a 0-30% 
acetonitrile + 0.08% TFA gradient solvent system over the course of 3 CVs. For an 
additional 3 CVs, a 30% acetonitrile gradient was maintained because products with 
permanent protective groups, particularly those with aromatic functionalities, elute off the 
column at this percentage. The column was then returned to its pre-equilibrium condition 
over the course of 3 CVs in order to prepare the column for another peptide injection. 
The program design for purification would sometimes vary depending on the complexity 
of the peptide, but all purification was based on the following program design which 
lasted 1.4 h per run. A blank run prior to each purification took place in order to assure 
that most if not all crude sample was removed to prevent contamination of the next 
sample to be purified.  
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To prep the C18 column for peptide purification and to remove any crude materials 
that might still be in the column from previous experiments, an equilibration program was 
utilized with 3 CVs of pure ddH2O followed by 3 CVs of 0-100% ACN. The ACN, 100%, 
was maintained for 3 CVs before returning to pure ddH2O, 0% acetonitrile, over the 
course of 3 CVs of which this gradient was maintained for an additional 3 CVs. The final 
equilibration step involved introducing ddH2O + 0.08% TFA over the course of 3 CVs 
and this gradient was maintained until peptide purification took place. 
Completion of peptide purification would lead to several 2.0 mL autoclaved Eppendorf 
tubes containing purified samples within an ACN/ddH2O solvent. These samples were 
dried using the speed vac or lyophilizer depending on the amount of material to be dried. 
Analysis using MALDI-TOF MS (Section 2.3) was used to determine purity and 
determination of correctly isolated product prior to conducting any experiments with the 
peptide. 
2.3 Matrix assisted laser desorption ionization time of flight mass spectrometry 
(MALDI-TOF MS) 
2.3.1 Introduction to MALDI-TOF MS instrumentation 
Matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-
TOF MS) is a soft ionization technique capable of producing singly charged ions of 
macromolecules. Like all mass spectrometers, the MALDI-TOF instrumentation contains 
an ion source used to ionize and transfer sample ions into the gas phase. In addition, a 
mass analyzer is used to separate these ions according to their individual mass-to-
charge (m/z) ratio and a detector is present to monitor the separate ionized sample ions. 
MALDI-TOF MS typically requires samples to be prepared with a matrix, which is 
composed of acid molecules that have strong optical absorption in the range of the laser 
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wavelength used in the instrumentation. Figure 2.4 gives an illustration of how a typical 
MALDI-TOF mass spectrometer works. 
 
Figure 2.4 Adaptation of MALDI-TOF MS Instrumentation.206 The sample is mixed 
with the matrix and crystallized on a metal plate. The metal plate is inserted into the 
instrument and bombarded with laser pulses. The pulses cause desorption and 
ionization of the sample, which is then accelerated into an electrostatic field allowing for 
ejection through a metal flight tube under vacuum. While in this tube, sample ions are 
separated by mass with smaller ions traveling faster than large ions into the detector. 
The detector divides ions according to their time-of-flight (TOF), which creates a mass 
spectrum containing analyte information by their mass-to-charge ratio (m/z) in the form 
of peaks with varying intensities.  
 
2.3.2 Materials and method for MALDI-TOF MS instrumentation in peptide 
studies 
The matrix used for all peptide analysis was α-cyano-4-hydroxycinnamic acid 
purchased from Sigma-Aldrich (St. Louis, MO). Matrix was freshly prepared by adding a 
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saturating amount of the yellow powder into a 1.7 mL autoclaved Eppendorf tube 
containing a 1:1 mixture of ddH2O in 0.1% TFA and ACN (Vf = 500 μL). Samples are 
prepared on a MALDI-TOF metal target plate by taking 2 μL of sample into a 0.5 mL 
polypropylene tube of which 2 μL of freshly prepared matrix is added. Contents were 
pipetted up and down to homogenize the sample with the matrix and then immediately 
spotted onto two allocated spots (2 μL each) on the MALDI-TOF metal plate. Samples 
were left to crystallize on the plate prior to insertion of the target into the instrument. 
Three calibration standards were used to ensure accuracy of mass information collected 
from each sample. The standards were purchased from Sigma-Aldrich were  angiotensin 
I (1296.48 g/mol), angiotensin II (1046.18 g/mol), and bradykinin fragment 1-5 (572.66 
g/mol). Peptides in this work were analyzed in the positive-ion reflectron mode with a 
mass range of approximately 500 Da (mass higher than the matrix) to at least double the 
mass of the anticipated mass of the peptide analyzed. This range would account for the 
presence of possible peptide dimers and crude versions of the peptide. 
The MALDI-TOF instrument used for peptide analysis was a Bruker Ultraflex (Bruker 
Daltonics, Billerica, MA) with a 384-well sample plate, reflectron and PSD fragmentation 
capability located in the Lumigen Instrumentation Center, Department of Chemistry, 
Wayne State University. The instrument was capable of resolving isotopes for species in 
the 5000 Da range and had a demonstrated useful mass range from 10 to approximately 
150,000 Da. Positive and negative ion modes were installed and automated acquisition 
of 384 samples were possible. The instrumentation was made available for walk-up use 
by trained users. Since the completion of this work, the instrument described has been 
replaced with an updated version from the same company. 
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2.4 RNAs used in this work 
2.4.1 Synthetic RNA 
Unmodified H69 (H69UUU) RNA with the sequence 5'-GGCCGUAACUAUAACGGUC-
3' (ε, 189,400 L/(mol*cm)), modified H69 (H69ΨΨΨ) with the sequence 5'-
GGCCGΨAACΨAΨAACGGUC-3' (ε, 187,000 L/(mol*cm)), and 5'-biotinylated modified 
H69 (5'-Bi-H69ΨΨΨ) with the sequence 5'-Biotin-GGCCGΨAACΨAΨAACGGUC-3' (ε, 
187,000 L/(mol*cm))  as well as 5'-biotinylated unmodified H69 (5'-Bi-H69UUU) with the 
sequence 5'-Biotin-GGCCGUAACUAUAACGGUC-3' (ε, 189,400 L/(mol*cm)), was 
purchased from Dharmacon (Lafayette, CO).207 RNA was purchased with 2'-deprotection 
and desalted. An additional ethanol precipitation with ammonium acetate was 
performed. Samples were washed in 70% ethanol and dried. Pellets were dissolved in 
minimum amounts of double deionized water (ddH2O), pH 7.0. Concentration 
determination was achieved by producing a diluted sample from the concentrated stock 
and obtaining the absorbance on a Beckman Coulter DU800 spectrophotometer 
(Beckman Coulter, Brea, CA) at 260 nm.  
2.4.2 Transcribed RNA – materials 
RNA transcription was also performed to produce H69UUU. The DNA template and T7 
promoter was purchased from Integrated DNA Technologies (Coralville, IA). The 
H69UUU template sequence used for transcription is 5'-
GACCGTTATAGTTACGGCCTATAGT GAGTCGTATTA-3' (ε, 359, 200 L/(mol*cm). The 
H69 T7 promoter sequence is 5'-TAATAC GACTCCTATAGG-3' (ε, 192, 600 L/(mol*cm).  
Transcription buffer (10x stock): 38 mM spermidine (Sigma-Aldrich, St. Louis, MO), 
101 mM dithiothreitol (DTT) (Fisher Scientific, Pittsburgh, PA), and 800 mM Tris-HCl, pH 
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8.0 (Fisher Scientific, Pittsburgh, PA). The nucleotide triphosphates (NTPs), ATP, CTP, 
GTP, UTP, and GMP, were purchased from Sigma-Aldrich (St. Louis, MO).  
2.4.3 Transcribed RNA – T7 RNA polymerase in vitro transcription 
To perform transcription, the working concentration for the template and primer DNA 
was 0.4 μM and 32 mM Mg2+. A 4x stock of NTPs with GMP, a 16 mM stock solution (4 
mM of each NTP) was produced. For a 1 mL reaction, 100 μL of 10x transcription buffer, 
200 μL of PEG 8000 (40%), 250 μL of 16 mM NTPs (+GMP) solution, 32 μL of 1 M 
MgCl2, DNA template and primer with a final concentration of 0.4 μM, and ddH2O was 
added up to 1 mL final volume. One hundred μL of T7 polymerase was added last. The 
reaction was placed in a 37 °C water bath for 3-5 h. Once the reaction was complete, the 
tube was centrifuged to remove the magnesium pyrophosphate precipitate. An ethanol 
precipitation with sodium acetate (NaOAc) (1 volume (V) of supernatant to 3 V of cold 
EtOH and 0.1 V of 3 M NaOAc) was performed on the supernatant of the transcription 
reaction. The precipitate, which contains the transcribed RNA, was dried in the speed 
vac. The sample was redissolved in loading buffer (9 M urea, 100 mM EDTA) prior to 
loading onto a 20% polyacrylamide denaturing gel (15 cm length x 20 cm wide, 2 mm gel 
thickness, 700 V, 1x TBE buffer, overnight).  
The gel was placed on a fluorescent TLC plate and RNA bands were visualized using 
UV shadowing from a hand-held UV lamp (254 nm). The bands were excised and 
underwent crush and soak conditions (350 mM NaOAc, pH 5.3, 0.1 M EDTA 4°C, 
vertical spinner, overnight). The supernatant was desalted using a Sep-pak column 
(Waters). RNA underwent CIP (alkaline phosphatase, calf intestinal, New England 
Biolabs, Ipswich, MA) digestion to remove the 5' phosphate of full-length RNA, which 
makes the transcribed product identical to its synthesized counterpart used in similar 
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work. Another 20% polyacrylamide gel and subsequent crush and soak and desalting 
step was repeated to attain purified transcribed RNA for experimental use.  
2.5 Circular dichroism 
2.5.1 Introduction to circular dichroism 
Circular dichroism (CD) is based on the differential absorption of circularly polarized 
components of plane-polarized radiation.208 Results that are obtained using CD depend 
on the structures of the samples, therefore their ability to interact differently with right- 
and left-handed polarized light provides global structural information. For a CD signal to 
be obtained, the sample being analyzed must be chiral. In addition to chirality, 
conformation is of extreme importance, as secondary structure information of both 
proteins and nucleic acids is often sought out. Different conformations, such as α helices 
and β sheets in proteins or A form and B form in nucleic acids, have unique CD profiles 
that can be used to analyze unknown or novel biomolecules.  
Compounds with similar structural components, such as secondary structure motifs, 
often demonstrate spectral similarities in CD, thus allowing for global trends to be 
identified.209 Differences in CD spectra can be used to determine global conformational 
changes amongst related biological molecules or during binding events.209 When 
different ligands are bound to a chiral target, changes in the CD spectra relative to the 
individual, unbound target spectrum can often be observed, yielding evidence that a 
binding event with a corresponding change in target conformation has occurred. 
Experiments using CD are of particular importance when high-resolution experiments 
cannot be performed due to increased sample requirements. It is also of great use when 
trying to determine whether high-resolution experiments should be performed if target or 
ligand sample amounts are limited. 
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To process data obtained using CD instrumentation, several equations must be utilized 
to convert raw data to a format that can be understood and compared against.208-211 
During the course of experimentation, unpolarized light information is obtained and is 
associated with reported absorbance, A, values, given that the log of the intensity of the 
incident light, I0, is divided by the intensity, I, after the light has traveled through the 
distance of the medium, as shown in Equation 2.1: 
Equation 2.1:  =    
Using the Beer-Lambert law, Equation 2.2, the distance of the medium, l, is taken into 
direct correlation with the sample concentration and the molar extinction coefficient. 
Equation 2.2:  =  	
 
The change in molar extinction coefficients is further derived based on data correlating 
to the right-handed circular polarized light, rcpl, and left-handed circularly polarized light, 
lcpl. The molar extinction coefficients for the lcpl and rcpl are denoted as εL and εR, 
respectively, in Equation 2.3, as it is shown extrapolated from the Beer-Lambert 
Equation 2.2. 
Equation 2.3: ∆	 =  	  −  	  = (  − /
) 
In the case of Equation 2.3, the molar circular dichroism, Δε, is defined by the difference 
between εL and εR as shown in Equation 2.4. 
Equation 2.4: ε = (εL + εR)/2 
Werner Kuhn further described the anisotropy factor, also known as the dissymmetry 
factor, to address how difficult it is to measure the CD in the region of any given 
absorption band.212 The dissymmetry factor is the ratio of the molar circular dichroism, 
Δε, divided by the molar extinction coefficient, ε, of the unpolarized light (Equation 2.4) 
as shown in Equation 2.5. 
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Equation 2.5: 
∆	
	 = 
(	 	)
(	 	)  
The dissymmetry factor is significant because it addresses the signal, in this case Δε, to 
noise, ε, ratio. The range for the dissymmetry factor is most commonly found around 10-4 
and rarely exceeds 10-2. 
Most CD instrumentation today addresses the molar circular dichroism, Δε, in terms of 
molar ellipticity, θ, which is the angular measurement relative to  ΔA = AL – AR as shown 
in Equation 2.6 and its unit is cm2/dmol.208 The molar ellipticity, θ, is more often than not 
reported over Δε in biochemistry based literature.208 
Equation 2.6: θ = 32.98ΔA 
Molar ellipticity eliminates the contributions given by the pathlength and concentration 
as shown in Equation 2.7.208 
Equation 2.7: [θ] = 100θ/lc = 3298Δε 
2.5.2 Circular dichroism for peptides 
As described in the previous section, generalized information regarding secondary 
structure can be determined using circular dichroism. In the case of peptides, three 
types of secondary structure, α helix, β sheet, and random coil can be identified by using 
circular dichroism.  
The α-helix secondary structure of peptides and proteins is characterized by three CD 
peaks, one positive (π-π*) from 190-195 nm, and two negative shown at 208 nm (π-π*) 
and 222 nm (n-π*), respectively. The β-sheet secondary structure produces one positive 
peak (π-π*) at 195-200 nm and one negative peak that ranges from 215 to 220 nm. 
Peptides without an α-helix or β-sheet secondary structure, known as a random coil, 
tend to have a negative peak at 200 nm (π-π*) and positive peak at 220 nm (n-π*). The 
peaks associated with each secondary structure are illustrated in Figure 2.5.213 
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Figure 2.5: Circular dichroism representation of peptide secondary structure. This 
figure is an adaptation of typical peptide secondary structure data associated with 
circular dichroism experimentation.213 
 
2.5.3 CD instrumentation and materials 
Potassium chloride and sodium cacodylate were purchased from Fisher (Waltham, 
MA). Cacodylate buffer components: 100 mM potassium chloride, 5 mM magnesium 
chloride, 10 mM sodium cacodylate, pH 7.0. A Chirascan CD spectrophotometer 
(Applied Photophysics, Leatherhead, United Kingdom), located in the RNA instrument 
room in the Department of Chemistry, Wayne State University, was used to perform all 
CD experiments. The Chirascan CD spectrophotometer was flushed with N2 gas for 3 h 
prior to warming up the lamp. The lamp warmed up for 1 h prior to use. The wavelength 
range used for binding experiments was 180 to 320 nm to account for peptide and 
nucleic acid ranges. A run with buffer only was used to get a background reading and 
subtracted from each sample. Three complete scans of each sample run in duplicate 
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was done to assure consistent in data collection. Data were exported into a Microsoft 
Excel file which was used to process the data and create graphical figures. 
2.5.4 Protocol for circular dichroism spectroscopy of peptides 
To perform binding studies with amidated peptides and RNA, a 10х stock of CD buffer 
containing 10 mM potassium phosphate buffer, pH 7.0, and 100 mM potassium fluoride 
was produced. Individual peptides were incubated with 25 μM of renatured RNA. 
Samples with a final volume of 220 μL were placed in a quartz cuvette and data 
collection took place on a Chirascan CD spectrophotometer. Prepared samples were 
lightly mixed and incubated at 37 °C for 15 min. Samples were stored on ice until data 
collection took place. All experiments were performed in duplicate with three complete 
scans of each sample.  
2.6 Isothermal titration calorimetry (ITC) 
2.6.1 Introduction to isothermal titration calorimetry 
Of the biophysical chemistry techniques available, isothermal titration calorimetry (ITC) 
is a direct, highly accurate form of measurement of the heat that generated or absorbed 
when two molecules interact with one another.214-215 This technique offers data with 
biological relevance because samples do not require labels and are not restricted by 
their molecular weights or optical clarity.  Results obtained from this instrumentation are 
highly accurate and absolute dissociation constants (Kd) can be determined.214-215 The 
only major limitation with this technique is the requirement for a large amount of material; 
however, the material can be recovered in the absence of protease/nuclease activity. 
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2.6.2 Isothermal titration calorimetry instrumentation 
The VP-ITC MicroCalorimeter (MicroCal™) (Northhampton, MA) was used for all 
experiments discussed in this report. An electronic feedback circuit is what makes ITC 
possible.214 It controls the heating elements that surround the reference and sample 
cells. When titrant, located in a specialized syringe with rotating spinner, is added to the 
titrate, located in the sample cell, the energy is monitored in order to maintain constant 
temperature of the reference and sample cells. This provides information regarding heat 
or energy, depending on the instrumentation, associated with each point of the titration. 
From this information the binding enthalpy can be determined when the cell volume and 
reactant(s) concentration is known. Figure 2.6 shows a schematic diagram of the ITC 
instrumentation. 
Figure 2.6 Schematic diagram of 
isothermal calorimetry 
calibration.214-215  This figure was 
adapted from a review written by Dr. 
Andrew Feig.215 Heat is monitored 
within the adiabatic jacket 
surrounding the sample and 
reference cells. As titrant is 
incrementally added, the stir bar 
constantly mixing the titrate, and final 
solution, absorbs or gives off heat. 
This causes changes in heat 
produced by the electronic feedback 
circuit in efforts to maintain 
temperature. When an energy 
change occurs, the change in 
temperature can be monitored giving 
thermodynamic information regarding 
the combination of the two samples. 
Depending on the instrumentation 
available, heat can be measured 
either by the change of temperature 
or the change in energy. The energy identified by the instrumentation is converted into a 
binding enthalpy and can be interpreted if the cell volume and the concentration of the 
reactants are known. 
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2.6.3 Protocol of isothermal titration calorimetry 
A Microcal Inc. ITC instrument (Northampton, MA) was used to complete all 
experiments. The experiments were conducted as previously described.216 Very briefly, 
the sample cell was passivated with 1 L filtered ddH2O, pH 7.2, followed by 1 L of 1x 
phosphate buffer A (10 mM potassium phosphate, 100 mM KCl, pH 7.2) or 1 L of 1x 
phosphate buffer B and the reference cell was filled with degassed water. The RNA and 
peptide were previously purified using the HPLC, was dried and re-suspended in 1x 
phosphate buffer (A or B). The RNA was renatured prior to all experimentation. RNA and 
peptide samples were degassed in a Thermovac (Northhampton, MA) at 25 °C for 8 min 
prior to loading the sample cell and syringe. The experiment was carried out at 25 °C. A 
typical experiment would have 18-25 injections (10 μL) with a duration of 30 s, and a 
spacing at 300 s per injection. The reference power was maintained at 29 μcal/sec. The 
concentrations of the RNA and peptide varied dependent on the experiment. Details can 
be found in Chapter 4 of this work. 
2.6.4 Isothermal titration calorimetry data analysis 
Data analysis involves consideration of several parameters utilized during the 
experimentation. When data are obtained, the information is systematically processed 
using ORIGIN software (MicroCal Inc., version 7.0, Northhampton, MA)). The software 
normalizes the heat of binding relative to the ligand concentration. Based on the data 
collected, systematic processing sets the baseline, performs a volume correction based 
on the dilution of the titrate during each injection, and integrates each peak from the 
baseline before the binding model is selected for final processing. Results obtained from 
the initial analysis can give information regarding dissociation constants, thermodynamic 
profiles, and can also be used to troubleshoot experimental problems such as buffer 
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mismatch and nuclease contamination.214-215 Results were exported as an ASCII file and 
figures were created using Microsoft Excel. 
One of the first parameters to address when data are obtained is how to remove 
irrelevant data pertaining to background heats. Since the observed enthalpy (ΔHobs) is a 
collective measurement of all heat sources within the sample cell, information will 
include binding data as well as background.214-215 There are two accepted methods 
utilized to remove background thermodynamic information, each with pros and cons to 
using them.214-215 The first would be to incorporate additional injections to the overall 
experiment in order to reach a saturation of the titrate and titrant. This information is then 
subtracted from the experimental run saving material and time. The limitation with this 
method is that the material used in the experimentation may undergo differences in their 
thermodynamic profile, which would then be construed as a result for the overall 
experiment. The second accepted method is to run a background heat omitting the 
titrate and injecting titrant into the buffer only. Although this method takes additional time 
and material, the material may be recovered for future experiments as long as 
degradation or contamination does not occur. In addition, if the titrate underwent any 
aggregate binding, evidence of this would be observed in the results. For the purpose of 
all experimentation associated with this work, the latter method was utilized to first 
observe titrant (peptide) behavior since ESI MS data did show greater than 1:1 binding 
stoichiometry for some H69 peptides. The peptide was recovered and re-purified to omit 
excess salts present in the buffer from interfering with future runs.  
The integrated data from the experiment are derived from deflections from the baseline 
as a result of a change in differential power required to maintain the sample and the 
reference cell at the same temperature and integrations of each peak is associated with 
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the heat of each injection (qi).214 Mapping of each integrated peak provides the fractional 
saturation of the binding reaction (F) based on the stoichiometry (n), the total 
concentration of the titrate (MT), the binding enthalpy (ΔH) and the cell volume (V), when 
the concentration of the titrant (BT) is known as shown in Equations 2.8 through 2.10.214-
215, 217-218 
Equation 2.8: '(  = nF+,-./ 
Equation 2.9: 01 − 0 21 +  34564 +
7
58964: + ;
34
564< = 0  
Equation 2.10:'( = =+,-. ;>1< ?@ −  A;@1 −  B34564<C  DℎFGF @ = 1 +  
34
564 + 
7
58964 
The solution obtained from Equations 2.8 through 2.10 can be applied into a non-
linear least squares analysis to solve for the enthalpy (ΔH), the binding constant of the 
reaction (KB), stoichiometry (n), where KB is used to determine Gibbs free energy (ΔG) 
(Equation 2.11) and entropy (ΔS, Equation 2.12).214-215, 217-218 
Equation 2.11: -H =  −IJK=(L3) 
Equation 2.12: -H = -. − J-M  
2.7 Electrospray ionization mass spectrometry (ESI MS) 
2.7.1 Introduction to electrospray ionization mass spectrometry 
Electrospray ionization is a process that converts solutes present in a solution into 
gas-phase ions that can be identified.219-220 This instrumentation can handle a wide array 
of sample types ranging from small compounds to large proteins and nucleic acids. The 
solution contains electrolyte ions that are converted into charged droplets at the heated 
electrospray capillary tip. These charged droplets are further consolidated by solvent 
evaporation, and repeated droplet disintegration forces the charged droplets into gas-
phase ions.221 
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In order to convert solution-phase ions into gas-phase ions, the solution needs volatile 
solvents such as methanol, ethanol, isopropanol, or acetonitrile incorporated into the 
sample preparation. Titrations of the sample material (ligand) to be tested for target 
interactions can provide important binding information. In situations involving equal 
ionization amongst all components in the sample, dissociation constants can be easily 
determined.222 In cases in which ionization of the samples is not equal, relative 
intensities of all charged species can be used to determine relative dissociation 
constants as is the case with peptide-RNA binding studies that will be described in 
Chapter 3. 
2.7.2 ESI MS materials, instrumentation, and method 
Binding studies were performed on a Micromass QuattroLC triple quadrupole mass 
spectrometer with an electrospray/APCI source and Waters Alliance 2695 LC, 
autosampler and photodiode array UV detector (Manchester, UK). This instrument was 
used to analyze polar and high molecular weight compounds ranging from under 100 Da 
to proteins over 80 kDa. The m/z range covers 2 to 4000 Da, but higher MW species can 
be measured since they take on multiple charges. The QuattroLC has an accurate mass 
option, which allows acquisition of mass data at low resolution (0.15 Da, 128 points/Da) 
but high accuracy (within 5 ppm). This instrument was available to trained users; 
however, is no longer available for use following the work described due to permanent 
disrepair. 
Peptides (0 – 120 µM), previously synthesized and purified (Section 2.2), were titrated 
with renatured synthetic H69 RNAs, Section 2.4, (2.7 - 3 µM) in 50% isopropanol 
(Sigma-Aldrich, St. Louis, MO) in ddH2O and ammonium acetate (Sigma-Aldrich, St. 
Louis, MO) (Cf = 150 mM) and incubated for 15 min at room temperature prior to 
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infusion. The spectrum of the infused sample was obtained for the mass-to-charge ratio 
(m/z) range of 1100–2400 to reveal complexes of RNA and peptide, as well as free 
RNA, in the (3-), (4-), and (5-) charge states. Note that complex formation in the (3-) 
charge state was never observed so information from the (3-) charge state (free RNA) 
was not included in the analysis. These values were used to calculate the relative 
dissociation constant, Kd, of the peptide to RNA. The sample (50 – 100 µL) was infused 
with a Hamilton® 100 µL glass syringe at a rate of 6 µL/min. A cone voltage of 40 for 
H69ΨΨΨ and H69UUU and 50 for 5'-Bi-H69ΨΨΨ and 5'-Bi-H69UUU RNA was 
maintained, and the spectra were analyzed with the Mass Lynx® V. 4.0 processor 
program (Waters, Milford, MA). 
2.7.3 Data analysis of ESI MS 
Results were obtained using Mass Lynx® software V. 4.0 (Waters, Milford, MA). 
Smoothing took place for each experiment by selecting the spectrum associated with an 
RNA-only run (in absence of peptide). The peak associated with the (4-) charge state of 
H69 RNA was selected and expanded due to its consistent and dominant presence 
throughout all ESI MS experimentation with H69 RNAs and selected peptides. The value 
associated with the peak width at 50% of the peak height was inserted into the Satvisky-
Golay algorithm.223 The result for the algorithm was then applied toward smoothing the 
rest of the spectra associated with the experiment. The relative fraction bound of RNA 
(Fr) involved taking the peak intensities associated with the (4-) and (5-) charge states of 
the RNA-peptide complex and dividing those values by the total intensities associated 
with the binding complex, as well as free RNA, at the (4-) and (5-) charge states. Peaks 
correlating to salt adducts associated with the binding complex, as well as free RNA, are 
included in this calculation. It is assumed that the peak area is proportional to the 
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concentration of the RNA in solution, and the dissociation constant for each peptide with 
H69 RNAs was obtained by plotting Fr vs. [peptide, μM] using a non-linear curve fitting 
with the quadratic equation (Equation 2.13).222, 224 Plotting of data took place on 
Kaleidograph (version 4.0) software. Equation 2.13 correlates data obtained from free 
RNA (R) relative to the RNA-peptide complex (RP). Peptide (P) is further seen in the 
quadratic portion of this equation. 
Equation 2.13:  
NOP
NQ NQR =  
([O]S [P]S 8T)(([O]S [P]S 8T)UB[O]S[P]S)
VU
1[O]S  
2.8 RNA-peptide fluorescence screening assay 
2.8.1 Introduction to the RNA-peptide fluorescence screening assay 
Screening peptides with ESI MS has yielded helpful information regarding the 
selectivity and affinity of modified heptamers to target RNA; however, the process of 
attaining this information was very time consuming in terms of both the synthesis and 
purification of individual peptides needed to perform the experiments. In many cases the 
peptides screened for dissociation constant determination consumes large amounts of 
peptide and RNA only to find that they are not better binders to the target RNA. It also 
requires a lot of RNA and peptide that cannot be recovered and re-used. This challenge 
has established a need for an assay that can screen libraries of peptide versus individual 
peptides. High-affinity peptides identified from a library-screening assay can then be 
synthesized, purified, and tested for selectivity and affinity can be confirmed. To address 
this challenge, a visual assay using quantum dots (Qdot) as fluorophores, flow cytometry 
as the method to screen hits, and mass spectrometry to identify the screened hits was 
developed. Identified peptides can then undergo binding studies with RNA to determine 
the relative affinity and selectivity. 
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2.8.2 Materials for the visual screening assay and SPPS protocol method 
modifications 
Materials used in this assay include 1x PBS buffer (freshly produced from a 10x stock: 
137 M sodium chloride (Fisher Scientific, Pittsburgh, PA), 2.7 mM potassium chloride 
(Sigma-Aldrich, St. Louis, MO), 100 mM sodium phosphate (Fisher Scientific, Pittsburgh, 
PA), and 18 mM potassium phosphate (Fisher Scientific, Pittsburgh, PA)). Qdot 605 with 
streptavidin conjugate was purchased from Life Technologies (Grand Island, NY). 5'-Bi-
H69ΨΨΨ RNA was purchased and prepared as described in Section 2.4.1. The 3-
amino-3-(2-nitrophenyl)propionic acid (ANP) was purchased from Advanced Chemtech 
(Louisville, KY). 
To test the overall design of this assay, H69 peptides with modifications in position one 
were tested. The rationale is that ESI MS data determined that position one 
modifications yielded both high and low affinity H69 peptides. Based on these findings, it 
is likely that other peptides with modifications at position one will also bind to the target 
H69, which would help test the validity of the assay. In order to first be able to identify 
the individual peptides and test for assay success, seven position 1 peptide variants 
along with individual peptides designed to serve as controls were produced as described 
in Section 2.2.4; however, the workup following the completion of the synthesis was 
modified to attain the product necessary for this work. Since the assay required the 
peptide to remain on the bead, Tentagel bead resin was used for this work. In order to 
identify the peptide post-screening, a photocleavable linker was incorporated during the 
synthesis to allow release of the peptide for later identification. Care was taken to protect 
the product from light exposure by wrapping the synthesis vessel in foil once the ANP 
linker was added to the resin. 
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In efforts to be sure that each bead containing peptide has adequate access to the 
biotinylated RNA and subsequent streptavidin-coated Qdot solution, an additional 
KGGGGG linker was added followed by 3-amino-3-(2-nitrophenyl)propionic acid (ANP, a 
linker cleavable by UV light). The lysine, a positively charged amino acid, would repel 
other lysines on the bead, which was designed to help prevent aggregation of the 
peptides on a single bead. This motif along with a 5-glycine and ANP linker helped 
enable individual peptide access the target RNA.  The ANP linker was incorporated for 
easy release of the peptide for later identification as cleavage produces an amidated C-
terminus of the desired peptide.225  
Since the solid support is not cleaved using the chemicals described in Section 2.2.4, 
peptides used in this project were washed several times with cold diethyl ether with 
water vacuum and shaking while still in the synthesis vessel. They were then washed 
with 1:1 ACN in ddH2O ten times at 10x resin volume followed by ddH2O, pH 7.2, ten 
times at 10x resin volume before being dried and stored at -20 °C in 1.7 mL autoclaved 
Eppendorf tubes wrapped in foil. The seven position 1 peptides were produced in a split-
pool manner and differ from one another by mass and can be identified using MALDI-
TOF MS (Section 2.3.2). Note that identifying peptides in pools containing six at a time 
is not considered efficient, but this approach was used for the purpose of assay design 
and testing, with the future goal of expanding to larger libraries. Table 2.1 represents all 
of the peptide sequences synthesized for this work. The peptides and the corresponding 
expected masses after UV cleavage. 
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Table 2.1 Peptides synthesized for the visual assay 
Peptide 
Chemical 
Formula 
Monoisotopic 
Mass (g/mol) 
Role in visual 
assay 
NQVANHQ-NH2 C32H52N14O11 808.39 positive control 
AAAAAAA-NH2 C21H38N8O7 514.29 negative control 
RQVANHQ-NH2 C34H58N16O10 850.45 
ESI MS selected, 
position 1 variant 
DQVANHQ-NH2 C32H51N13O12 809.38 position 1 variant 
MQVANHQ-NH2 C33H55N13O10S1 825.39 position 1 variant 
FQVANHQ-NH2 C37H55N13O10 841.42 position 1 variant 
GQVANHQ-NH2 C30H49N13O10 751.37 position 1 variant 
PQVANHQ-NH2 C30H53N13O10 755.40 position 1 variant 
SQVANHQ-NH2 C31H51N13O11 781.38 position 1 variant 
 
Although the exact parameters for the completion of this assay were not directly from 
one piece of literature, the bead assay with Qdot usage was adapted from work 
previously reported by Tom Kodadek, Webster Santos, and Gomika 
Udugamasooriya.188, 195, 226-227 Their work primarily used fluorescence microscopes for 
detection, whereas the work discussed in this document uses flow cytometry. Results 
from this experimentation were attained using the Microscopy, Imaging and Cytometry 
Resources Core at Wayne State University, School of Medicine. This service was 
performed by Eric Van Buren, flow cytometry core manager, using a SH800 cell sorter 
(model LE-SH800ZFP, Sony Biotechnology, Tokyo, Japan). A violet laser (405 nm) was 
used to excite Qdot605 and a 600/60 bandpass filter (570-630 nm) was used to capture 
its fluorescence. Forward scatter (FSC) and back scatter (BSC) were generated from a 
blue laser (488 nm). The blue laser was also used to monitor autofluorescence (AF) 
using a 525/50 bandpass filter. A 100 μm sorting chip was used to flow samples through 
for detection and beads that held high fluorescent activity were sorted individually in a 96 
well plate. Low-speed, low-pressure sorting conditions were used (20 psi sheath 
pressure, 26 kHz drop drive frequency).  
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2.8.3 Instrumentation for the visual screening assay - introduction to flow 
cytometry 
Flow cytometry is instrumentation that is capable of measuring and analyzing the 
samples relative size, granularity, and relative fluorescence intensity simultaneously.228-
229 The detector records how the sample, whether it's a cell, particle, or bead in this 
case, scatters incident laser light, which in turn emits fluorescence.  A flow cytometer is 
composed of three essential systems.228-229 The first is fluidics, which is normally the 
buffer, or sheath fluid, which transports samples through the instrumentation in single-
lined format.228-229 The second system, optics, consists of lasers needed to illuminate the 
sample from the fluidic stream.228-229 Optical filters are also utilized in conjunction with 
fluorescently labeled samples to transmit detected signals to the appropriate 
detectors.228-229 The final system, electronics, takes the detected light signals from the 
optical filters and converts them into electronic signals, which are then processed 
computationally.228-229 Figure 2.7 shows a schematic representation of the flow 
cytometry instrumentation. 
Figure 2.7: Flow cytometry 
scheme.230 The sheath fluid, 
system fluidics, shuttles 
samples individually pass the 
laser source, system optics, 
of which the laser in 
conjunction with fluorescence 
filters, provides physical 
information regarding the 
sample. This information is 
converted to electronic 
signals and evaluated using 
system electronics, which 
provides data that can be 
analyzed further. 
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2.8.4 Protocol for the RNA-peptide fluorescence screening assay 
The solid-support Tentagel® M NH2 microbeads were used for this work. These beads 
were 10 μm dried, but when incubated in buffer can swell up to three times in size. As 
long as these beads did not exceed 100 μm in size, they can successfully pass through 
the flow cytometer. The flow cytometer was also accepting of the PBS buffer used 
throughout the binding portion of the experiments preventing dissociation of the 
fluorophore from the peptide synthesized on the solid support. In conjunction with the 
swelling property of the beads, the capacity was approximately 0.2 mmol/g. For any one 
bead, approximately 0.1 fmol of material was available. The seven position 1 variants as 
well as individual peptides specific to this technique were prepared using 0.1-0.15 g of 
solid support and the SPPS protocol described in Section 2.2.4 and work-up 
modifications discussed in Section 2.8.2. After cleavage with the trifluoroacetic acid 
solution containing organic scavengers, the beads still maintain their connection with the 
peptide synthesized on them. The beads were thoroughly washed with cold fresh ether 
to remove residual cleavage solution followed by a 50% acetonitrile solution in double 
deionized water (ddH2O),  followed by thorough washes with ddH2O, pH 7.2. The 
samples were lyophilized to dryness and stored at -20 °C until needed.  
Peptides were incubated with biotinylated RNA at 4 °C in 1x PBS, pH 7.4 for a 
minimum of 1 h on a vertical spinner. The samples were incubated with Qdot 605 with 
streptavidin coating (1 μL of 1 μM stock/100 μL of PBS in sample) for 1 h on a vertical 
spinner at 4 °C. Samples were wrapped in foil to prevent light from damaging the 
fluorophore. After incubation, each sample was washed several times with fresh cold 1x 
PBS to remove any unbound biotinylated-RNA and Qdot. The samples were then 
submitted to the flow cytometry core for selection and sorting. The instrument was set to 
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select for the emission wavelength of the quantum dot (Qdot) that was pre-bound to the 
RNA and subsequently peptide complex.  
Samples from the position 1 variants, along with NQVANHQ and RQVANHQ, were 
sorted into individual wells of a 96-well plate. The plate was exposed to UV light (365 
nm, 1 h) provided by a hand-held lamp allowing for peptide release from the bead 
(Figure 2.8).188, 225  
 
Figure 2.8 Tentagel peptide with ANP linker deprotection scheme. A 10 μm (dried) 
Tentagel® M NH2 microbead is shown with a lysine-(glycine)5 amino acid sequence 
linker followed by the photocleavable ANP linker and desired peptide for the visual assay 
study. After 1 h of UV irradiation (365 nm), the ANP undergoes radical chemistry to 
release the desired peptide with an amide present on the C-terminus. 
 
The lamp was rigged to sit on top of a box containing an open slot to shine UV light 
through. Inside the box was placed over the 96-well plate with samples. The plate was 
lined up directly beneath the UV lamp. Post UV-cleavage, 50 μL of ddH2O was added to 
each well containing sample and allowed to sit at room temperature for 20 min allowing 
the peptide to be released from the plate surface. Each sample was placed in individual 
0.5 mL autoclaved Eppendorf tubes (polypropylene) and dried down in the speed vac. 
Samples were stored in the -20 °C freezer until mass analysis (ESI MS/MALDI-TOF MS) 
could be performed. The solution from each well was analyzed using MS to determine 
the molecular weight. The value obtained from mass analysis was compared to those of 
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the library and the peptide was identified. Figure 2.9 shows a general scheme of the 
visual screening assay. 
 
Figure 2.9 Visual screening assay scheme. The peptide library was incubated with the 
target RNA (5'-Bi-H69ΨΨΨ). After binding, excess RNA was washed away. Fluorophore 
incubation using streptavidin-coated quantum dot (Qdot605) binds to the biotinylated 
RNA. Excess Qdot was washed away prior to flow cytometry experimentation. Flow 
cytometry detects Qdot and sorted individual beads into a 96-well plate (one bead/well). 
UV light (365 nm) reacted with the linker which released the peptide. Mass spectrometry 
was used to determine the mass of the peptide and identification occurred.  
 
Samples used in the experiment along with specific parameters tested are further 
discussed in Chapter 4 of this work.  
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CHAPTER 3 USING ESI MS TO DETERMINE ROLES OF PEPTIDIC SIDE CHAINS IN 
RNA BINDING INTERACTIONS 
3.1 Introduction 
Original selection experiments previously identified NQVANHQ-NH2, referred to as the 
parent sequence, as a moderate binder to H69 rRNA.197 This sequence is hypothesized 
to underrepresent H69 binders due to the implicated role of the target H69 in translation. 
The participation of H69 in translation during the amplification stage of phage display 
makes the identification of high-affinity binders unlikely. To test this hypothesis, an 
alanine and arginine scan of the parent sequence was carried out with two main 
objectives:  
1) to determine which amino acids in specific positions of the parent sequence are 
important for selective and high-affinity binding, and  
2) to determine whether the introduction of a positively charged amino acid, arginine, 
can enhance binding affinity to the negatively charged RNA construct.  
The original selection yielded heptameric peptides, which stands to reason that not all 
residues/positions are necessary for potent binding. Since there are no charged amino 
acids in the original sequence, due to the properties of the phage used in the original 
selection,197 a positively charged amino acid may enhance binding affinity.  
The rationale behind the alanine and arginine scan is simple. Alanine is a non-bulky, 
non-polar amino acid and can be used to determine which positions of the parent 
sequence are important for selective binding and which positions can undergo further 
modifications for enhanced affinity in addition to selectivity. Arginine is a positively 
charged amino acid that may enhance affinity to the negatively charged RNA. Due to 
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limitations of the original selection, peptides containing charged amino acids were not 
identified, leading to the potential for enhanced binding during these modified scans. 
3.2 Peptide synthesis 
3.2.1 SPPS – methods 
The protocol for SPPS was described in Section 2.2.4. The alanine and arginine scan 
syntheses employed approximately 0.2-0.3 mmol of Rink Amide AM resin 
(Novabiochem, LaJolla, CA) for each peptide. Purification of each peptide was done by 
HPLC according to the protocol described in Section 2.2.6, and characterization of the 
purified peptides was done by using MALDI-TOF MS (Section 2.3.2). 
3.2.2 SPPS – results 
Fourteen peptides were synthesized as shown in Table 3.1. Figures 3.1 through 3.14 
demonstrate the purity of each peptide by MALDI-TOF MS. Each figure shows a mass 
range at least twice the mass of the expected peptide in order to rule out the presence of 
crude peptide with incomplete deprotection as well as peptide dimer formation. An 
expanded profile revealed that, in all cases, salt is present, and in most cases, an MH+ - 
15 mass peak (small relative to the MH+) is also present. The MH+ - 15 peak, which is 
prevalent in most of the peptides shown, is likely due to de-amidation within the peptide, 
either in the side chains associated with asparagine and glutamine and/or the amidated 
C-terminus. Protein degradation has been identified in another work, ultimately 
questioning the lifetime of synthesized proteins due to de-amidation of amidated side 
chains of amino acids.231 These results are not surprising, as these peptides are very 
hydrophilic and are often eluted from the HPLC column with a low acetonitrile (ACN) 
gradient (0-5%) where salt is still present. Efforts were made to remove the salt, such as 
injecting the original elutions for further purification or changing gradient conditions and 
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solvent composition (ACN to methanol (MeOH)); however, salt was always present in 
the samples. Monoisotopic and average masses were calculated for each peptide using 
MassLynx V4.0 software. MALDI-TOF MS was performed as described in Section 2.3.2. 
Table 3.1 summarizes the data for each peptide, including the chemical formula, the 
average mass obtained from the positive-ion mode, and the observed masses (of the 
most abundant species). 
Table 3.1 MALDI-TOF MS predicted and observed masses for alanine and arginine 
scans‡ 
Peptide Chemical 
Formula 
Predicted 
Avg. MH+ 
Observed 
MH+ 
Observed 
M + Na+ 
Observed 
M + K+ 
AQVANHQ C31H51N16O10 766.8 766.7 788.9 805.1 
NAVANHQ C30H49N13O10 752.8 752.2 774.2 790.9 
NQAANHQ C30H48N14O11 781.8 781.6a - - 
NQVANHQ C32H52N14O11 809.9 809.6 831.6 847.9 
NQVAAHQ C31H51N16O10 766.8 765.9 - - 
NQVANAQ C29H50N12O11 743.8 743.4 765.5 781.5 
NQVANHA C30H49N13O10 752.8 752.4 774.4 791.3 
RQVANHQ C34H58N16O10 851.9 851.4 873.8 889.9 
NRVANHQ C33H56N16O10 837.9 837.5 859.5 - 
NQRANHQ C33H55N17O11 866.9 866.4 888.6 905.5 
NQVRNHA C35H59N17O11 895.0 894.7 916.3 - 
NQVARHQ C34H58N16O10 851.9 851.1 873.1 - 
NQVANRQ C32H57N15O11 827.9 827.9 849.9 - 
NQVANHR C33H56N16O10 837.9 837.2 - - 
‡ All of the peptides are amidated at the C-terminus 
†The observed masses reported are the most abundant species except 
where noted (a M-15). 
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Figure 3.1 MALDI-TOF MS spectrum for AQVANHQ-NH2. A. AQVANHQ-NH2 with a 
mass range of 550 – 2025 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.2 MALDI-TOF MS spectrum for NAVANHQ-NH2. A. NAVANHQ-NH2 with a 
mass range of 550 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.3 MALDI-TOF MS spectrum for NQAANHQ-NH2. A. NQAANHQ-NH2 with a 
mass range of 550 – 1350 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.4 MALDI-TOF MS spectrum for NQVANHQ-NH2. A. NQVANHQ-NH2 with a 
mass range of 550 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.5 MALDI-TOF MS spectrum for NQVAAHQ-NH2. A. NQVAAHQ-NH2 with a 
mass range of 550 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.6 MALDI-TOF MS spectrum for NQVANAQ-NH2. A. NQVANAQ-NH2 with a 
mass range of 525 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.7 MALDI-TOF MS spectrum for NQVANHA-NH2. A. NQVANHA-NH2 with a 
mass range of 525 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.8 MALDI-TOF MS spectrum for RQVANHQ-NH2. A. RQVANHQ-NH2 with a 
mass range of 400 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.9 MALDI-TOF MS spectrum for NRVANHQ-NH2. A. NRVANHQ-NH2 with a 
mass range of 500 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.10 MALDI-TOF MS spectrum for NQRANHQ-NH2. A. NQRANHQ-NH2 with a 
mass range of 550 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.11 MALDI-TOF MS spectrum for NQVRNHQ-NH2. A. NQVRNHQ-NH2 with a 
mass range of 500 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.12 MALDI-TOF MS spectrum for NQVARHQ-NH2. A. NQVARHQ-NH2 with a 
mass range of 500 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.13 MALDI-TOF MS spectrum for NQVANRQ-NH2. A. NQVANRQ-NH2 with a 
mass range of 500 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide.  
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Figure 3.14 MALDI-TOF MS spectrum for NQVANHR-NH2. A. NQVANHR-NH2 with a 
mass range of 500 – 1650 Da. B. An expanded view of A showing the parent peak and 
corresponding salt peaks for the peptide. 
 
In addition to MALDI-TOF MS, the absorbance of each purified peptide stock was 
checked. Impure peptides most often contain bulky aromatic groups associated with the 
permanent protective groups during the synthesis. Incomplete deprotection during the 
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final cleavage always left traces of these peptides in the crude form, which was 
observed by MALDI-TOF MS. Since MALDI-TOF MS is not quantitative, an argument 
could be made that the presence of crude material is technically possible even if it isn't 
readily visualized on the mass spectrometer. To rule out this possibility, the absorbance 
at 280 nm was measured. Since these peptides do not contain aromatic side chains, a 
reading of zero helped confirm the purity of each one. 
3.3 Binding studies of H69 peptides containing modification 
3.3.1 ESI MS – method  
The goal of this work was to determine the binding affinity and selectivity of 
synthesized H69 modified peptides of the parent sequence in order to identify novel 
tight-binding species. It was also of great importance to study the modified (H69ΨΨΨ) 
and unmodified (H69UUU) H69 RNAs with these peptides in order to determine possible 
binding interactions with modified nucleotides present in H69ΨΨΨ. To determine 
apparent dissociation constants for each peptide, electrospray ionization mass 
spectrometry (ESI MS) was performed with each peptide and H69 RNAs. The method is 
described in Section 2.7.2. Previous studies demonstrated that ESI MS is useful for 
determining apparent dissociation constants between RNA and ligands;197, 216 however, 
note that the ionization efficiencies are not equivalent between the RNA and peptide. 
This means that consideration must be taken into account when processing the data, as 
the decrease of free RNA is not readily seen with increasing concentration of peptide; 
therefore, dissociation constants achieved from this instrumentation are apparent or 
relative and should not be assumed to be absolute. To represent this, Figure 3.15 gives 
a truncated set of ESI MS spectra from a NQVANHQ-NH2 binding study with H69ΨΨΨ. 
One can easily see that the ionization efficiencies are not equal and that the presence of 
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peptide dimer at increasing peptide concentration also plays a role in overall ionization 
efficiencies. Complete titration data for all peptide studies can be seen in Appendix A.  
 
Figure 3.15 Truncated ESI MS spectra of a binding study with NQVANHQ-NH2 and 
H69ΨΨΨ RNA. Over increasing concentrations of peptide, 1:1 binding complexes 
between peptide and RNA can be visualized at the (4-) and (5-) charge states in parallel 
with free RNA peaks at the same charge states. All information obtained from this data, 
including salt adducts, was used to determine apparent dissociation constants. 
 
3.3.2 ESI MS with alanine scan peptides - results 
The data shown in this section revealed that modified peptides often had different 
binding affinities relative to the H69 RNA (H69ΨΨΨ and H69UUU) studied. In addition, 
many of these peptides had dissociation constants that differed from that of the parent, 
revealing that modification to the sequence did impact selectivity. The results from the 
alanine scan are represented as titration curves, in which the relative amount of bound 
peptide (y-axis) is plotted against the peptide concentration (x-axis). The data were fit to 
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a quadratic equation to give the apparent dissociation constant, Kd, as described in 
Section 2.7.3. The data used to make these plots are given in Appendix A. Each plot 
represents a minimum of two separate experiments with each titration point was done in 
duplicate. Note that all peptides used in this study were amidated at the C-terminus. In 
addition, note that the fraction bound values for the data shown were not normalized, 
revealing that saturation was not obtained. Saturation cannot be determined because 
the ionization efficiencies between RNA-peptide complex and free RNA are not equal. 
More often than not, the concentration of peptide-RNA complex is very low compared to 
free RNA, and although complex intensities may increase with increasing peptide 
concentration, the free RNA intensities did not decrease to a measurable degree. 
Increasing peptide concentration also led to the incidence of peptide dimer, which would 
also affect peak intensities of the peptide-RNA complex as well as free RNA, thus 
making it difficult to determine whether saturation occurred. This effect can be observed 
in the data found in Appendix A.    
Binding studies on the parent sequence NQVANHQ-NH2 were performed with both 
H69ΨΨΨ and H69UUU RNAs in order to determine an apparent dissociation constant 
for comparison to the modified alanine and arginine scan results. As shown in Figure 
3.16, NQVANHQ-NH2 has an apparent dissociation constant of 4.6 μM with H69ΨΨΨ 
and 23.6 μM with H69UUU. There is a 5-fold difference in binding affinity favoring the 
modified H69 RNA with this peptide, which is indicative of selective binding. All data in 
this chapter will be compared to the apparent dissociation constant of the parent 
sequence with H69ΨΨΨ RNA, since this RNA most closely represents the wild-type 
RNA. The only structural difference between the two RNAs is the presence of 
pseudouridine (Ψ) in the modified construct at loop residues 1911, 1915, and 1917, as 
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shown in Figure 1.10. Since the only differences between the two RNAs resides in the 
loop region with the presence of modified nucleotides, the evidence supports binding to 
this region of RNA. 
 
 
Figure 3.16 Titration plots of ESI MS data for NQVANHQ-NH2. A. Titration plot for 
NQVANHQ-NH2 bound to H69UUU. The apparent dissociation constant is 23.6 ± 5.4 
μM. B. Titration plot for NQVANHQ-NH2 bound to H69ΨΨΨ. The apparent dissociation 
constant is 4.6 ± 1.7 μM.  
 
Figure 3.17 shows the titration plot from ESI MS experiments for AQVANHQ-NH2 with 
H69UUU with an apparent Kd of 9.9 μM. No binding was observed when this modified 
peptide was titrated with H69ΨΨΨ RNA. AQVANHQ-NH2 was shown only to bind with 
H69UUU, suggesting that position 1 with an asparagine is important for binding to the 
modified H69. 
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Figure 3.17 Titration plot of ESI MS data for AQVANHQ-NH2 with H69UUU. Titration 
plot for AQVANHQ-NH2 bound to H69UUU. The apparent dissociation constant is 9.9 ± 
2.1 μM. No binding was observed with H69ΨΨΨ. 
In the case of NAVANHQ-NH2, apparent dissociation constants revealed selectivity for 
H69ΨΨΨ, with a Kd of 4.6 μM compared to that of H69UUU, with a Kd of 52.8 μM. The 
result is shown in Figure 3.18. 
 
 
Figure 3.18 Titration plots of ESI MS data for NAVANHQ-NH2. A. Titration plot for 
NAVANHQ-NH2 bound to H69UUU RNA. The apparent dissociation constant is 52.8 ± 
9.7 μM. B. Titration plot for NAVANHQ-NH2 bound to H69ΨΨΨ. The apparent 
dissociation constant is 4.6 ± 1.8 μM. 
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Figure 3.19 shows titration data for the peptide NQAANHQ-NH2, which also includes 
information for 1:2 and 2:1 RNA to peptide stoichiometry. The apparent Kd for this 
peptide with H69UUU is 1 μM and 5 μM with H69ΨΨΨ. Although these dissociation 
constants support good affinity for their respective targets, a lack of points at lower 
concentrations of peptide made it challenging to fit the data. In addition, the binding 
stoichiometry also played a role in the binding constant determination, as all information 
was incorporated into the calculation. The absence of valine in position 3 of this peptide 
appears to increase its promiscuity in binding. The binding affinity for H69UUU has 
increased when compared to the parent sequence, therefore selectivity for the modified 
H69 has been compromised. 
 
Figure 3.19 Titration plots of ESI MS data for NQAANHQ-NH2. A. Titration plot for 
NQAANHQ-NH2 bound to H69UUU. The apparent dissociation constant is 1.0 ± 0.5 μM.  
B. Titration plot for NQAANHQ-NH2 bound to H69ΨΨΨ. The apparent dissociation 
constant is 5.0 ± 1.0 μM.  
 
Binding studies with NQVAAHQ-NH2 revealed no observable binding with H69ΨΨΨ 
compared to an apparent Kd of 14.3 μM with H69UUU as shown in Figure 3.20. Since 
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no observable binding was indicated for H69ΨΨΨ, this peptide is selective for H69UUU; 
however, this dissociation constant has a value that matches closely that of the parent 
sequence with H69UUU, suggesting that an asparagine to an alanine modification does 
not enhance affinity nor alter its selectivity for the unmodified RNA; however, based on 
this finding, it appears that position 5 is important for affinity binding to H69ΨΨΨ.  
Of particular interest is the lack of binding associated with NQVANAQ-NH2, either with 
H69ΨΨΨ or H69UUU, which suggests that the presence histidine at position 6 is 
essential for modified or unmodified RNA binding. 
 
 
 
 
Figure 3.20 Titration plot of ESI MS 
data for NQVAAHQ-NH2. Titration plot 
for NQVAAHQ-NH2 bound to H69UUU. 
The apparent dissociation constant is 
14.3 ± 6.5 μM. No binding was observed 
with H69ΨΨΨ. 
 
 
 
 
 
 
Binding studies with NQVANHA-NH2, shown in Figure 3.21, revealed a 13.4 μM Kd 
with H69ΨΨΨ and 47.5 μM Kd with H69UUU. This peptide has a 3.5-fold higher binding 
affinity for H69ΨΨΨ RNA over H69UUU. Although this peptide shows a dominant 
selectivity for H69ΨΨΨ over H69UUU, there is nearly a 3-fold lower binding affinity for 
H69ΨΨΨ when compared to the parent sequence. This result suggests that further 
modifications at position 7 of the peptide may not enhance binding affinity, even if the 
selectivity remains favorable for the modified construct. 
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Figure 3.21 Titration plots of ESI MS data for NQVANHA-NH2. A. Titration plot for 
NQVANHA-NH2 bound to H69UUU. The apparent dissociation constant is 47.5 ± 9.9 
μM. B. Titration plot for NQVANHA-NH2 bound to H69ΨΨΨ. The apparent dissociation 
constant is 13.4 ± 4.7 μM. 
 
To briefly summarize the binding data for the alanine scan, H69ΨΨΨ, in most cases, 
had the greatest affinity over H69UUU for the modified peptides. Thus, these results 
demonstrate that the parent sequence selected by phage display has the potential for 
further improvement with respect to H69 binding and/or selection for modified versus 
unmodified RNA. Position 6 is of particular interest since modification yielded no 
observable binding, suggesting that either histidine is essential for binding in that 
position or perhaps a side-chain with similar properties in that position is necessary for 
binding. Modifications at position 2 revealed greater selectivity for H69ΨΨΨ over 
H69UUU; however, the Kd values were not significantly different than those of the parent 
sequence with the modified RNA. Changes in position 3 led to increased promiscuity in 
binding with greater than 1:1 stoichiometry observed. 
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3.3.3 ESI MS with arginine scan peptides - results 
As shown in the previous section with the modified alanine scan, the arginine scan 
also yielded results pertaining to selectivity and affinity for the two different H69 RNAs, 
further supporting that the introduction of modifications can enhance binding affinity for 
H69 RNAs. These results highlight the advantage of chemical synthesis over phage-
display selection, following initial lead identification by phage display. 
Binding studies with RQVANHQ-NH2, shown in Figure 3.22, revealed a 4-fold greater 
affinity for H69ΨΨΨ, with a Kd of 2.4 μM, compared to H69UUU with an apparent Kd of 
10.0 μM. In addition, this peptide was shown to have a 2-fold greater affinity for H69ΨΨΨ 
over the parent sequence (4.6 μM).  
 
Figure 3.22 Titration plots of ESI MS data for RQVANHQ-NH2. A. Titration plot for 
RQVANHQ-NH2 bound to H69UUU. The apparent dissociation constant is 10.0 ± 4.3 
μM. B. Titration plot for RQVANHQ-NH2 bound to H69ΨΨΨ. The apparent dissociation 
constant is 2.4 μM ± 0.5 μM. 
 
Binding studies with NRVANHQ-NH2, shown in Figure 3.23, yielded very similar 
dissociation constants despite the different H69 RNAs that were used for the binding 
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study. The apparent Kd of 35.5 μM was determined for H69UUU and a Kd > 40 μM for 
H69ΨΨΨ. A dissociation constant could not be determined because of non-specific 
interactions.  This result combined with the alanine scan suggests that modifying the 
peptide at position 2 with a positively charged amino acid, such as arginine, does not 
enhance binding affinity or selectivity.  
Figure 3.23 Titration plots of ESI MS data for NRVANHQ-NH2.  A. Titration plot for 
NRVANHQ-NH2 and H69UUU. The apparent dissociation constant is 35.5 μM ± 4.3 μM. 
B. Titration plot for NRVANHQ-NH2 and H69ΨΨΨ. The apparent dissociation constant is 
greater than 40 μM. 
 
NQRANHQ-NH2 bound to RNA had overlapping masses with the free RNA so 5'-Bi-
H69ΨΨΨ (biotinylated H69) and 5'-Bi-H69UUU were used to distinguish between the 
complex and the free RNA. In studies pertaining to this work, biotinylated H69 was 
shown to have the same binding properties as free H69 with the parent peptide. When 
bound to 5'-Bi-H69ΨΨΨ, as shown in Figure 3.24, the peptide had a dissociation 
constant relatively similar to the parent sequence bound to H69ΨΨΨ. Greater than 1:1 
binding stoichiometry was observed with this peptide, as can be seen in Appendix A. No 
binding was observed with 5'-Bi-H69UUU. Once again, in correlation with the 
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modification of position 3 with the alanine scan, the arginine scan also suggests 
promiscuity in binding when the valine is replaced with a different amino acid. It is 
possible that a non-polar, bulky amino acid could replace valine without a change in 1:1 
stoichiometry.  
 
 
 
Figure 3.24 Titration plot of ESI MS 
data for NQRANHQ-NH2. Titration 
plot for NQRANHQ-NH2 bound to 5'-
Bi-H69ΨΨΨ. The apparent 
dissociation constant is 6.0 ± 2.2 μM. 
No binding was observed with 5'-Bi-
H69UUU.   
 
 
 
 
 
 
 
Binding studies with NQVRNHQ-NH2, shown in Figure 3.25, revealed a nearly 5-fold 
lower affinity than the parent peptide, suggesting that an alanine at position 4 is 
necessary for high-affinity binding. The Kd with H69UUU was 21.7 μM and >20 μM for 
H69ΨΨΨ since non-specific interactions made it impossible to determine an apparent 
dissociation constant. This result suggests that position 4 could play a role in binding to 
H69, although, further work is needed to support this hypothesis. 
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Figure 3.25 Titration plots of ESI MS data for NQVRNHQ-NH2.A. Titration plot for 
NQVRNHQ-NH2 and H69UUU. The apparent dissociation constant is 21.7 ± 5.7 μM. B. 
Titration plot for NQVRNHQ-NH2 and H69ΨΨΨ. The apparent dissociation constant is 
greater than 20 μM. 
 
Binding studies with NQVARHQ-NH2, Figure 3.26, revealed an apparent Kd of 16.5 
μM with H69UUU and no observable binding with H69ΨΨΨ. This result supports the 
previous conclusion that modification with a positively charged amino acid binding to 
occur to the modified H69 construct. 
 
 
 
Figure 3.26 Titration plot of ESI MS 
data for NQVARHQ-NH2 with 
H69UUU RNA. Titration plot for 
NQVARHQ-NH2 bound to H69UUU. 
The apparent dissociation constant is 
16.5 ± 5.5 μM. No binding was 
observed with H69ΨΨΨ. 
 
 
 
89 
 
 
 
Binding studies with NQVANRQ-NH2, Figure 3.27, revealed a 3-fold worse affinity for 
H69UUU, 14.4 μM, compared to H69ΨΨΨ, 4.5 μM. In this case, only the (4-) charge 
state was observed and used in the calculations. Binding between this peptide and 
H69ΨΨΨ, and the parent sequence (4.6 μM) with the same RNA, yielded very similar 
dissociation constants. Perhaps the hydrogen-bonding potentials offered by histidine and 
arginine are important for overall binding to the RNA. With no binding observed with 
alanine at position 6, it's intriguing to speculate the importance of this position for overall 
binding affinity and selectivity. 
 
Figure 3.27 Titration plots of ESI MS data for NQVANRQ-NH2. A. Titration plot for 
NQVANRQ-NH2 and H69UUU. The apparent dissociation constant is 14.4 ± 3.1 μM. B. 
Titration plot for NQVANRQ-NH2 and H69ΨΨΨ. The apparent dissociation constant is 
4.5 ± 1.7 μM. 
 
Binding studies with NQVANHR-NH2, as shown in Figure 3.28, revealed that binding 
with H69UUU and H69ΨΨΨ produced similar dissociation constants, within the error, 
between the two RNAs. This result suggests that the arginine modification at position 7 
does not enhance affinity or selectivity. The dissociation constant is at least 4-fold 
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greater than that of the parent sequence for H69ΨΨΨ. When comparing dissociation 
constants for this peptide and the parent sequence with H69UUU, one will find that they 
are very similar to one another. Due to limited availability of H69ΨΨΨ at the time of this 
experiment, 5'-Bi-H69ΨΨΨ was used to attain this information. 
 
Figure 3.28 Titration plots of ESI MS data for NQVANHR-NH2. A. Titration plot for 
NQVANHR-NH2 bound to H69UUU. The apparent dissociation constant is 20.5 ± 2.8 
μM. B. Titration plot for NQVANHR-NH2 bound to 5'-Bi-H69ΨΨΨ. The apparent 
dissociation constant is 31.8 ± 7.3 μM. 
 
3.4 Summary of alanine and arginine scanning 
Mass spectrometry studies with H69 RNAs and the alanine and arginine scan peptides 
gave informative results regarding which amino-acid positions are important for affinity 
and selective binding. Results from this study also validated the original selection 
process197 with emphasis of binding taking place through the H69 loop region, although 
interactions with the H69 stem cannot be ruled out. This validation is clear when 
comparing apparent dissociation constants between the modified and unmodified H69 
RNA constructs, which is further discussed in Section 3.4.1 and 3.4.2. The results also 
support the fact that peptide ligands can be designed to target RNA containing modified 
nucleotides.  
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Table 3.2 compiles the information from each binding study in addition to providing a 
binding ratio of the averaged Kds from H69ΨΨΨ and H69UUU. The lower the ratio, the 
greater affinity the peptide has for H69ΨΨΨ over H69UUU. H69 RNA binding ratios 
could not be obtained in instances in which binding was not observed or could not be 
obtained due to non-specific interactions.  
Table 3.2 Apparent Kds of alanine and arginine scan peptides with H69 RNAs 
Peptide Kd H69ΨΨΨ, μM Kd H69UUU, μM H69UUU/H69ΨΨΨ 
AQVANHQ-NH2 NBO 9.9 ± 2.1 - 
NAVANHQ-NH2 4.6 ± 1.8 52.8 ± 9.7 12 
*NQAANHQ-NH2 5.0 ± 1.0 1.0 ± 0.5 0.2 
NQVANHQ-NH2 4.6 ± 1.7 22.9 ± 5.6 5 
NQVAAHQ-NH2 NBO 14.3 ± 6.5 - 
NQVANAQ-NH2 NBO NBO - 
NQVANHA-NH2 13.4 ± 4.7 47.5 ± 9.9 3.5 
RQVANHQ-NH2 2.4 ± 0.5 10.0 ± 4.3 4.2 
NRVANHQ-NH2 >40 35.5 ± 10.1 - 
*NQRANHQ-NH2 †6.0 ± 2.2 NBO - 
NQVRNHQ-NH2 >20 21.7 ± 5.7 - 
NQVARHQ-NH2 NBO ‡16.5 ± 5.5 - 
NQVANRQ-NH2 4.5 ± 1.8 14.4 ± 3.1 3.2 
NQVANHR-NH2 †31.8 ± 7.3 20.5 ± 2.8 0.6 
NBO-no binding observed; *2:1 Peptide to RNA stoichiometry observed; †5'-Bi-H69ΨΨΨ 
RNA used instead of H69ΨΨΨ; ‡ Only the (4-) charge state was observed. 
 
In addition to Table 3.2, Figure 3.29 provides a visual representation of binding ability 
of each peptide. The Kd values for each peptide tested were normalized to that of 
NQVANHQ-NH2 with H69ΨΨΨ. The comparison reveals that amino acid substitutions 
can lead to peptides with varying affinity to H69 relative to the parent peptide identified 
from phage display. One peptide (RQVANHQ-NH2) showed almost 2-fold greater affinity 
for H69ΨΨΨ than the parent, whereas seven peptides had more than a 50% reduction in 
affinity (AQVANHQ-NH2, NQVAAHQ-NH2, NQVANHA-NH2, NRVANHQ-NH2, 
NQVRNHQ-NH2, NQVARHQ-NH2, and NQVANHR). Perhaps surprisingly, half of these 
peptides with significantly reduced affinity contained arginine, showing that additional 
positive charge does not necessarily enhance RNA binding. With the exception of one 
peptide (NQAANHQ-NH2), all of the peptides tested had significantly lower affinity for 
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H69UUU compared to H69ΨΨΨ, and five showed enhanced specificity for H69ΨΨΨ over 
H69UUU (NAVANHQ-NH2, NQVANHQ-NH2, NQVANHA-NH2, RQVANHQ-NH2, and 
NQVANRQ-NH2). Note that the plot in Figure 3.29 does not take into account greater 
than 1:1 binding stoichiometries as observed with modifications in position 3. Based on 
this result, RQVANHQ-NH2 provides the best relative binding affinity of the peptides 
tested to H69ΨΨΨ, and good (4-fold) selectivity for H69ΨΨΨ over H69UUU.  
 
Figure 3.29 Bar graph representation of modified peptides and H69 RNAs relative 
to NQVANHQ-NH2 bound to H69ΨΨΨ. The apparent dissociation constant of 
NQVANHQ-NH2 bound to H69ΨΨΨ divided by the apparent dissociation constant of 
each peptide with respective H69 RNA yields a numerical value. Any value above one 
represents a peptide that bound to its target with greater affinity than the parent peptide 
to H69ΨΨΨ. Spaces where no bar is observed represents peptides that produced no 
binding complex with H69 RNA. 
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3.4.1 Peptide binding with H69ΨΨΨ 
 
For H69ΨΨΨ, RQVANHQ-NH2 has a 2-fold better affinity than the parent sequence. A 
positively charged amino acid with H-bonding potential at position 1 enhanced binding, 
whereas replacing the asparagine with alanine, a non-polar, non-bulky amino acid 
abolished binding. This result suggests a specific interaction between asparagine and 
H69ΨΨΨ.  
Replacing position 2 of the parent peptide with alanine did not alter the dissociation 
constant relative to the parent, suggesting that the glutamine in that position may not be 
imperative for RNA binding. Alternatively, there could be a specific interaction with the    
–CH3 functionality of alanine. When position 2 was replaced with an arginine, the 
binding affinity decreased significantly (>10-fold), suggesting that the positive charge or 
long chain on the amino acid impairs the peptide interaction. This result suggests a 
preference for hydrophobic functional groups at position 2 over charged residues.  
Peptides with modifications at position 3, regardless of the composition 
(alanine/arginine), have comparable affinity to that of the parent sequence, suggesting a 
minimal role in H69ΨΨΨ binding. However, greater than 1:1 stoichiometry was observed 
upon RNA binding, which suggests that position 3 in the parent may be important for 
inhibiting peptide-peptide interactions. Since these studies were limited to alanine and 
arginine, it would be of interest to see if other amino acids that are nonpolar and with 
similar levels of bulkiness, such as leucine or isoleucine, can also maintain the 1:1 
stoichiometry and affinity. Interestingly, this position also played a role in specificity for 
modified over unmodified H69 RNA, which will be discussed in the next section.  
Position 4 is an alanine in the parent sequence, so no change was made in the alanine 
scan. A 4-fold lower binding affinity was observed when the residue was modified with 
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arginine, suggesting that alanine (or an amino acid with similar properties) is important 
for binding to H69ΨΨΨ.  
Position 5 variant peptides yielded no observable binding to H69ΨΨΨ, signifying that 
asparagine, or perhaps an amidated amino acid, is essential for binding to H69. 
Replacing the histidine at position 6 with alanine also abolished binding, whereas the 
arginine variant behaved similarly to the parent. Since both side-chains of histidine and 
arginine have hydrogen-binding capabilities, perhaps this attribute is important for 
H69ΨΨΨ binding. Position 7 modifications both led to worse binding to modified H69 
RNA, suggesting the importance of glutamine or other amidated amino acids for binding. 
Although the parent sequence NQVANHQ did not reveal homology with amino acid 
sequences associated with ribosomal recycling factors and proteins with contact sites to 
H69, there are amino acids within the sequence present with individual amino acids of 
the ribosomal recycling factor (V20, H23, N24),172 suggesting that functional groups 
present in the peptides studied are essential for selective binding. 
3.4.2 Peptide binding with H69UUU 
This summary will compare the apparent dissociation constants between peptide 
variants bound to the unmodified version of H69 (H69UUU). Modifying position 1 with 
alanine or arginine led to a 2-fold better affinity to H69UUU in both cases. This result 
differs from that with H69ΨΨΨ, suggesting a specific interaction with the RNA loop.  
Position 2 alterations led to 2-fold worse binding profiles in both cases. This result is 
not necessarily similar to that of H69ΨΨΨ binding, in which a modification with alanine 
led to an equivalent apparent dissociation constant to the parent bound to H69ΨΨΨ. The 
arginine-modified peptide bound similarly to H69ΨΨΨ with overlapping error between the 
two RNAs.  In the case of RNA binding, neither peptide modification bound better than 
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the parent with H69ΨΨΨ, suggesting that position 2 with a glutamine, or similar amino 
acid is important for binding interactions to take place with H69UUU. Position 3 variants, 
when bound with alanine, also yielded results with greater than 1:1 binding stoichiometry 
as observed with H69ΨΨΨ (titration spectra can be observed in Appendix A), despite the 
fact that a higher affinity was identified, further supporting that the valine, or an amino 
acid with similar properties, is needed for binding interactions to occur. 
Position 4 when modified with arginine did not lead to a significant change in binding 
profiles against H69UUU when compared to the same peptide binding to H69ΨΨΨ, 
suggesting that position 4 could be further modified to find potentially better ligands for 
the unmodified RNA. This is further supported when binding is 4-fold worse than the 
parent sequence binding to H69ΨΨΨ. Position 5 variants didn't lead to higher affinity 
ligands (~4-fold worse affinity) compared to the parent sequence suggesting that the 
asparagine and alanine residues are not important for binding to H69UUU. This result is 
interesting because a positively charged amino acid had about the same effect on 
binding as a non-bulky, non-polar amino acid.  
Position 6 (alanine-modified peptide) had no binding to H69ΨΨΨ. Position 7, when 
modified with alanine, led to a peptide with 2-fold lower binding affinity compared to the 
parent bound to H69UUU. Modifying this position with arginine produced a peptide that 
bound with similar binding affinity to that of the parent sequence bound to H69UUU.  
Results pertaining to binding with H69UUU provided evidence of selective binding to 
modified nucleotides; that is, being able to compare directly with H69ΨΨΨ studies 
revealed differences in apparent Kds indicative of selective binding. It would also be 
interesting to have modified peptides selective for the unmodified H69 in order to disrupt 
ribosomal association. Since the modifications on H69 are added post-transcriptionally,12 
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it is hypothesized that these modifications occur prior to subunit association when H69 
exposed for enzymatic activity. 
3.5 Histidine modifications to NQVANHQ-NH2 with H69 RNA binding 
Due to the fact that replacement of histidine with alanine at position 6 led to a complete 
loss of binding to H69, the possible role of histidine in RNA binding was of interest. Four 
additional peptides were synthesized, shown in Figure 3.30, to determine if the 
presence of histidine at positions 5 or 7 of the peptide sequence would enhance RNA 
binding. Two peptides contained an alanine at position 6 in place of histidine, with a 
histidine residue located at position 5 or 7. This would help determine whether histidine 
is needed at position 6 specifically, or if the presence of histidine was sufficient for 
selective and/or strong binding. The other two peptides contained a histidine in position 
6, as with the parent sequence, with an additional histidine at position 5 or 7. These two 
peptides would help determine if the additional histidine had the ability to enhance 
binding affinity for H69.  
 
Figure 3.30 Four histidine-modified peptides were synthesized for binding 
interaction studies. Left, the parent sequence NQVANHQ-NH2 underwent histidine 
modification in positions 5 and 7 to produce NQVAHHQ-NH2 and NQVANHH-NH2, 
respectively. Right, the alanine modified peptide at position 6 underwent further 
modification with histidine at positions 5 and 7 to produce NQVAHAQ-NH2 and 
NQVANAH-NH2, respectively.  
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A one-shot binding study, shown in Figure 3.31, was performed with each of the four 
peptides using 3 μM H69ΨΨΨ and 20 μM of each of the four histidine scan peptides. 
These conditions had been established previously with the parent peptide; therefore, a 
direct comparison could be made regarding relative affinity of the newly synthesized 
peptides and the parent sequence.  
 
Figure 3.31 One-shot binding studies of histidine-modified peptides with H69ΨΨΨ 
rRNAs. Four peptides containing histidine modifications (underlined) relative to the 
parent sequence NQVANHQ-NH2 were tested to determine if binding exists with 
H69ΨΨΨ rRNAs. 
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The peptide NQVAHAQ-NH2 yielded no observable binding to H69ΨΨΨ, so the one-
shot experiment was repeated with 30 μM peptide, producing the same result. This 
finding correlates well with the alanine and arginine scan results, Table 3.2, in which no 
binding to H69ΨΨΨ was observed when modifications were made at position 5. 
Similarly, alanine replacement at histidine of position 6 had abolished binding to 
H69ΨΨΨ. Therefore, binding was not recovered by addition of histidine at the 
neighboring position. Figure 3.31 provided a one-shot profile of the four synthesized 
peptides compared to the parent sequence. The intensity values of the peptide-RNA 
complex were compared, and one peptide (NQVAHHQ-NH2) was a promising compound 
with potentially better binding than the parent sequence. However, a titration with 
peptide NQVAHHQ-NH2 (Cf = 0-60 μM) and H69ΨΨΨ (Cf = 3 μM) was completed 
yielding a dissociation constant of 16.0 ± 3.5 μM (Figure 3.32). This result indicates an 
approximately 3-fold lower binding affinity relative to the parent, providing further support 
that position 5 (N) is important for H69ΨΨΨ binding. 
 
 
 
Figure 3.32 Binding curve for 
NQVAHHQ-NH2 with H69ΨΨΨ. The 
curve for NQVAHHQ-NH2 with H69ΨΨΨ 
has an apparent dissociation constant of 
16.0 ± 3.5 μM. 
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3.6 Conclusions 
This study provides information regarding the development of peptide ligands to 
selectively target H69 RNAs. Although the original selection was for the wild-type H69, 
studying both the modified and unmodified constructs gave further proof that ligands can 
be designed to target modified nucleotides as many of the modified peptides studied 
revealed selectivity for H69ΨΨΨ over H69UUU. This also validates the argument that 
tight binders are unlikely to be identified using the phage display technique due to the 
RNA target being an essential part of the amplification process; however, it also 
supported the screening rationale in the original phage experiments leading to the 
identification of a peptide ligand that selectively targeted the modified nucleotides 
present in the loop region of H69 RNA. The alanine and arginine scans provided new 
information about the roles of each amino acid in the selected sequence and which ones 
play key roles in H69 binding and/or selectivity. Although the peptides used in this 
particular study are unlikely candidates for antibiotic development, further modifications 
could make that goal a reality in addition to helping elucidate the function of H69. 
Modifying position 3 with alanine provided evidence of strong binding, although 
selectivity was greatly decreased. Modification of position 1 with arginine provided the 
most selective peptide to H69ΨΨΨ with a 2-fold greater affinity than the parent 
sequence. Future studies may give us a clearer understanding of how these peptides 
may bind to their target as well as the impact on ribosome function, since our results 
reveal that certain positions with specific amino acid allocations are more important than 
others. 
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CHAPTER 4 BIOPHYSICAL AND BIOCHEMICAL BINDING STUDIES OF SELECTED 
H69 PEPTIDES 
4.1 Introduction 
From the ESI MS binding studies with modified H69 peptides and H69UUU and 
H69ΨΨΨ rRNAs, a few were selected for further characterization in order to obtain more 
detailed information regarding these binding interactions. Techniques used to obtain 
information were circular dichroism (CD) and isothermal titration calorimetry (ITC). Note 
that CD experiments were performed in collaboration with Dr. Jun Jiang, a post-doc 
working with the Chow group, and results revealed no significant change between free 
RNA and RNA-peptide complex. Peptide samples were provided by using SPPS and 
HPLC purification as described in Section 2.2, and RNA samples were either obtained 
through transcription (by Dr. Jun Jiang) or purchased as synthetic constructs from 
Dharmacon. In addition to these techniques, a visual screening assay was developed in 
order to identify novel peptide ligands in future RNA-targeting studies. 
4.2 Biophysical experiments of H69 RNA and selected H69 peptides 
4.2.1 Circular dichroism of selected modified peptides with H69 RNAs 
Circular dichroism, described in Section 2.6 of this work, was used to identify changes 
regarding free RNA and peptide species relative to complex formation. Since 
RQVANHQ-NH2 had been shown to bind with higher affinity through ESI MS than the 
parent sequence (NQVANHQ-NH2) identified previously,197 it was of interest to study this 
binding interaction further. Figure 4.1 provides a set of data corresponding to H69UUU 
RNA (unbound, Cf = 4 μM), the peptide NQVANHQ-NH2 (unbound, Cf = 112 μM), and 
complex between H69UUU RNA and NQVANHQ-NH2 (Cf = 4 μM RNA: 126 μM peptide). 
In addition, the change (Δ) in peptide and RNA was also visualized in order to determine 
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whether changes due to the binding event occurred. Equations 4.1 and 4.2 define how 
the difference in spectra (Δ) for peptide or RNA, respectively, was obtained from the CD 
data.  
Equation 4.1: Δpeptide = CD of RNA-peptide complex - CD of RNA 
Equation 4.2: ΔRNA = CD of RNA-peptide complex - CD of peptide 
The unbound peptide showed a characteristic profile for random coil secondary 
structure, as shown in Figure 2.3, which correlates exactly with an independent CD 
experiment with NQVANHQ-NH2 performed previously (data not shown). The random 
coil secondary structure provides evidence that these peptides are flexible and may not 
depend on a specific conformation for RNA binding. 
 
Figure 4.1 Circular dichroism spectra of NQVANHQ-NH2 with unmodified H69. A 
spectral range from 190 to 320 nm was used to observe circular dichroism changes for 
NQVANHQ-NH2, H69UUU, and NQVANHQ-H69UUU complex. H69UUU (yellow) 
overlaps with the H69UUU + NQVANHQ (green) spectrum. The data shown in this figure 
were obtained by Dr. Jun Jiang. 
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When observing changes in RNA conformation, one normally looks in the 260 nm 
region as absorbance is observed at this region due to the structural components of 
RNA. As shown in Figure 4.1, there was no discernable difference between unbound 
and bound H69UUU to peptide, suggesting that the binding event may not change the 
global conformation of the RNA or that perhaps a binding event had not occurred. What 
was most interesting in this figure lies within the 190 to 230 nm range as shown in 
Figure 4.2. In this range, the most definitive changes between bound and unbound 
species of RNA and peptide were observed. 
 
Figure 4.2 An expanded view of CD spectra of NQVANHQ-NH2 and H69UUU. An 
expanded view of the CD profile previously shown in Figure 4.1 ranged from 190 nm to 
230 nm. A change due to binding of H69UUU RNA and NQVANHQ-NH2 was observed 
at approximately 193 nm. 
 
At approximately 193 nm, NQVANHQ-NH2 (outlined in red) most closely represents a 
random coil secondary structure; however, when bound with H69UUU RNA (outlined in 
green) a definitive change was observed suggesting α-helical properties. The α-helix 
secondary structure of peptides and proteins is characterized by three CD peaks, one 
positive (π-π*) from 190-195 nm, and two negative shown at 208 nm (π-π*) and 222 nm 
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(n-π*), respectively.213 Although the data shown in Figure 4.2 doesn't exactly show all 
three identifiers, two are observed suggesting that the peptide takes on a more defined 
conformation when bound to the RNA. To further support this, note that free RNA 
(outlined in orange) had a different pattern from that of the RNA-peptide complex in this 
same region, further suggesting that a conformational change with the peptide may be 
occurring. Based on these data, the suggestion is that the peptide may be the only 
moiety within the sample making an observable change, which could explain why no 
difference was observed at 260 nm for the RNA (Figure 4.1).  
When this experiment was repeated with RQVANHQ-NH2 (Cf = 112 μM), a modified 
peptide identified to have a greater affinity than the parent sequence, similar findings 
were observed as shown in Figure 4.3. 
 
Figure 4.3 Circular dichroism spectra of RQVANHQ-NH2 with unmodified H69 RNA.  
A spectral range from 190 to 320 nm was used to observe circular dichroism changes for 
RQVANHQ-NH2, H69UUU, and RQVANHQ-H69UUU complex. H69UUU RNA (orange) 
overlaps with the H69UUU + RQVANHQ spectrum after 220 nm. The data shown in this 
figure were obtained by Dr. Jun Jiang. 
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Figure 4.3 yielded a similar profile shown in Figure 4.1 in which H69UUU RNA 
revealed no difference to the complex at 260 nm; however, a change was observed in 
the 190-230 nm region as shown in Figure 4.4. Although the difference associated with 
complex formation was not as dramatic as that observed with NQVANHQ-H69UUU, the 
change in peptide spectrum was most discernable at 193 nm, suggesting that 
conformational changes of the peptide did occur upon RNA binding.  
 
Figure 4.4 An expanded view of CD spectra of RQVANHQ-NH2 and H69UUU. An 
expanded view of the CD profile previously shown in Figure 4.3 ranged from 190 nm to 
230 nm. A change due to binding of H69UUU RNA and RQVANHQ-NH2 was observed 
at approximately 193 nm. 
 
The CD experiment was repeated with modified H69 RNA (Cf: 14.5 μM H69ΨΨΨ, 116 
μM peptide) and H69 peptides. The first complex studied was between H69ΨΨΨ and 
NQVANHQ-NH2 as shown in Figure 4.5. The results yielded slightly different results 
when compared to the unmodified construct in regards to peptide binding. The spectra 
share similarities at 260 nm, which revealed no observable change; that is, no peak shift 
or hypo/hyperchromicity was observed when H69ΨΨΨ was bound to NQVANHQ-NH2. 
When focused on that result alone, it would appear that the peptide binding does not 
-40
-30
-20
-10
0
10
20
30
40
190 200 210 220 230
C
D
, 
m
d
e
g
wavelength, nm
Expanded CD of RQVANHQ and H69UUU
RQVANHQ
H69UUU RNA
H69UUU + RQVANHQ
ΔRQVANHQ
ΔH69UUU
105 
 
 
 
change the overall RNA conformation as one might have expected when a binding event 
has occurred. The greatest change was observed in the 190 to 230 nm wavelength 
region where it appeared that the peptide conformation had changed upon binding to 
H69ΨΨΨ, but not in the same fashion as it had with the unmodified construct. 
 
Figure 4.5 Circular dichroism spectra of NQVANHQ-NH2 with modified H69. A 
spectral range from 190 to 320 nm was used to observe circular dichroism changes for 
NQVANHQ-NH2, H69ΨΨΨ, and NQVANHQ-H69ΨΨΨ complex. H69ΨΨΨ RNA (orange) 
overlaps with H69ΨΨΨ and NQVANHQ after 220 nm. The data shown in this figure were 
obtained by Dr. Jun Jiang. 
 
Since it is unclear from the original figure which specific changes occurred, Figure 4.6 
shows an expanded view with a wavelength range of 190 to 230 nm.  
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Figure 4.6 An expanded view of CD spectra of NQVANHQ-NH2 and H69ΨΨΨ. An 
expanded view of the CD profile previously shown in Figure 4.5 ranged from 190 nm to 
230 nm. 
 
In this case, the binding complex shows a similar profile to the free peptide; that is, a 
random coil profile. Although a change was observed when bound, it appears that the 
peptide remains more flexible rather than displaying a specific structural conformation 
upon RNA binding. This is a particularly interesting finding since it contrasted with 
findings with the unmodified RNA construct. 
Similar findings were observed when the CD experiment was performed with 
RQVANHQ-NH2 and H69ΨΨΨ as shown in Figure 4.7. At 260 nm, no observable 
change between complex and free RNA was observed, suggesting that the overall 
conformation of the RNA construct remained the same.  
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Figure 4.7 Circular dichroism spectra of RQVANHQ-NH2 with modified H69. A 
spectral range from 190 to 320 nm was used to observe circular dichroism changes for 
RQVANHQ-NH2, H69ΨΨΨ, and RQVANHQ-H69ΨΨΨ complex. The H69ΨΨΨ RNA 
spectrum overlaps with H69ΨΨΨ + RQVANHQ after 220 nm. The data shown in this 
figure were obtained by Dr. Jun Jiang. 
 
An expanded view as shown in Figure 4.8 revealed results similarly observed with 
NQVANHQ-NH2 bound to H69ΨΨΨ, in which a shift was observed upon binding; 
however, the peptide conformation was still a random coil. Although a change in peptide 
and RNA was observed in the wavelength region of 190 to 220 nm, the spectral trends 
remained very similar, suggesting that a pronounced physical change may not have 
occurred upon binding. 
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Figure 4.8 An expanded view of CD spectra of RQVANHQ-NH2 and H69ΨΨΨ. An 
expanded view of the CD profile previously shown in Figure 4.7 ranged from 190 nm to 
230 nm.  
 
4.2.2 Isothermal titration calorimetry (ITC) with RQVANHQ-NH2 and H69UUU 
As discussed in Sections 2.6.2 through 2.6.4, ITC experiments were performed with 
RQVANHQ-NH2 and H69UUU. The H69UUU was transcribed, purified, and desalted by 
Dr. Jun Jiang. The RQVANHQ-NH2 was synthesized and purified as described in 
Section 2.2. Parameters such as temperature, buffer composition, and titrate (RNA) and 
titrant (peptide) concentrations were tested in order to determine the most ideal 
conditions for the experiments. The area under the curve of μcal/sec versus minutes was 
integrated for each injection (Origin V.7.0, Microcal, Inc.) to determine the heat 
pertaining to each injection. These parameters were inspired by literature covering RNA 
and protein/peptide binding studies.214, 216, 232 
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Figure 4.9 ITC with RQVANHQ-NH2 and H69UUU in phosphate buffer A.  Titrant 
(RQVANHQ-NH2) was systematically injected into the sample cell containing only 
phosphate buffer A at 25 °C (no titrate (RNA), black) in order to determine the 
thermodynamic profile used to subtract. The thermodynamic profile representing 
RQVANHQ-NH2 as the titrant and H69UUU as the titrate is outlined in red.  
For each buffer used as well as any change in concentration regarding the titrant 
(peptide, 500 μM stock) and titrate (RNA, 3 μM stock), a run without the titrate to 
determine the background for later subtraction during the data analysis was performed. 
Figure 4.9 shows data for a run without titrate and data with the titrate. Phosphate buffer 
A (10 mM potassium phosphate, 100 mM KCl, pH 7.2) The overall thermodynamic 
profile was found to be exothermic based on the subtraction of the peptide titrated into 
buffer from peptide titration into RNA (Figure 4.10). As shown in Figure 4.9, the heat of 
dilution is very high for the background and is indicative of high salt being present. This 
was not surprising since the peptide contained salt despite efforts to remove it during 
purification.  
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Figure 4.10 ITC of RQVANHQ-NH2 and H69UUU in phosphate buffer A. The result 
from peptide titration into phosphate buffer A was subtracted from the result obtained 
with the peptide titration into RNA. The overall thermodynamic profile is exothermic. 
 
Since it was not possible to remove the endogenous salt in the peptide sample, nor 
was it possible to determine how much salt was actually present outside of the buffer 
conditions, an argument was made that if the buffer salt concentration was high enough, 
the salt present in the peptide sample would become negligible when compared to the 
overall solution. To address this possibility, the salt concentration was increased in the 
phosphate buffer (phosphate buffer B) to 150 mM potassium chloride with the reasoning 
that the higher the salt concentration of the overall solution, the salt present in the 
peptide sample would then be negligible and no longer interfere with the thermodynamic 
profile associated with peptide binding to RNA. Figure 4.11 shows data correlating to a 
run in phosphate buffer B (10 mM potassium phosphate, 150 mM potassium chloride, 
pH 7.2). The RNA and peptide stock concentrations remained the same (3 μM and 500 
μM, respectively).  
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Figure 4.11 ITC with RQVANHQ-NH2 and H69UUU in phosphate buffer B. Titrant 
(RQVANHQ-NH2) was systematically injected into the sample cell containing only 
phosphate buffer B at 25 °C (no titrate (RNA), black) in order to determine the 
thermodynamic profile used to subtract. The thermodynamic profile representing 
RQVANHQ-NH2 as the titrant and H69UUU as the titrate is outlined in red. 
 
Figure 4.11 revealed a much higher thermodynamic profile than what was seen with 
phosphate buffer A, yet the same trend was observed. It appears that salt concentration 
does impact the overall thermodynamic profile and increasing the salt concentration in 
the buffer did not yield the negligible effects that were anticipated; however, it is 
important to note that the difference obtained from subtracting the thermodynamic profile 
of the peptide into buffer from thermodynamic profile of the peptide into RNA still showed 
an exothermic reaction as shown in Figure 4.12. 
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Figure 4.12 ITC of RQVANHQ-NH2 and H69UUU in phosphate buffer B. The result 
from peptide titration into phosphate buffer B was subtracted from the result associated 
with peptide titration into RNA. The overall thermodynamic profile is exothermic. 
 
The end result of these experiments despite testing different buffer conditions and 
temperatures (data was also collected at 37 °C, not shown) revealed that salt presence 
in the samples may interfere with the overall goal of observing binding interactions 
between H69UUU and the modified peptide ligand RQVANHQ-NH2. It is likely that 
similar results would be observed with H69ΨΨΨ binding studies as the salt problem 
resides with the peptide sample. These peptides are extremely hydrophilic and often 
come out in pure water or exceedingly low acetonitrile gradients (0-5%) during HPLC 
purification. Salt is traditionally removed in the 0-5% acetonitrile gradient. Of particular 
importance is the exothermic profiles identified despite the buffer choice, suggesting that 
binding events are taking place. Another concern was the possibility of peptide 
aggregation since it was observed at high concentrations of peptide in ESI MS 
experiments. In the case of ITC, aggregation may not have played a role since the 
thermodynamic profiles associated with peptide in buffer did not yield information 
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pertaining to a binding event independent of RNA. A possible future experiment would 
be to reverse the roles of the titrate and titrant so that RNA is then titrated into peptide. 
Perhaps if the salt endogenous to the peptide is already present in the sample cell, its 
presence may not interfere with the titration of the RNA into the peptide. 
4.3 The design and optimization of a visual screening assay to select peptide 
ligands that target H69 RNAs 
4.3.1 Introduction to the RNA-peptide fluorescence screening assay 
Screening peptides with ESI MS has yielded helpful information regarding the 
selectivity and affinity of modified heptamers to target RNA; however, the process of 
attaining this information was very time consuming in terms of both the synthesis and 
purification of individual peptides needed to perform the experiments. In many cases, the 
peptides screened for dissociation constant determination consumed large amounts of 
peptide and RNA only to find that they were not better binders to the target RNA. It also 
required a lot of RNA and peptide that could not be recovered and re-used. This 
challenge established a need for an assay that can screen libraries of peptide versus 
individual peptides. High-affinity peptides identified from a library-screening assay can 
then be synthesized, purified, and tested for selectivity and affinity. To address this 
challenge, a visual assay using quantum dots (Qdot) as fluorophores, flow cytometry as 
the method to screen hits, and mass spectrometry to identify the screened hits was 
developed. Peptides identified by this approach can then undergo binding studies with 
RNA to determine the relative affinity and selectivity. To test the assay design, details of 
which can be found in Section 2.8, a small set of peptide variants (position 1) were 
synthesized using manual SPPS as summarized in Table 4.1. 
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Table 4.1 Peptides synthesized for the visual assay 
Sample # 
for FC* 
sorting 
Peptide Chemical 
Formula 
Monoisotopic 
Mass (g/mol) 
Role in visual 
assay 
8 NQVANHQ-NH2 C32H52N14O11 808.39 positive control 
6 AAAAAAA-NH2 C21H38N8O7 514.29 negative control 
9 RQVANHQ-NH2 C34H58N16O10 850.45 ESI MS selected 
 DQVANHQ-NH2 C32H51N13O12 809.38 position 1 variant 
 MQVANHQ-NH2 C33H55N13O10S1 825.39 position 1 variant 
 FQVANHQ-NH2 C37H55N13O10 841.42 position 1 variant 
10 GQVANHQ-NH2 C30H49N13O10 751.37 position 1 variant 
 PQVANHQ-NH2 C30H53N13O10 755.40 position 1 variant 
 SQVANHQ-NH2 C31H51N13O11 781.38 position 1 variant 
 RQVANHQ-NH2 C34H58N16O10 850.45 position 1 variant 
*FC = flow cytometry 
 
4.3.2  Sample submission for flow cytometry experiment 
Samples were prepared as described in Section 2.8.4. Additional fresh 1x PBS was 
provided with the samples. The following lists samples that were submitted for flow 
analysis and sorting: 1) blank beads; 2) blank beads + Qdot 605; 3) blank beads + RNA 
+ Qdot 605; 4) RNA + Qdot 605; 5) Positive control + RNA + Qdot 605; 6) Negative 
control + RNA + Qdot 605; 7) Mix of positive and negative control + RNA + Qdot 605 
(with sorting); 8) NQVANHQ + RNA + Qdot 605 (with sorting); 9) RQVANHQ + RNA + 
Qdot 605 (with sorting); and 10) Position 1 variants + RNA + Qdot 605 (with sorting). 
Blank beads were 10 μm Tentagel without peptide. The first three samples were 
designed to observe whether non-specific binding of either the streptavidin-coated Qdot 
605 (Qdot 605) and/or the Qdot 605 bound to the biotinylated H69ΨΨΨ (5'-Bi-H69ΨΨΨ) 
RNA occurred with the blank bead. Sample four was submitted to determine whether 
RNA complexed to Qdot 605 would be observed as a false-positive during the flow 
cytometry experiment. Samples five through ten contained beads with synthetic peptide 
with a photocleavable linker on each. Sample five contained beads with NQVANHQ and 
was considered the positive control due to its previous identification using fluorescence 
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as described previously.227 In addition, preliminary studies with this instrumentation had 
shown positive results with this peptide each time. Sample six contained Tentagel beads 
with AAAAAAA, which is a peptide that did not bind to H69 RNA in preliminary 
experiments. Samples seven through ten were sorted into individual wells of a 96-well 
plate. Sample seven contained a mixture of the positive and negative control. Sample 
eight contained the parent sequence (essentially the positive control submitted for 
sorting). Sample nine contained RQVANHQ, a modified H69 peptide identified to bind 
with greater affinity than the parent sequence using ESI MS. Sample ten contained 
seven members of the position 1 variant pool, with peptide identities and corresponding 
chemical formulas and masses given in Table 4.1. Samples were prepared as described 
in Section 2.8.4. and submitted to the Microscopy, Imaging and Cytometry Resources 
Core at Wayne State University, School of Medicine. This service was performed by Eric 
Van Buren, flow cytometry core manager, using a SH800 cell sorter (model LE-
SH800ZFP, Sony Biotechnology, Tokyo, Japan). 
4.3.3  Data analysis from the flow cytometry core of submitted samples 
The flow cytometry core provides data pertaining to each sample submitted in three 
separate figures. The first, illustrated in Figure 4.13, represents the template for a dot 
plot analysis in which each bead is cycled through the instrument and two lasers 
systematically pass light through each bead. The forward scatter (FCC) provides 
information related to the size of the bead/particle/cell that it hits and is represented in 
the x-axis. The side scatter (SSC) provides information related to the complexity of 
bead/particle/cell; that is, what's on the surface (smooth, rigid, etc.). Combined, it sorts 
the beads to populations correlating to sample population(s) to be further analyzed and 
removing samples pertaining to debris. The pound sign shown in the top right corner in 
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this figure represents the percentage of beads/particles/cells from the total introduced in 
the instrument selected for further analysis. The unit corresponding with the x-axis and 
y-axis correlates to the number of beads/particles/cells present in the whole sample 
introduction to the instrument. 
 
Figure 4.13 Dot plot determination of the sample population used in flow 
cytometry. Samples introduced into the flow cytometry instrumentation are exposed to 
forward and side scattering light providing information on size and complexity of each 
sample. The dot plot systematically determines the differences between a sample 
population and debris present in the buffer. 
 
From the initial dot plot, the selected sample population is further analyzed to separate 
single beads (singlets) from aggregates (doublets, etc.) as shown in Figure 4.14. As the 
bead/particle/cell passes through the flow cytometer, light reveals aggregates to have 
the same height as singlets (y-axis); however, the x-axis represents the peak area of 
each sample passing through and this difference creates new populations separating 
aggregates from single beads. The pound sign shown within the singlet gating 
population represents the percentage of this overall selection found to be singlets. This 
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population undergoes the final analysis providing fluorescence information on the 
sample. Note that most publications do not usually provide dot plots, such as Figures 
4.13 and 4.14, as this is the physical selection and processing that leads to the data 
desired from sample submission. The dot plots will be shown for each of the peptide and 
control to draw attention to sample counts and debris present in each whole sample 
submitted, since this is a new application of flow cytometry. 
 
Figure 4.14 Dot plot determination separating singlets and aggregates from the 
selected population. The population selected from the initial sample submission 
undergoes further analysis to select for single beads over aggregates.  
 
The third and final dot plot diagram shown is the most important for experimental 
analysis. Figure 4.15 shows a dot plot providing a population determination of positive 
versus negative fluorescent hits. Since it is known that Tentagel beads with peptide 
synthesized on their surface autofluoresce green,227 it is important to be able to identify 
true positive hits over negative ones. The x-axis represents green emission at 525 nm ± 
25 nm (525/50) and the y-axis represents red emission at 600 ± 60 nm (600/60). 
Quantum dot 605 (Qdot 605) emits at 605 nm. The gate represented in Figure 4.15 was 
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determined specifically for the experiment displayed in this report. Since a negative 
control was submitted, that population was taken into account with the autofluorescence 
so that anything not in that population would be seen as a positive hit. The negative 
region also accounts for background signal. The pound sign within the gated positive-hit 
region represents the percentage of beads that had Qdot 605 emission.  
 
Figure 4.15 Dot plot determination of Qdot 605 emission. Green emission (525 ± 25 
nm) versus red emission (600 ± 30 nm) was established to separate true positive hits 
from false-positives known to fluoresce green. 
 
Before discussing the individual results, it is important to understand that these results 
are not quantitative. The suggested improvements for further work will be discussed in 
the future directions chapter (Chapter 6). Certain parameters may affect a given 
population so that it isn't quantitative, such as degree of binding, possible degradation, 
amount of RNA, and Qdot molecules available for binding relative to the number of 
beads available, etc. This will be discussed further after the results are shown. 
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Sample one contained 10 μm Tentagel beads without synthetic peptide and the results 
are shown in Figure 4.16. When compared to dot plots of other samples, one can clearly 
see the overall uniformity of the beads giving concentrated populations (red). This is 
likely due to the fact that the samples do not have synthetic peptide and therefore have 
lower complexity compared to its synthetic counterpart.  
 
 
Figure 4.16 Sample one – blank beads diagrams for bead selection. Entire sample 
of blank beads (Event count 25000) introduced into the instrument are visualized in the 
left panel and a topographical observation correlating to bead colonies with similar size 
and shape were analyzed to omit debris present in the sample. The middle panel shows 
the population selected for Qdot 605 emission omitting aggregates. The right panel 
represented Qdot 605 emission detection (top left segregated corner) versus green 
autofluorescence and background emission. The value in the top left corner of the right 
panel represents the percentage of beads in that dot plot shown to have positive 605 nm 
emission. 
 
 Figure 4.17 shows data of blank beads incubated with Qdot 605 to determine whether 
the streptavidin-coated quantum dot could non-specifically bind to the beads without 
peptides. As with the blank bead control, the right panel shows that very few beads 
(19/21269) have any emission profile. This results supports that non-specific binding of 
the bead to Qdot 605 did not occur. 
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Figure 4.17 Sample two – blank beads with Qdot 605 diagrams for bead selection. 
The entire sample of blank beads (Event count 23763) with Qdot 605 incubation were 
introduced into the instrument and visualized in the left panel to separate the sample 
population from debris. The middle panel represented the population selected for further 
analysis as it selected for singlet beads over aggregates and the right panel represented 
the emission profile congruent with Qdot 605 binding. 
Figure 4.18 shows data of blank beads incubated with 5'-Bi-H69ΨΨΨ RNA followed by 
incubation with Qdot 605. This control sample was designed to determine whether the 
RNA could bind to blank beads, which would in turn be visualized since the biotinylated 
RNA couples to the Qdot 605. This result also indicated that non-specific binding with 
the RNA-Qdot complex did not occur. 
 
Figure 4.18 Sample three – blank beads with biotinylated RNA and Qdot 605 
diagrams for bead selection. The entire sample of blank beads (Event count 25000) 
with RNA and Qdot 605 incubation were introduced into the instrument and visualized in 
the left panel to separate the sample population from debris. The middle panel 
represented the population selected for further analysis as it separated singlet beads 
from aggregates, and the right panel represented the emission profile congruent with 
Qdot 605 binding. 
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Figure 4.19 shows data from samples containing no beads, but contained just RNA 
and Qdot 605. The concern was that RNA-Qdot 605 that might not have been washed 
away during the assay protocol and might be visualized as false positives during the flow 
cytometry experiment. The results indicated that this detection did not exist as the flow 
cytometer needs a physical particle to do a selection. 
 
Figure 4.19 Sample four – biotinylated RNA and Qdot 605 diagram for possible 
selection. The entire sample containing RNA-Qdot 605 conjugate (Event count 7) was 
introduced into the instrument to determine whether selection could take place 
increasing the likelihood of possible false positive results. As shown, there were no 
samples shown to have an emission profile for Qdot 605. 
 
Figure 4.20 shows data from samples containing the positive control incubated with 
biotinylated RNA and Qdot 605. Focusing attention on the right panel, the peptide 
samples contained Qdot 605 and the emission profile was altered compared to the 
controls. Note that many of these beads did not show fluorescence despite the 
expectation for binding to Qdot 605. This is likely due to two reasons. The first goes back 
to the synthesis. Since there was no HPLC purification, beads likely contain failed 
sequences/incomplete protective group cleavages, which may not bind to the RNA-Qdot 
605 complex. The second may be due to the amount of RNA and Qdot 605 used in the 
assay protocol. Addition of more RNA and Qdot may increase the amount of sample 
bound for flow cytometry analysis. This outcome was observed for the rest of the 
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samples discussed in this report and will be discussed in greater detail in the future 
directions portion of this work.  
 
Figure 4.20 Sample five – positive control peptide NQVANHQ with biotinylated 
RNA and Qdot 605 diagram for flow cytometry detection. The left panel represents 
the entire sample submitted (Event count 7034) for flow analysis with sample population 
selected over debris. The middle panel represents the population of singlet beads 
selected over aggregates for further Qdot 605 emission analysis. The selection was 
consistent with previous samples submitted in this study. The right panel shows the 
selected population with samples having Qdot 605 emission, indicative of RNA binding 
to the peptide sample. 
 
Also of significance is the population shown in the left panel of Figure 4.20. There is a 
greater amount of debris particles of varying size and complexity compared to the 
previous controls. This is due to the fact that synthetic peptide is present on each bead. 
Ultimately, it changes the size and complexity based on how much peptide and the 
different sequences available amongst different samples. It makes this selection process 
more significant because fewer beads overall are selected for further analysis. We were 
not concerned at this point because the goal was to first establish visualization of Qdot 
605 emission.  
Figure 4.21 shows data from the negative control. The negative control was the 
peptide AAAAAAA incubated with biotinylated RNA and Qdot 605. This data was 
different from the blank bead control because of the presence of synthetic peptide. The 
population complexity increased (observed in the left panel), which meant that fewer 
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beads were selected for further analysis. In the case of the negative control, 41% of the 
original population was selected for further analysis of which approximately 88% of the 
new population contained singlet beads that were acceptable for Qdot analysis. The 
other main difference between the negative control and the blank bead control is the 
population seen in the right panels of Figures 4.21 and 4.16. The blank bead control 
(Figure 4.16) revealed a population closer to zero; whereas a 103 fluorescence intensity 
was observed, indicative of greater autofluorescence. In general, beads without peptide 
did not autofluoresce nearly as much as beads with peptide.  
Figure 4.21 Sample six – negative control peptide AAAAAAA with biotinylated 
RNA and Qdot 605 diagram for flow cytometry detection. The left panel represents 
total sample introduction (Event count 4360) into the flow cytometer. The middle panel 
shows the singlet population selected for further 605 nm emission detection. The right 
panel shows the selected population (from the middle panel) with specific focus on Qdot 
605 detection. Note that no Qdot 605 was detected. 
 
Figure 4.22 shows a 1:1 mixture of the positive and negative control. Note that this 
sample was produced independently of the individual positive and negative control; that 
is, beads were not removed from the individual positive and negative controls and mixed 
together. In addition to the screening, the brightest hits were individually placed into 
individual wells of a 96-well plate for MS conformation of the identity of the peptide. Only 
one plate containing 96 wells was used for the collection. It is interesting to see that a 
greater population of the selected singlets revealed Qdot 605 emission. Although a 1:1 
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mixture of positive and negative control beads were prepared, it seems that not many of 
the negative control beads made it through the selection process, either because their 
size and complexity was too different compared to the positive control or too much 
aggregation had occurred preventing further selection and analysis.  
Figure 4.22 Sample seven – mixture of the positive and negative control with 
biotinylated RNA and Qdot 605 diagram for flow cytometry detection and sorting. 
The left panel represents the entire sample introduced (event count 8111) to the flow 
cytometer as well as the population gated away from debris. The middle panel 
represents the singlet population selected from the total sample for further analysis. The 
right panel shows the 605 nm emission profile for the samples. 
 
Figure 4.23 shows samples of NQVANHQ, the parent sequence and are samples 
from the same bead stock that was used for the positive control. Note that the samples 
were from an independent preparation; that is, the beads were not pulled from the 
positive control sample prep and submitted for sorting. This sample was also subjected 
to sorting and one 96-well plate was used to collect beads with the brightest 
fluorescence intensity indicative of binding to the 5'-Bi-H69ΨΨΨ and Qdot 605. There 
were also a greater number of beads available for this sample (approximately 16,000) 
compared to previous samples as such a greater population was observed in the debris 
region of the initial gating. This means that the complexity and sizes of the beads varied 
and only the beads that met the initial requirements for selection made it to the next 
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round. In this case, approximately 51% of the beads introduced made it to the next 
analysis board where singlets and aggregates were further separated. 
Figure 4.23 Sample eight – NQVANHQ with biotinylated RNA and Qdot 605 
diagram for flow cytometry detection and sorting. The left panel represents the 
entire sample introduction (event count 15757) into the flow cytometry instrumentation. 
An increase in the amount of debris and beads with differing complexity is likely due to 
the increase in the number of beads introduced to the instrument relative to previous 
samples. The middle panel represents the singlet population selected for further 
analysis, and the right panel represents the emission profile of beads that fluoresce at 
605 nm. Beads showing the brightest fluorescence were sorted into individual wells of a 
96-well plate for later MS analysis. 
 
Figure 4.24 shows samples of RQVANHQ, a modified H69 peptide that was identified 
to have a higher affinity to the RNA studied in this work using ESI MS. Further 
confirmation of binding to 5'-Bi-H69ΨΨΨ was desired and samples containing this 
peptide were subjected to this assay and the brightest beads were selected for later MS 
validation. Of particular interest in this set is that nearly 100,000 beads were available for 
analysis, which is also why it is likely that only 6% of these beads showed Qdot 605 
emission since incubation of the beads with Qdot 605 occurs on a vertical spinner in 0.5 
mL Eppendorf tubes, it is unlikely that all beads were exposed equally to the fluorophore. 
Compared to other samples submitted in which 5-10,000 beads were analyzed for Qdot 
605 emission, there were approximately eight times more beads available and it was not 
likely that there was enough room in the sample tube for the RNA and Qdot 605 to coat 
all of those beads. The results are promising, but binding conditions need further 
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optimization. Of the 78,328 beads analyzed for Qdot 605 emission, 4,762 beads (6%) 
were positive hits. This result can be compared to sample eight, which showed 43% of 
its beads with positive Qdot 605 emission (of 6,711 beads, 2,879 beads were positive 
hits). There were more positive hits for RQVANHQ than NQVANHQ.  
Figure 4.24 Sample nine – RQVANHQ with biotinylated RNA and Qdot 605 diagram 
for flow cytometry detection and sorting. The left panel represents the entire sample 
introduction (event count 96809) into the flow cytometry instrumentation. The middle 
panel represents the singlet population selected for further analysis, and the right panel 
shows the emission profile of beads that fluoresce at 605 nm. Beads showing the 
brightest fluorescence were sorted into individual wells of a 96-well plate for later MS 
analysis. 
 
Figure 4.25 shows samples from a pool of position 1 variants containing a total of 
seven different peptides. The rationale behind the design of this small pool of peptides 
was to study the ability to identify peptides post-visual assay selection using mass 
spectrometry. Identifying a small number of samples may not be efficient long-term, but 
this approach was used for the purpose of testing the assay design. Variants in position 
1 were made since previous ESI MS studies (Chapter 3) revealed that modification to 
position 1 enhanced affinity to H69 RNAs. Of the 28,009 beads available for Qdot 605+ 
emission, 2,386 (9%) were positive hits. For flow cytometry selection, samples revealing 
the beads highest intensity were sorted into a 96-well plate for later MS identification of 
samples.  
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Figure 4.25 Sample ten – position 1 variants with biotinylated RNA and Qdot 605 
diagram for flow cytometry detection and sorting. The left panel represents the 
entire sample introduction (event count 33566) into the flow cytometry instrumentation. 
The middle panel represents the singlet population selected for further analysis, and the 
right panel shows the emission profile of beads that fluoresce at 605 nm. Beads showing 
the brightest fluorescence were sorted into individual wells of a 96-well plate for later MS 
analysis. 
 
4.3.4 Summary of flow cytometer results 
The visual and physical selection of beads based on the secondary binding of 
streptavidin-coated Qdot 605 to biotinylated RNA previously incubated with the peptide 
was successful. Based off a "positive-hit" selection with the appropriate controls, this set 
of experiments confirmed that variant RQVANHQ does bind to H69ΨΨΨ and that one or 
more peptides from the position variant 1 pool also bind to H69ΨΨΨ.  
To further support that RQVANHQ binds to H69ΨΨΨ RNA, the fluorescence intensities 
were plotted against the positive and negative control as shown in Figure 4.26. As the 
intensity of RQVANHQ is greater than that of the positive control, RQVANHQ is a 
positive binder to H69 RNA. Position 1 variants also revealed positive binding indicating 
that one or more peptides within than pool also bind to H69 RNA.  
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Figure 4.26 Bar graph of Qdot 605+ emission detection. The fluorescence intensity 
was determined for each sample selection and compared to the positive control. Any 
value at or above one indicated a positive Qdot 605 profile indicative of positive binding 
to H69 RNA. 
 
Table 4.2 gives the event counts (beads) for each sample introduced into the flow 
cytometer (panel 1), the number of singlets available for Qdot 605 detection (panel 2), 
and the number of beads from each sample found to be positive Qdot 605 emission 
(Qdot 605+) (panel 3). In the case of panel 3 Qdot 605+ detection, the percentage value 
represents the percent of beads available for that event that led to Qdot 605+ detection. 
For example, the RQVANHQ sample had 78,328 beads available for Qdot 605+ 
detection and 6% of those beads were positive for Qdot 605 meaning that 4,762 beads 
from the 78,328 bead population were detected at 605 nm. These values should not be 
taken as indicators for the degree of binding (weak vs. strong), but should be evaluated 
on the presence of binding. Since the binding interaction is based on secondary binding; 
that is, the fluorophore binds to the RNA which is already bound to the peptide bead, not 
a direct binding of fluorophore to bead, it's important to optimize conditions by 
consistently preparing the same approximate amount of beads and to incubate them 
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with saturating amounts of RNA and Qdot 605 to assure that tight binders get sorted 
during the flow cytometry experiment.  
Table 4.2 Event counts of each sample for Qdot 605+ detection 
Sample 
# 
Sample Identification 
Event Count 
(% selection 
for singlet 
count) 
panel 1 
Singlet Count 
(% selection 
Qdot 605 
emission 
detection) 
panel 2 
Event Count 
(% Qdot 605+ 
emission) 
panel 3 
1 blank bead 25,000 (95%) 23,842 (89%) 21,269 (0%) 
2 blank bead + Qdot 605 25,000 (95%) 23,763 (91%) 21,698 (0%) 
3 blank bead + RNA 
+Qdot 605 
25,000 (94%) 23,637 (89%) 21,134 (0%) 
4 RNA + Qdot 605 7 (0%) - - 
5 positive control 7,034 (70%) 4,933 (93%) 4562 (25%) 
6 negative control 4,360 (41%) 1,776 (88%) 1,561 (0%) 
7 1:1 mixture of positive 
and negative control 
8,111 (89%) 7,251 (91%) 6,587 (62%) 
8 NQVANHQ 15,757 (51%) 8,019 (84%) 6,711 (43%) 
9 RQVANHQ 96,809 (92%) 89,192 (88%) 78,328 (6%) 
10 position 1 variants 33,566 (92%) 30,982 (90%) 28,009 (9%) 
 
4.3.5  Sample workup from the flow cytometry core 
Samples with the brightest fluorescence from Figures 4.22 through 4.25, indicative of 
Qdot 605-RNA-peptide binding, were placed into individual wells of a 96-well plate. Four 
sample tubes (7-10) were submitted for sorting of the beads with the brightest emission 
profiles at 605 nm and collected into 96-well plates. Each well plate (four total) was 
exposed to UV irradiation at 365 nm as described in Section 2.8.4. After 1 h of 
incubation under UV light, 50 μL of ddH2O, pH 7.2 was added to each well and the plate 
was allowed to sit at room temperature for a minimum of 20 min in order to remove the 
peptide from the surface of the well plate. Samples were placed into 0.5 mL autoclaved 
polypropylene tubes, were dried in the speed vac, and stored in the -20 °C freezer for 
later MS analysis. 
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4.3.6 Mass analysis of peptides from the flow cytometry experiment 
To determine whether the peptides could be identified directly from the Tentagel beads 
used in the flow analysis, a mass spectrometry approach was taken. The long-term goal 
is to obtain sequences of peptides from large randomized libraries. Highly sensitive 
mass spectrometry instrumentation must be used for this process, since very little 
peptide material is available from the individual bead. For this purpose, a collaboration 
was established with Dr. Sarah Trimpin and her group. 
Samples from plate one (96-well plate containing samples from the 1:1 positive and 
negative control) as well as two samples from plate four (6 position 1 variants) were 
tested for peptide identification/validation. Since this approach has not been used 
before, most samples were used to optimize conditions. A SYNAPT G2 mass 
spectrometer from Waters was modified by the Trimpin group to accept sample 
crystallized with matrix. The sample was crystallized with either 3-nitrobenzonitrile 
(3NBN) or 3,3'-dichlorobenzidine (DCB) matrix on a pipet tip, which was then placed 
against the inlet aperture opening of the SYNAPT G2 mass spectrometer. The matrices 
used did not require heat to increase ion abundance, which was ideal for this 
experiment. Modifications to the mass spectrometer allow for lower heat configurations 
when compared to traditional electrospray ionization mass spectrometers. The source 
temperature used for all samples tested was 30 °C. The mass spectrometer 
modifications and specifications unique to the Trimpin group was published in Analytical 
Chemistry.233  
To determine whether this instrumentation was suitable for this work, dried samples in 
individual 0.5 mL autoclaved polypropylene tubes were dissolved in 2 μL of ddH2O, 50% 
methanol, or 50% acetonitrile. The matrix, 3NBN or DCB (2 μL), was added to each 
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dissolved sample for crystallization on the tip of a 200 μL pipet tip and exposed to the 
mass spectrometer inlet for mass analysis. Both positive and negative ion modes were 
employed in these optimization experiments. These steps were performed by Trimpin 
lab member Dr. Christian Reynolds. Mass spectra were visualized using MassLynx V. 
4.1 software and I processed the data using V. 4.0. Most data only showed mass 
information for the matrix or artifact products that had no correlation with the peptide; 
however, two samples did yield information from the peptide sample, which is discussed 
in the following section. 
Figure 4.27 shows the mass data obtained from a bead selected from sample seven 
which contained a mixture of the positive and negative control peptides. In this case, the 
positive control, NQVANHQ-NH2 photocleaved product, was observed. Note that no 
liquid chromatography (LC) was used and the panel associated with LC was directly 
related to the length of time that the pipet tip containing crystallized sample was exposed 
to the MS inlet for mass detection. The amidated peptide product from ANP cleavage, 
NQVANHQ-NH2, has an exact mass of 809.402 Da. The observed mass of 810.90 Da is 
a minimum of 1 Da above the expected mass expected; however, upon further analysis, 
the masses associated with the matrix as well as degraded product of the matrix are 
also off by a minimum of 1 Da. No calibration was performed prior to the sample runs, 
which may account for the +1 mass discrepancy.  The highest intensity peaks of the 
mass spectrum (top panel, Figure 4.28) are associated with degraded forms of the 
matrix and were found in samples containing with the 3,3′-dichlorobenzidine (DCB) 
matrix (m/z = 253.13).234 Dechlorination of DCB produced a degradation product that 
can be identified at m/z = 217.234  
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Figure 4.27 TOF MS of NQVANHQ-NH2 from one bead selected from sample seven 
by flow cytometry. The mass spectrum (top) was isolated from the 0.78 time point of 
the chromatogram (bottom right). The bottom left panel is associated with the expanded 
region of the top panel revealing the identity of the peptide NQVANHQ-NH2 selected 
from the flow cytometer.  
 
The mass 202.934 appears to be the (4-) charge state of 810.901 associated with the 
peptide product. The (2-) and (3-) charge states were observed as well; however, their 
intensities were significantly lower and could not be separated from the noise.  The (4-) 
charge state of the peptide was visualized at a higher intensity than the (1-) charge. 
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Although these data do seem to identify the anticipated peptide mass, the amount of 
material available for analysis may be too little for future sequencing experiments. 
Plate 4 from the flow cytometry collection contained individual peptide samples from 
the peptide library. It was not processed completely; that is, UV cleavage took place, but 
50 μL of ddH2O was not added to each well yet in order to see if peptide analysis could 
take place directly on the well plate. To get the peptide off of the plate, 2-5 μL of 1:1 
acetonitrile in water was added to well A1 and mixed. The 3NBN matrix was added to 
the sample for crystallization and the sample was analyzed in the positive-ion mode. 
Figure 4.28 show data using this method, and although the results looks promising, this 
was one of a few samples that were tested and this was the only sample that showed 
discernable results. Based on the peptide library synthesized, the identity of the peptide 
in this well was GQVANHQ-NH2. Other charge states were not observed for this sample 
as was the case under the conditions represented in the last figure. It's unclear whether 
there is enough sample to do sequencing analysis. 
To further look at sensitivity of MS applications, MALDI-TOF MS was used to 
determine whether detection of peptide from a single bead was possible. Samples were 
dried down prior to spotting them on the MALDI-TOF MS target. The matrix α-cyano-4-
hydroxycinnamic acid was freshly produced as a saturated solution in 1:1 ACN in ddH2O 
+ 0.1% TFA. Two μL was added to each sample and spotted in one allocated slot on the 
target. This was carried out to concentrate the sample for optimum results. Interestingly, 
peptides were observed using MALDI-TOF MS; however, with lower concentration, 
intensity remained low increasing the signal-to-noise ratio. Note that other components 
were observed in the sample since which was expected as purification could not be 
performed prior to the assay or after the cleavage due to the probability of losing 
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material during this process. Figure 4.29 shows MALDI-TOF MS data correlating to the 
selection of a single 10 μm bead containing RQVANHQ from the flow cytometry 
selection experiment.  
 
Figure 4.28 Determination of unknown from a seven-membered pool containing 
position 1 variants. The mass 376.23 is the (2+) charge state of GQVANHQ-NH2 (top), 
observed from 0.63 minute point (bottom). This sample was obtained from flow 
cytometry Qdot 605+ selection and was cleaved from a single 10 μm (dried) bead. 
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Figure 4.29 MALDI-TOF MS of RQVANHQ from flow cytometry selection 
experiments. A.  MALDI-TOF MS spectrum of RQVANHQ from 96-well plate position 
3A11. The sample spotted was obtained from a single 10 μm bead selected from flow 
cytometry instrumentation based on the detection of Qdot 605 emission. The sample 
was dried prior to addition of matrix and spotted in position C11 of the MALDI-TOF 
target. B. An expanded view revealing the MH+ of RQVANHQ at 851.6 Da.  
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To further study peptide obtained from bead sorting, MALDI-TOF MS was used to 
observe peptide samples from beads that were subjected to RNA-binding and 
subsequent flow cytometry. Figure 4.30 represents a 20 μL of beads in 1x PBS buffer 
that were subjected to UV irradiation (365 nm) for 1 h and characterized using MALDI-
TOF MS. As shown in this figure, individual masses correlating to the seven position 1 
variants could not be easily identified due to the presence of crude material from the 
original synthesis and the high signal-to-noise ratio.  
 
Figure 4.30 MALDI-TOF MS of bead mixture pre-flow cytometry. A small sample of 
beads were irradiated with UV light to cleave the peptide from the solid support. MALDI-
TOF MS was used to determine whether the seven split-pool position 1 variants could be 
identified. 
 
Once the visual assay was completed and individual beads were sorted into a 96-well 
plate by the flow cytometer, ten beads (10 μm) were cleaved (UV, 365 nm), combined, 
and characterized using MALDI-TOF MS. Figure 4.31 shows MALDI-TOF MS data from 
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the combined mixture of beads post-flow cytometry selection and it was interesting to 
see that at least two peptides were detected from the selection (RQVANHQ and 
PQVANHQ). 
 
Figure 4.31 MALDI-TOF MS post-flow cytometry 10 bead (10 μm) mixture. Ten 
beads sorted by the flow cytometer were cleaved, combined, and characterized using 
MALDI-TOF MS. PQVANHQ had an observed MH+ mass of 756 Da and a predicted 
MH+ mass of 756 Da. RQVANHQ had an observed MH+ mass of 851 Da and a predicted 
MH+ mass of 851 Da. 
 
4.3.7  Conclusions 
CD experimentation provided evidence for conformational differences of the peptide 
before and after binding to H69 RNAs. It seems that H69 peptides conformationally 
change from a random coil configuration to a α-helical conformation and that this only 
occurs with the unmodified H69 RNA. This is interesting because the parent sequence 
was selected based on H69 wild-type binding and H69ΨΨΨ most closely represents this 
original construct. It appears that the peptide retains its random coil structure upon 
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binding to H69ΨΨΨ. It would be interesting to test other modified H69 peptides to 
determine whether this trend is based on positional modification or upon binding to 
H69UUU. 
The visual assay and subsequent screening using flow cytometry instrumentation was 
successful. Peptides were successfully synthesized on 10 μm beads, incubated with 
biotinylated RNA followed by streptavidin-coated quantum dot (Qdot 605), and passed 
through the flow cytometer. The cytometer was able to identify hits based on RNA and 
Qdot binding. The parameter that needs to be further optimized is the concentration of 
RNA and Qdot 605 added to the bead samples. Since bead samples are not uniform, 
preparation is not consistent. Individual beads are impossible to see with the naked eye, 
so the workup is done in a volume-based sample prep in 0.5 mL polypropylene tubes. 
The tubes have markings on them giving approximate volumes and about 100 μL of 
beads are added to each tube. As one can see from the data shown in this report, there 
was a significant difference in the amount of beads screened in sample preparation. The 
beads were not weighed out since so little material was needed for each sample 
preparation, and it was important to avoid light as much as possible in order to avoid 
premature cleavage of the UV linker. With these challenges, it was difficult to determine 
just how much RNA and Qdot to add; however, this experiment suggests that increasing 
the amount of each could provide more positive hits during the flow analysis. This is 
discussed further in Chapter 6. 
From the flow cytometer instrumentation side of the experiment, these beads were 
often found aggregated or adhering to the side of the tubing (polyethylene) used for the 
experiment. This could account for the inconsistency in sample bead available for each 
screening. Incorporation of a 40 μm filter was used to prevent sample from getting stuck 
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in the instrument, which would have prevented successful screening of the samples. 
Even with these potential set-backs in flow cytometry, whether due to sample prep or 
sample storage, the visual assay was a success and information obtained from this 
experiment further validated binding of the parent sequence to H69 RNA as well as 
provided further support that the modified H69 peptide RQVANHQ bound to the target 
RNA. MALDI-TOF MS analysis has also provided evidence that information can be 
obtained from a single bead (10 μm dried) selected from flow cytometry; however, it is 
clear that the amount of material available is not enough for sequencing analysis. 
Experiments that can help resolve this limitation are discussed further in the future 
directions chapter (Chapter 6). 
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CHAPTER 5 BINDING STUDIES BETWEEN HELIX 69 RNA AND AMINOGLYCOSIDE 
ANTIBIOTICS198 ‡ 
‡ adapted from ref 198 
5.1 Introduction 
Although it has been previously established that aminoglycoside antibiotics bind 
primarily to the A site (h44) of the small subunit of the bacterial ribosome235-236 and 
translational processes by causing tRNA to misread mRNA codons,237 aminoglycosides 
have also been found to bind to H69 of the large bacterial subunit.232, 238 This finding is 
not surprising since H69 was previously shown to interact with h44 of the small subunit 
at the interface of both the small and large bacterial subunits.13, 239-240 
With the information already available, aminoglycosides have an established role in 
translation inhibition and make secondary contacts with H69 of the large ribosomal 
subunit. This led to the question of what, if any, conformational changes occurred when 
these compounds bound to H69. As H69 is believed to be essential for ribosomal 
function, it was important to investigate this question in order to learn more about this 
motif. Dr. Yogo Sakakibara and Dr. Sanjaya Abeysirigunawardena had previously 
revealed that H69 underwent structural rearrangements during ribosomal association or 
with changing solution conditions with particular focus on positions A1913 and A1918.177-
178, 241 These nucleotide arrangements were influenced by Mg2+ concentrations, pH, and 
temperature.177-178, 241 Position A1913 was already an implicated nucleotide important for 
high-fidelity translation and efficient termination, which made it an interesting focus to 
monitor aminoglycoside antibiotics, inducing conformational changes of H69.174, 242-243 Dr. 
Sakakibara and Dr. Abeysirigunawardena investigated the conformational states of H69 
RNAs by incorporating an adenine analogue, 2-aminopurine (2AP), at position 1913.198 
141 
 
 
 
This analogue is often used to monitor ligand-induced RNA conformations due to its 
ability to fluoresce when not stacked with other nucleotide bases.244-248 Figure 5.1 shows 
the structures of 2AP and adenine.  
 
Figure 5.1 Chemical structures of 2-aminopurine and adenine. 2-Aminopurine, left, 
and adenine, right, are isomers of each other and have the same mass.  
 
Figure 5.2 shows the secondary structures of the wild-type H69 and the modified and 
unmodified H69 secondary structures with the incorporation of 2AP at position 1913. 
These constructs enabled the conformational states of H69 to be monitored in solution. 
Since the 2AP analogue is sensitive to changes in environment and undergoes 
significant decreases in fluorescence intensity when base stacked, the fluorescence of 
2AP was expected to diminish because of increased base stacking if nucleotide 1913 
formed a local conformation similar to that observed in 50S subunits. An increase in 
fluorescence intensity was expected if 2AP1913 became more exposed to solvent, as 
seen in full 70S ribosomes.198 
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Figure 5.2 Secondary structures of H69 RNAs with 2-aminopurine. Wild-type H69, 
left is compared to the secondary structures of 2-aminpurine H69 (2AP-H69ΨΨΨ), 
middle, and 2-aminopurine H69UUU (2AP-H69UUU), right. Modification to position 1913 
from an adenine to a 2-aminopurine and a m3Ψ to a Ψ in position 1915 are the only 
differences between the modified structures and the wild-type H69. 
 
Drs. Sakakibara and Abeysirigunawardena used this established method to detect 
conformational changes that occurred upon binding of the RNA to the aminoglycoside 
antibiotic under different conditions and was able to determine apparent dissociation 
constants for each aminoglycoside antibiotic tested with each H69 RNA. To support 
these findings, ESI MS was performed on all of the H69 RNAs with neomycin and 
paromomycin, and apparent dissociation constants were determined. 
5.2 ESI MS binding studies with H69 RNAs and select aminoglycoside antibiotics 
To obtain dissociation constants (Kds) for the aminoglycosides used in this binding 
study, ESI MS was utilized. The instrumentation used can be found in Section 2.7.2 and 
processed as described in Section 2.7.3. The protocol used to determine the 
dissociation constants can be found in the published manuscript.198  
Unmodified (H69UUU) and modified (H69ΨΨΨ) sequences of H69 (Section 2.4.1) 
were used in addition to the incorporation of 2AP at position A1913 of both RNAs198 
(2AP-H69UUU and 2AP-H69ΨΨΨ) giving a total of four RNAs to use in aminoglycoside 
binding studies. The aminoglycosides neomycin and paromomycin were tested for 
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binding with each H69 RNA. Unless otherwise stated, all figures associated with binding 
results in Sections 5.2.1 through Section 5.2.4 are adaptions from the published 
manuscript.198 
5.2.1 ESI MS results of aminoglycoside binding studies with H69UUU 
H69UUU is a 19-nucleotide stem-loop construct that contains three uridines in place of 
the canonical pseudouridine (Ψ) in positions 1911, 1915, and 1917. Since the 
modification exists only after post-transcriptional processes have occurred, this construct 
is studied to determine similarities and differences in binding affinity and selectivity. 
Binding experiments were performed with neomycin and paromomycin in duplicate 
leading to the binding curves shown in Figure 5.3. Titration ESI MS spectra associated 
with this plot can be found in Appendix B. The duplicate set of data revealed some 
inconsistencies due to varying ionization efficiencies under different conditions. Dr. 
Anne-Cecile Duc had previously tested the same construct with paromomycin to reveal a 
dissociation constant of 8 ± 2, which was included in our publication.198 The binding 
curves in Figure 5.3 revealed a 2.5-fold difference binding affinity in favor of neomycin 
(1.4 μM) over paromomycin (3.7 μM). In comparison to the 8 μM Kd identified by Dr. Duc, 
and supported by data found in Appendix B, there is a 6-fold difference in binding 
affinity favorable to neomycin. 
144 
 
 
 
 
Figure 5.3 Titration plots of neomycin and paromomycin bound to H69UUU. 
Binding studies with H69UUU, neomycin, left, has a dissociation constant of 1.4 ± 0.6 
μM. Paromomycin, right, has a dissociation constant of 3.7 ± 0.9 μM. 
 
5.2.2 ESI MS results of aminoglycoside binding studies with 2AP-H69UUU 
The second construct tested for binding was 2AP-H69UUU. The 2AP replaced the 
A1913 of H69UUU construct. As discussed earlier in this chapter, 2AP is an analogue of 
adenine; therefore, the mass of this construct is identical to that of H69UUU. Figure 5.4 
represents the binding results of 2AP-H69UUU with neomycin and paromomycin, 
respectively. Once again, neomycin binding led to greater binding affinity to 2AP-
H69UUU (1.8 μM) over paromomycin (9 μM) with a 5-fold difference in apparent Kds. 
Interestingly, these findings matched, within error, to the findings observed in Figure 5.3, 
suggesting that the 2AP modification does not impact the binding ability of the 
aminoglycosides to the RNAs. 
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Figure 5.4 Titration plots of neomycin and paromomycin bound to 2AP-H69UUU. 
Binding studies with 2AP-H69UUU, neomycin, left, has a dissociation constant of 1.8 ± 
0.3 μM. Paromomycin, right, has a dissociation constant of 9 ± 3 μM. 
 
5.2.3 ESI MS results of aminoglycoside binding studies with H69ΨΨΨ 
The third construct tested with aminoglycosides was H69ΨΨΨ. This modified H69 
construct contained three Ψ in positions 1911, 1915, and 1917. This is the closest 
representation to the wild-type H69 as shown in Figure 5.2. Figure 5.5 represented 
results from binding studies of H69ΨΨΨ with the aminoglycosides neomycin and 
paromomycin. Neomycin bound to H69ΨΨΨ (1.2 μM) with an 8-fold greater affinity over 
paromomycin (10 μM). As observed with the unmodified H69 counterparts, neomycin 
appears to be a better binder than paromomycin. 
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Figure 5.5 Titration plots of neomycin and paromomycin bound to H69ΨΨΨ. 
Binding studies with H69ΨΨΨ, neomycin, left, has a dissociation constant of 1.2 ± 0.4 
μM. Paromomycin, right, has a dissociation constant of 10 ± 3 μM. 
 
5.2.4 ESI MS results of aminoglycoside binding studies with 2AP- H69ΨΨΨ 
The fourth construct tested with aminoglycosides was 2AP-H69ΨΨΨ.The 2AP 
modification replaced A1913 and is the only difference from H69ΨΨΨ. Figure 5.6 
represented results from binding studies of 2AP-H69ΨΨΨ with the aminoglycosides 
neomycin and paromomycin. A 7-fold difference in binding affinity was observed in favor 
of neomycin bound to 2AP-H69ΨΨΨ (1.6 μM) over paromomycin (11 μM). These 
findings correlate very well to the H69ΨΨΨ, without 2AP, with apparent Kds comparable 
relative to the aminoglycoside binding; that is, neomycin binding to 2AP-H69ΨΨΨ (1.2 
μM) and H69ΨΨΨ (1.8 μM) led to the same Kd, within error. This suggests that the 2AP 
modification does not impact binding of the aminoglycosides as a difference in 
dissociation constants was not observed. This finding was also observed with the 
unmodified H69 counterparts with aminoglycoside binding. 
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Figure 5.6 Titration plots of neomycin and paromomycin bound to 2AP-H69ΨΨΨ. 
Binding studies with 2AP-H69ΨΨΨ, neomycin, left, has a dissociation constant of 1.6 ± 
0.7 μM. Paromomycin, right, has a dissociation constant of 11 ± 3 μM. 
 
5.2.5 Discussion of combined data from aminoglycoside H69 RNAs study 
Aminoglycosides bound to the four H69 RNAs were studied using ESI MS. In the 
previous sections of this chapter, data pertaining to each set of titrations were combined 
and error was determined for each concentration of the aminoglycoside tested. Full 
titration spectra corresponding with both aminoglycosides bound to each of the four H69 
RNAs tested can be found in Appendix B of this work. This data provided evidence of 
equal ionization efficiencies, with the exception of the binding studies associated with 
H69UUU and paromomycin discussed earlier in this work, which supported the titration 
plots described in previous sections of this chapter. Figure 5.7 gives a one-shot view of 
each RNA bound to neomycin at or near the calculated dissociation constant.  As 
shown, the intensity peaks associated with the free RNA at the (4- ) charge state and the 
neomycin-RNA (4-) have similar heights. When comparing to the overall titration spectra 
found in H69 RNAs, in Appendix B, one will see that with increasing concentration of 
neomycin, the free RNA peak would decrease with increasing complex formation of 
neomycin bound to the RNA.  
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Figure 5.7 One-shot profiles for H69 RNAs bound to neomycin. Each spectrum 
within this figure shows a concentration of neomycin closest to the dissociation constant 
plotted in Figures 5.3 through 5.6. The complex formation peak intensity is nearly if not 
the same height as the free RNA at the (4-) charge site which correlated with the 
apparent dissociation constant obtained from a duplicate set of titrations for each RNA 
and neomycin.  
 
Figure 5.7 provides an important finding in that the incorporation of 2AP had no impact 
on the apparent dissociation constant making it a suitable analogue for binding studies. 
The similar Kds between the 2AP- and A-containing constructs were important because 
the values for 2AP-H69UUU and 2AP-H69ΨΨΨ were about the same. In contrast 
difference in fluorescence was observed for 2AP-H69UUU and 2AP-H69ΨΨΨ.  This 
result revealed that the conformational changes observed between 2AP-H69UUU and 
2AP-H69ΨΨΨ do not impact the overall dissociation constants. In other words, a 
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mechanism-based assay vs. straight Kd measurement are combined to gain a deeper 
understanding of the binding mode. More specifically, the use of both ESI MS and 
fluorescence-based studies was critical for understanding the base flipping of A1913 
upon aminoglycoside binding. 
Paromomycin yielded apparent dissociation constants with titration spectra showing 
near-equivalent ionization efficiencies of aminoglycoside-RNA binding versus free RNA. 
Figure 5.8 gives a one-shot profile of each RNA bound to paromomycin near its 
calculated dissociation constant. Despite the higher dissociation constants to H69 RNAs 
compared to neomycin binding studies, paromomycin revealed similar binding trends to 
H69 RNAs; that is, overlapping Kds were observed with 2AP-H69ΨΨΨ (11 μM) and 
H69ΨΨΨ (10 μM) and with 2AP-H69UUU (9 μM) and H69UUU (8 μM, obtained by Dr. 
Duc198), respectively. This adds further evidence with a different aminoglycoside 
antibiotic that changes in fluorescence should be compared to other binding 
measurements such as ESI MS. 
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Figure 5.8 One-shot profiles for H69 RNAs bound to paromomycin. Each spectrum 
within this figure shows a concentration of paromomycin closest to the dissociation 
constant plotted in Figures 5.2 through 5.5. The complex formation peak intensity is 
nearly if not the same height as the free RNA at the (4-) charge site which correlated 
with the apparent dissociation constant obtained from a duplicate set of titrations for 
each RNA and paromomycin. 
 
To further visualize the similarities of apparent dissociation constants, Table 5.1 
combines the dissociation constants obtained from ESI MS and compares them to the 
dissociation constants obtained from Dr. Sakakibara's fluorescence data testing the 
same products. What was of interest is the similarity in apparent dissociation constants 
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despite the difference in the techniques used to obtain them. Of particular interest is the 
fact that the dissociation constants found using ESI MS were similar to those found 
using fluorescence-based techniques. This comparison provides evidence that despite 
the RNA used or the aminoglycoside tested, the incorporation of 2AP into an RNA did 
not impact the overall result making this technique combination useful in studying the 
binding modes of RNAs and their ligands.198 
           Table 5.1 Aminoglycoside binding with H69 RNAs198 
Ligand Method RNA type Kd [μM] 
 fluorescence 2AP-H69ΨΨΨ 2.5 ± 0.2 
 ESI MS 2AP-H69ΨΨΨ 1.6 ± 0.7 
neomycin ESI MS H69ΨΨΨ 1.2 ± 0.4 
 fluorescence 2AP-H69UUU 2.0 ± 0.4 
 ESI MS 2AP-H69UUU 1.8 ± 0.3 
 ESI MS H69UUU 1.4 ± 0.6 
 fluorescence 2AP-H69ΨΨΨ 7 ± 1 
 ESI MS 2AP-H69ΨΨΨ 11 ± 3 
paromomycin ESI MS H69ΨΨΨ 10 ± 3 
 fluorescence 2AP-H69UUU ND 
 ESI MS 2AP-H69UUU 9 ± 3 
 
5.3 Determination of a dual-binding mode between a H69-selected peptide with 
H69 RNAs and neomycin 
Crystallography and model studies have been done with H69 RNA and 
aminoglycosides revealing that aminoglycosides have a secondary target site to the 
stem region of H69.232, 238 As discussed in Chapter 3, H69 peptides have been shown to 
bind to the loop region since evidence has shown that there is selectivity of many of the 
peptides to H69ΨΨΨ over H69UUU. Hypothetically, it may be possible that a dual-
binding mode of a H69 peptide and neomycin bound to H69 RNA is possible. The one 
possible limitation would be that binding of the aminoglycoside could alter the overall 
conformational state of the RNA making a binding interaction with the peptide unlikely or 
152 
 
 
 
that a higher concentration of peptide would be necessary to visualize a binding 
interaction. 
Experiments were performed and analyzed using ESI MS as described in Section 
2.7.2 and Section 2.7.3. Neomycin concentration was maintained at 10 μM, H69 RNA at 
2.7 μM, and peptide concentrations varied from 0 to 100 μM (five to six different 
concentrations). Although a mass peak associated with 1:1:1 binding of the RNA, 
neomycin, and peptide was observed earlier on in the titration, it was visualized clearly 
at 60 μM NQVANHQ-NH2 as shown in Figure 5.9.  
 
Figure 5.9 An ESI MS spectrum revealing a 1:1:1 complex of H69UUU RNA-
Neomycin-NQVANHQ-NH2. This spectrum revealed a profile of which free H69UUU, 
peptide dimer, a 1:1 H69UUU-neomycin, and 1:1:1 H69UUU-neomycin-NQVANHQ-NH2 
complex at the (4-) charge state was observed.  
The experiment was repeated with H69ΨΨΨ RNA (2.7 μM), neomycin (10 μM), and 0 - 
100 μM NQVANHQ-NH2 (five to six different concentrations). The same complex was 
visualized at 40 μM NQVANHQ-NH2 as shown in Figure 5.10. Titrations pertaining to 
these binding studies did not yield usable information to determine apparent dissociation 
constants mostly due to the increase in noise with higher peptide concentrations and the 
already high concentration of neomycin used during the study. The fact that no peptide-
neomycin peak was observed is promising assuring that the peptide is indeed binding to 
RNA independently of the aminoglycoside. 
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Figure 5.10 ESI MS spectrum revealing a 1:1:1 complex of H69ΨΨΨ RNA-
Neomycin-NQVANHQ-NH2. This spectrum revealed a profile of which free H69ΨΨΨ, a 
1:1 H69ΨΨΨ-neomycin, and 1:1:1 H69ΨΨΨ-neomycin-NQVANHQ-NH2 complex at the 
(4-) charge state was observed. 
 
5.4 Future directions 
 
Aminoglycoside binding studies using ESI MS provided useful information that could 
be of use in future projects with H69-selected peptides. Since it is not likely that small 
heptameric peptides will make viable drugs, binding studies with aminoglycosides 
provide a possible resolution toward making the peptides identified to target H69 RNAs 
more "druggable". A possible direction to take the information provided in this chapter 
would be to conjugate H69 peptides to aminoglycosides or portions of aminoglycosides 
necessary for selective binding. In the case of aminoglycosides, the neamine core would 
be an excellent start for conjugation experiments. This fragment-based drug design 
approach could be tested with ESI MS as well as other biophysical techniques (NMR, 
ITC, CD) leading to both structural and quantifiable data regarding selectivity, binding 
location, and binding affinity. 
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS 
6.1.1 The use of ESI MS to determine roles of peptidic side chains in RNA binding 
interactions 
Chapter 3 provided evidence to support the use of modified peptidic ligands to target 
H69 RNAs. The ESI MS technique provided information regarding binding affinity, 
selectivity, and apparent dissociation constants of each modified peptide bound to H69 
RNAs. This technique provided useful information with regard to which positions of the 
heptamer contributed to H69 RNA binding, allowing an opportunity to design novel 
peptides with increased selectivity and affinity to the target RNA (Figure 6.1). 
 
Figure 6.1 Summary of H69 RNA binding with peptide modifications. Modified 
(H69ΨΨΨ) and unmodified (H69UUU) H69 RNAs underwent binding studies with 
modified H69 peptides using ESI MS. For H69ΨΨΨ, changes at positions 1 and 6 
yielded modified peptides with greater affinity than the parent sequence. Positions 2 and 
3 (red) gave apparent dissociation constants in the same range as the parent sequence. 
Numeral values give an x-fold difference in affinity when compared to H69UUU. 
H69UUU results suggested that modifications in positions 1, 3, 5, and 6 could lead to 
peptides with greater affinity to unmodified H69 when compared to the modified parent 
RNA. Position 4 and 7 variants had similar apparent dissociation constants when 
compared to the parent peptide. 
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H69ΨΨΨ, the modified RNA sequence closest to the wild-type construct, demonstrated 
greater binding affinity to two modified peptide variants, RQVANHQ-NH2 and 
NQVANRQ-NH2, when compared to the selected parent sequence, NQVANHQ. Based 
on the ESI MS results, modifications at position 1 and 6 with alanine led to either very 
poor or no observable binding to the H69 RNAs. In addition, RQVANHQ-NH2 had a 4-
fold greater affinity to the modified construct over H69UUU, revealing modest selectivity 
for H69ΨΨΨ. Similarly, NQVANRQ-NH2 had a 3-fold greater affinity for H69ΨΨΨ over 
H69UUU. Modifications at positions 2 and 3 to alanine produced peptides with similar 
apparent dissociation constants to the parent sequence; however, position 2 
(NAVANHQ-NH2) had a 12-fold greater affinity for H69ΨΨΨ over H69UUU, further 
supporting selectivity to the H69 RNA closest in composition to the wild-type sequence 
that was used to identify the parent peptide in phage-display experiments.197 It is 
important to have selectivity to the modified construct over the unmodified since the only 
difference between the two is the presence of Ψ, a post-transcriptional modification that 
has implicated roles in several essential processes as discussed in Chapter 1. To 
collect further evidence of these roles, studying the modified nucleosides is important, 
which is why designing peptides that selectively target modified H69 is imperative for 
solving this challenge.  
H69UUU, an unmodified H69 RNA (no Ψ), demonstrated greater affinity for several of 
the modified peptides than modified H69 when compared to the parent peptide 
sequence. In particular, modifications at positions 1, 3, 5, and 6 led to modified variants 
with greater affinity for H69UUU. Changes at positions 4 and 7 led to modified peptide 
variants with similar dissociation constants as the parent sequence for H69UUU. The 
ability to generate modified variants capable of binding to H69UUU with higher affinity 
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than NQVANHQ suggests that the loop region is the primary target since these findings 
were different than those obtained with H69ΨΨΨ. These findings suggest that these 
modified H69 peptides target modified nucleotides present within the H69 construct. It 
would be useful to have H69UUU-targeting peptides in order to potentially reveal 
mechanistic functions of H69 prior to post-transcriptional modification. 
6.1.2 Using mass spectrometry to determine binding locations and binding 
affinities of modified peptides targeting H69 RNAs 
ESI MS provided useful information regarding binding affinity and selectivity within the 
determination of apparent dissociation constants. Although this technique provided 
opportunities for quantitative analysis of these binding interactions, mass spectrometry 
could be further used to determine the binding location. Utilizing an MS/MS 
bombardment approach could provide information regarding the binding location by 
studying fragments obtained from the mass experiment.249-257 The experiment would 
begin by incubating the modified peptide variant with the target RNA. Bombardment of 
the sample would produce fragments; however, complex formation between the peptide 
and RNA remain intact.249-257 Knowing the masses and chemical formulas of each 
component makes identification of complex between peptide and RNA fragment 
possible, which would then provide a binding location(s) of the peptide on the target 
RNA.249-257 Another mass technique that could be used to gain the same information is 
one developed by Dr. Patrick A. Limbach in which nucleases are utilized on samples and 
subsequent mass analysis provides fragments without the need for hard ionization 
techniques.258 Mass spectrometry could provide invaluable information and should be 
further explored in the study of peptide – RNA interactions.  
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6.2.1 Biophysical binding studies of selected H69 peptides 
Biophysical techniques such as circular dichroism (CD) and isothermal titration 
calorimetry (ITC) provide different, but complementary, information regarding peptide-
RNA binding complexes. CD experimentation has the ability to reveal the differences in 
conformation between complexed and uncomplexed RNA and peptide moieties, and ITC 
experimentation has the ability to provide absolute binding constants under 
physiologically relevant better conditions. Although both of these techniques were used 
in this work, complications led to the necessity for further optimization. CD experiments 
revealed that the global conformation of RNA remained unchanged upon peptide 
binding; however, studies with H69UUU revealed the conformational changes between 
that of bound peptide (α helix) and unbound peptide (random coil). These differences 
were not observed with the modified RNA construct. ITC experiments did provide 
evidence that an exothermic reaction took place upon binding of RNA and peptide; 
however, binding constants could not be determined based on the conditions used.  
The development of a screening assay utilizing flow cytometry provided evidence 
supporting modified peptide binding to H69ΨΨΨ RNA. This assay depended on 
secondary binding between RNA and peptide simultaneously bound to a fluorophore-
containing entity (Qdot 605). Flow cytometry was able to not only identify individual 
beads emitting at 605 nm, but also sorted the brightest hits for mass analysis and 
subsequent peptide identification. These findings are promising because they can 
expedite the identification of novel peptide ligands targeting RNA for further biophysical 
and biochemical analysis.  
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6.2.2 Expanding on biophysical binding studies of selected H69 peptides 
Biophysical studies besides mass spectrometry provided some evidence regarding 
RNA and peptide binding; however, further optimization is necessary to give more 
conclusive results. In the case of circular dichroism, it would be interesting to test other 
peptide variants to determine whether modification position vs. the binding to the H69 
RNA construct (H69ΨΨΨ or H69UUU) is important for conformational changes. ITC 
results revealed an exothermic reaction indicative of a chemical interaction (binding 
event) having taken place; however, although this technique is capable of providing 
absolute binding constants, that was not achieved in this case. Since endogenous salt in 
the peptide sample is likely the culprit and removal of the salt was challenging, it might 
be worth doing a titration in which the peptide resides in the sample cell and the RNA in 
the syringe. This role reversal may provide novel information despite the salt 
concentration within the peptide sample.  
An alternative approach involves further modification of the peptide, thereby providing 
a sequence that can be desalted and studied. For instance, modifying position 3 to a 
phenylalanine could provide a sequence that could be desalted without disturbing 
binding to the RNA. ESI MS studies revealed that modifications to alanine and arginine 
at residue 3 led to promiscuous binding, suggesting the need for a bulky nonpolar group 
for selective binding to H69 RNA. Modifying this position with an aromatic amino acid 
would allow improved HPLC purification and desalting since aromatic functional groups 
elute at higher ACN concentrations (30%). Prior to ITC experimentation, ESI MS studies 
should be performed with this modified variant and H69UUU and H69ΨΨΨ. This 
approach would allow determination of whether the modification has binding affinity and 
selectivity comparable to previously selected peptides and whether ITC experiments 
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should be performed. If ESI MS validates the usefulness of the modified variant, ITC 
experiments could be further optimized with ligand devoid of endogenous salt, and a 
buffer match between the peptide and RNA could be maintained.  
Additionally, biochemical experimentation such as enzymatic footprinting could be 
used for these studies. Enzymatic footprinting works on the premise that nucleases have 
predicted cleavage or hydrolyzing patterns on nucleic acids that are disrupted when the 
nucleic acid is complexed with a ligand. These reactions are monitored using 
radiolabeled nucleic acids monitored by gel electrophoresis. Furthermore, titrations of 
the ligand and target can provide dissociation constants for modified peptides.216 These 
experiments were performed, but findings were inconclusive. The greatest challenge 
was the inability to consistently quench the nuclease, which often led to over-digestion of 
the RNA. The use of an RNAse inhibitor would aid in resolving this challenge and could 
yield conclusive findings.  
The visual assay provided very promising results, giving additional evidence that 
binding between modified peptides and H69ΨΨΨ did occur; however, more could be 
done to increase the sensitivity of detection of the fluorophore. Designing a compound 
that could be used as a calibrant would provide more information regarding the number 
of fluorophore moieties that had bound to an individual bead. This value could be 
extrapolated and compared to samples containing randomized peptide libraries in which 
not only 605 nm emission is detected. Knowing the number of fluorophore molecules 
bound to a single bead would lead to stricter selection parameters, which would allow 
sorting of individual beads with the highest signal intensity to take place. 
Another parameter that should also be optimized for the flow cytometry experiment is 
the amount of sample submitted. Ideally, samples should be incubated with saturating 
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amounts of RNA and fluorophore in order to assure complete binding to each possible 
site available. Samples were previously prepared by a visual dependence on the volume 
markings on the sample tubes with the assumption that the beads associated with each 
sample were the same in size. Dried samples could be weighed on sensitive precision 
balances, and the amount of peptide material available for flow analysis could be better 
approximated. This approach would give a better indication of how much RNA and 
fluorophore to add leading to the optimal concentration of reagents per sample 
submission.  
This flow cytometry assay is promising; however, it would be more effective if large 
randomized libraries could be synthesized and tested with the assurance that peptide 
sequencing could take place after sorting. There are two limitations preventing the 
current set of peptides from being sequenced. The first is that the flow cytometer cannot 
accept beads greater than 100 μm in size forcing the usage of smaller beads (10 μm). 
The second is that the amount of material on the bead is very low (fmol) and insufficient 
for reliable sequencing. Since beads swell to a minimum of three times their dried size 
and synthesizing material onto them adds to their size, one is limited to small beads (10 
μm) with low capacity (0.23 mmol/g). If a high-loading resin could be produced with a 
more compact size, more material would be available for sequencing and this challenge 
would be solved. RAPP-polymere has produced high capacity beads that remain small 
in size. For instance, the 75 μm beads have the same capacity (0.48 mmol/g) as the 140 
μm beads which are nearly double in size. If this could be applied to an even smaller 
bead, this assay would be more effective. A second option would be to test other beads; 
that is (e.g. 20 and 30 μm) and solvents for peptide synthesis to vary the degree of 
swelling. It may be possible to work with a larger bead with greater capacity without 
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exceeding the 100 μm limitation. Preliminary findings have determined that total mass 
identification is possible from material on a single bead; it's now a matter of attaining 
enough material to do sequencing, which would make this assay optimal for large-scale 
selections.  
6.3.1 Binding studies between helix 69 and aminoglycoside antibiotics led to the 
establishment of a dual binding mode of aminoglycoside and peptides to helix 69 
RNAs 
ESI MS binding studies were performed with modified and unmodified H69 RNAs with 
and without 2-aminopurine in position A1913.198 The dissociation constants correlated 
well with dissociation constants obtained using fluorescence-based techniques 
performed by Dr. Yogo Sakakibara, which showed the value in using two techniques for 
comparison because they give complementary information such as stoichiometry vs. 
conformational changes.198 Crystallography and model studies have been done with H69 
RNA and aminoglycosides, revealing that aminoglycosides target the stem region of 
H69.232, 238 As discussed in Chapter 3, H69 peptides have been proposed to bind to the 
loop region, there is selectivity of many of the variants to H69ΨΨΨ over H69UUU. 
Aminoglycoside antibiotic binding studies with H69 RNAs led to additional experiments 
with peptides. Results revealed 1:1:1 binding complexes with RNA, neomycin, and 
peptide. These findings were not limited to H69ΨΨΨ, but also demonstrated with 
H69UUU. Also of interest was the absence of aminoglycoside-peptide peaks, suggesting 
that these small compounds bind to RNA independently.  
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6.3.2 A fragment-based drug design approach for producing peptide-
aminoglycoside compounds for H69 binding studies 
ESI MS studies gave supporting data that a 1:1:1 binding complex with RNA-peptide-
aminoglycoside exists. Docking studies using PDB files of known crystal structures of 
the bacterial ribosome can be used to study possible conjugation profiles between the 
neamine core of aminoglycosides and winner peptides. This modeling approach could 
provide the best synthetic direction for compounds containing peptide and 
aminoglycosides. With the successful synthesis of such compounds, ESI MS could be 
used to attain apparent dissociation constants, which would provide valuable information 
that could be applied to in vivo applications such as ribosomal inhibition assays and MIC 
studies.  
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APPENDIX A: ESI MS TITRATION DATA FOR H69 MODIFIED PEPTIDES WITH H69 
RNAS 
This appendix contains ESI MS titration spectra correlating to results shown in Chapter 
3 of this work.  
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Table A1 Peptide sequence and molecular formula for mass determination 
  
Mass Lynx V.4.0 
Peptide Sequence Molecular Formula 
Molecular 
Weight 
RQVANHQ-NH2 C34H58N16O10 850.5 
NRVANHQ-NH2 C33H56N16O10 836.4 
NQRANHQ-NH2 C33H55N17O11 865.4 
NQVRNHQ-NH2 C35H59N17O11 893.5 
NQVARHQ-NH2 C34H58N16O10 850.5 
NQVANRQ-NH2 C32H57N15O11 827.4 
NQVANHR-NH2 C33H56N16O10 836.4 
AQVANHQ-NH2 C31H51N13O10 765.4 
NAVANHQ-NH2 C30H49N13O10 751.4 
NQAANHQ-NH2 C30H48N14O11 780.4 
NQVANHQ-NH2 C32H52N14O11 808.4 
NQVAAHQ-NH2 C31H51N13O10 765.4 
NQVANAQ-NH2 C29H50N12O11 742.4 
NQVANHA-NH2 C30H49N13O10 751.4 
 
Table A2 H69 RNAs 
Sample Molecular Formula 
Molecula
r 
Weight 
(3-) (4-) (5-) 
H69UUU/H69ΨΨ
Ψ C181H225N73O130P18 6057.9 2018.3 1513.5 1210.6 
5'-Bi-H69UUU/ 
5'-Bi-H69ΨΨΨ 
C197H253N76O135P19S 6463.0 2153.3 1614.7 1291.6 
 
 
 
167 
 
 
 
 
Figure A1 AQVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 1. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 120 μM. Biotinylated modified RNA (5'-Bi-H69ΨΨΨ) was used to 
enhance the intensities of peptide-RNA complex.  
 
168 
 
 
 
 
Figure A2 AQVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 2. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 120 μM. Biotinylated modified RNA (5'-Bi-H69ΨΨΨ) was used to 
enhance the intensities of peptide-RNA complex.  
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Figure A3 AQVANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM.  
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Figure A4 AQVANHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM.  
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Figure A5 NAVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 1. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 120 μM.  
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Figure A6 NAVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 2. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 120 μM.  
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Figure A7 NAVANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM.  
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Figure A8 NAVANHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM.  
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Figure A9 NQAANHQ-NH2 with H69UUU set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A10 NQAANHQ-NH2 with H69UUU set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A11 NQAANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A12 NQAANHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A13 NQVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 1. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 120 μM. 
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Figure A14 NQVANHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 2. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 120 μM. 
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Figure A15 NQVANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A16 NQVANHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A17 NQVAAHQ-NH2 with H69UUU set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A18 NQVAAHQ-NH2 with H69UUU set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A19 NQVAAHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A20 NQVAAHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A21 NQVANAQ-NH2 with H69UUU set 1 of 1. ESI MS titration spectra 
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 
through 120 μM. 
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Figure A22 NQVANAQ-NH2 with 5'-Bi-H69ΨΨΨ set 1 of 1. ESI MS titration spectra 
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 
through 100 μM. 
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Figure A23 NQVANHA-NH2 with H69UUU set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
100 μM. 
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Figure A24 NQVANHA-NH2 with H69UUU set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
100 μM. 
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Figure A25 NQVANHA-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
60 μM. 
192 
 
 
 
 
Figure A26 NQVANHA-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
60 μM. 
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Figure A27 RQVANHQ-NH2 with H69UUU set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
50 μM. 
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Figure A28 RQVANHQ-NH2 with H69UUU set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
50 μM. 
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Figure A29 RQVANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
60 μM. 
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Figure A30 RQVANHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
60 μM. 
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Figure A31 NRVANHQ-NH2 with H69UUU set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A32 NRVANHQ-NH2 with H69UUU set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A33 NRVANHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
60 μM. 
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Figure A34 NRVANHQ-NH2 with H69ΨΨΨ 5'-Bi-H69ΨΨΨ set 2. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 60 μM. Biotinylated modified H69 RNA (5'-Bi-H69ΨΨΨ) was 
added to enhance the intensity of the peptide-RNA complex. 
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Figure A35 NQRANHQ-NH2 with 5'-Bi-H69UUU set 1. ESI MS titration spectra 
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 
through 50 μM. 
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Figure A36 NQRANHQ-NH2 with 5'-Bi-H69UUU set 2. ESI MS titration spectra 
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 
through 50 μM. 
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Figure A37 NQRANHQ-NH2 with 5'-Bi-H69ΨΨΨ set 1. ESI MS titration spectra 
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 
through 60 μM. 
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Figure A38 NQRANHQ-NH2 with 5'-Bi-H69ΨΨΨ set 2. ESI MS titration spectra 
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 
through 60 μM. 
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Figure A39 NQVRNHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 1. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 120 μM. 
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Figure A40 NQVRNHQ-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 2. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 120 μM. 
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Figure A41 NQVRNHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
60 μM. 
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Figure A42 NQVRNHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
60 μM. 
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Figure A43 NQVARHQ-NH2 with H69UUU set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A44 NQVARHQ-NH2 with H69UUU set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A45 NQVARHQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A46 NQVARHQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A47 NQVANRQ-NH2 with H69UUU set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A48 NQVANRQ-NH2 with H69UUU set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A49 NQVANRQ-NH2 with H69ΨΨΨ set 1. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A50 NQVANRQ-NH2 with H69ΨΨΨ set 2. ESI MS titration spectra contained 
peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 through 
120 μM. 
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Figure A51 NQVANHR-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 1. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 120 μM. 
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Figure A52 NQVANHR-NH2 with H69UUU and 5'-Bi-H69ΨΨΨ set 2. ESI MS titration 
spectra contained peptide-RNA complexes and free RNA. Peptide concentrations 
ranged from 0 through 120 μM. 
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Figure A53 NQVANHR-NH2 with 5'-Bi-H69ΨΨΨ set 1. ESI MS titration spectra 
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 
through 120 μM. 
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Figure A54 NQVANHR-NH2 with 5'-Bi-H69ΨΨΨ set 2. ESI MS titration spectra 
contained peptide-RNA complexes and free RNA. Peptide concentrations ranged from 0 
through 120 μM. 
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APPENDIX B: ESI MS TITRATION DATA FOR H69 RNAS WITH AMINOGLYCOSIDE 
ANTIBIOTICS 
This appendix contains ESI MS titration spectra correlating to results shown in Chapter 
5 of this work.  
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Table B1 Sample molecular formulas for mass determination 
Sample 
Molecular 
Formula Exact Mass (3-) (4-) (5-) 
H69UUU/H69ΨΨΨ C181H225N73O130P18 6057.9 2018.3 1513.5 1210.6 
2AP-H69UUU/ 
2AP-H69ΨΨΨ 
C181H225N73O130P18 6057.9 2018.3 1513.5 1210.6 
Biotin of RNA C16H28N3O5SP 405.1    
Paromomycin C23H45N5O14 615.3    
Neomycin C23H46N6O13 614.3    
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Figure B1 Paromomycin with H69UUU set 1. Aminoglycoside antibiotic at varying 
concentrations is titrated with H69UUU RNA. 
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Figure B2 Paromomycin with H69UUU set 2. Aminoglycoside antibiotic at varying 
concentrations is titrated with H69UUU RNA. 
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Figure B3 Neomycin with H69UUU set 1. Aminoglycoside antibiotic at varying 
concentrations is titrated with H69UUU RNA. 
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Figure B4 Neomycin with H69UUU set 2. Aminoglycoside antibiotic at varying 
concentrations is titrated with H69UUU RNA. 
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Figure B5 Paromomycin with H69ΨΨΨ set 1. Aminoglycoside antibiotic at varying 
concentrations is titrated with H69ΨΨΨ RNA. 
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Figure B6 Paromomycin with H69ΨΨΨ set 2. Aminoglycoside antibiotic at varying 
concentrations is titrated with H69ΨΨΨ RNA. 
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Figure B7 Neomycin with H69ΨΨΨ set 1. Aminoglycoside antibiotic at varying 
concentrations is titrated with H69ΨΨΨ RNA. 
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Figure B8 Neomycin with H69ΨΨΨ set 2. Aminoglycoside antibiotic at varying 
concentrations is titrated with H69ΨΨΨ RNA. 
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Figure B9 Paromomycin with 2AP-H69UUU set 1. Aminoglycoside antibiotic at 
varying concentrations is titrated with 2AP-H69UUU RNA. 
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Figure B10 Paromomycin with 2AP-H69UUU set 2. Aminoglycoside antibiotic at 
varying concentrations is titrated with 2AP-H69UUU RNA. 
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Figure B11 Neomycin with 2AP-H69UUU set 1. Aminoglycoside antibiotic at varying 
concentrations is titrated with 2AP-H69UUU RNA. 
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Figure B12 Neomycin with 2AP-H69UUU set 2. Aminoglycoside antibiotic at varying 
concentrations is titrated with 2AP-H69UUU RNA. 
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Figure B13 Paromomycin with 2AP-H69ΨΨΨ set 1. Aminoglycoside antibiotic at 
varying concentrations is titrated with 2AP-H69ΨΨΨ RNA. 
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Figure B14 Paromomycin with 2AP-H69ΨΨΨ set 2. Aminoglycoside antibiotic at 
varying concentrations is titrated with 2AP-H69ΨΨΨ RNA. 
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Figure B15 Neomycin with 2AP-H69ΨΨΨ set 1. Aminoglycoside antibiotic at varying 
concentrations is titrated with 2AP-H69ΨΨΨ RNA. 
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Figure B16 Neomycin with 2AP-H69ΨΨΨ set 2. Aminoglycoside antibiotic at varying 
concentrations is titrated with 2AP-H69ΨΨΨ RNA. 
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In the development of peptide ligands to target H69, SPPS and ESI MS was used to 
determine if 1) peptides could bind to modified H69 and 2) if increased affinity for the 
target RNA could be enhanced with modification. An alanine and arginine scan was 
synthesized and tested for this determination. Selected peptides were then tested using 
biophysical techniques such as circular dichroism and isothermal titration calorimetry. An 
assay was also designed to increase the efficiency of peptide ligand selection in which 
novel peptides with high affinity and selectivity could be identified for future projects. This 
assay was done using flow cytometry, instrumentation capable of identifying beads, 
bound to the target RNA conjugated to a fluorophore, based on fluorophore emission, 
and sorting them into 96-well plates for MS analysis.  
The last part of the research focused on aminoglycoside-H69 RNA interactions. ESI 
MS was used to obtain binding affinities and stoichiometries of 2AP- and A-containing 
H69 RNAs. The findings revealed that the binding mode had not changed between these 
two sets of RNAs, which revealed the value for using ESI MS in combination with other 
techniques, such as fluorescence, to give a complete picture of the binding mode 
(stoichiometry, affinity, selectivity) in comparison with conformational changes that may 
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occur upon binding. Further exploration of aminoglycoside-H69 RNA interactions took 
place with the H69 peptide NQVANHQ-NH2 to determine whether a fragment-based 
drug design approach could be used to create small compounds for future in vivo 
applications. 
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